DERIVATIVES OF CONDENSED BICYCLIC 2-(HETH)ARYL-SUBSTITUTED HETEROCYCLES, THEIR USE AND INTERMEDIATES, COMPOSITION, AND METHOD FOR CONTROLLING PESTS

Description

Descriptive Report of the Invention Patent for 2(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES, THEIR USE AND INTERMEDIATES, COMPOSITION, AND METHOD FOR CONTROLLING PESTS.

[0001] The present invention relates to novel derivatives of 2-(het)aryl-substituted fused bicyclic heterocycle of Formula (I), to the use thereof as acaricides and / or insecticides for controlling animal pests, particularly arthropods and especially insects and arachnids, and to processes and intermediates for the preparation thereof.

[0002] 2-(het)aryl-substituted fused bicyclic heterocycle derivatives that have insecticidal properties have already been described in the literature, for example, in WO 2010 / 125985, WO 2012 / 074135, WO 2012 / 086848, WO 2013 / 018928, WO 2014 / 142292 and WO 2014 / 148451, and also WO 2015 / 000715.

[0003] However, the active ingredients already known according to the documents cited above have some disadvantages in application, either because they exhibit only a narrow application range or because they do not have satisfactory insecticidal or acaricidal activity.

[0004] New derivatives of 2-(het)aryl-substituted fused bicyclic heterocycles have now been found, and these have advantages over known compounds, examples of which are better biological or environmental properties, a wide range of application methods, better insecticidal or acaricidal activity, and also good compatibility with agricultural plants. 2-(het)aryl-substituted fused bicyclic heterocycle derivatives can be used in combination with additional agents to improve efficacy, especially against insects that are difficult to control.

[0005] The present invention therefore provides new compounds of Formula (I) Petition 870210086398, dated 09 / 20 / 2021, page 5 / 177 2 / 162 (I)

[0006] where

[0007] A1 is nitrogen, =N+-O- or =C-R4,

[0008] A2 is -N-R5, oxygen or sulfur,

[0009] A3 is oxygen, =NH or =N-CN,

[00010] A4 is nitrogen, =N+-O- or =C-R4,

[00011] A5 is nitrogen, =N+-O- or =C-R4,

[00012] R1é (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)cyanoalkyl, (Ci-C6)hydroxyalkyl, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)haloalkoxy-(C1C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkenyloxy-(C1-C6)alkyl, (C2C6)haloalkenyloxy-(C1-C6)alkyl, (C2-C6)haloalkenyl, (C2C6)cyanoalkenyl, (C2-C6)alkynyl, (C2-C6)alkynyloxy-(C1-C6)alkyl, (C2C6)haloalkynyloxy-(C1-C6)alkyl, (C2-C6)haloalkyl, (C2C6)cyanoalkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl-(C3C8)cycloalkyl, (C1-C6)alkyl-(C3-C8)cycloalkyl, halo(C3-C8)cycloalkyl, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, (C3-C8)cycloalkylamino, (C1-C6)alkylcarbonylamino, (C1-C6)alkylthio-(C1-C6)alkyl, (C1C6)haloalkylthio-(C1-C6)alkyl, (C1-C6)alkylsulfinyl-(C1-C6)alkyl, (C1C6)haloalkylsulfinyl-(C1-C6)alkyl, (C1-C6)alkylsulfonyl-(C1-C6)alkyl, (C1C6)haloalkylsulfonyl-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkylthio-(C1C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkylsulfinyl-(C1-C6)alkyl,(C1-C6)alkoxy(C1-C6)alkylsulfonyl-(C1-C6)alkyl, (C1-C6)alkylcarbonyl-(C1-C6)alkyl, (C1-C6)haloalkylcarbonyl-(C1-C6)alkyl, (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)haloalkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkylsulfonylamino, aminosulfonyl-(C1-C6)alkyl, (C1-C6)alkylaminossulfonyl-(C1-C6)alkyl, di(C1-C6)alkylaminossulfonyl-(C1-C6)alkyl, Petition 870210086398, dated 09 / 20 / 2021, page. 6 / 177 3 / 162

[00013] or is (C1-C6)alkyl, (C1-C6)alkoxy, (C2-C6)alkenyl, (C2C6)alkynyl, (C3-C8)cycloalkyl, each of which is mono- or polysubstituted identically or differently by aryl, heteroyl or heterocyclyl, where aryl, heteroyl or heterocyclyl may each independently be mono- or polysubstituted identically or differently by halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, aminosulfonyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1C6)alkylsulfonyl, (C1-C6)alkylsulphimino, (C1-C6)alkylsulphimino-(C1C6)alkyl, (C1-C6)alkylsulphimino-(C2-C6)alkylcarbonyl, (C1C6)alkylsulfoximino, (C1-C6)alkylsulfoximino-(C1-C6)alkyl, (C1C6)alkylsulfoximino-(C2-C6)alkylcarbonyl, (C1-C6)alkoxycarbonyl, (C1C6)alkylcarbonyl, (C3-C6)trialkylsilyl or benzyl, or

[00014] R1 is an aryl, heteroyl or heterocyclyl group, each of which is mono- or polysubstituted identically or differently by halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, (C1-C6)alkyl, (C3C8)cycloalkyl, (C1-C6)-alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1C6)alkylsulfimino, (C1-C6)alkylsulfimino-(C1-C6)alkyl, (C1C6)alkylsulfimino-(C2-C6)alkylcarbonyl, (C1-C6)alkylsulfoximino, (C1C6)alkylsulfoximino-(C1-C6)alkyl, (C1-C6)alkylsulfoximino-(C2C6)alkylcarbonyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C3C6)trialkylsilyl, (=O) (only in the case of heterocyclyl) or (=O)2 (only in the case of heterocyclyl),

[00015] R2a, R2b, R3 and R4 are, each independently, hydrogen, cyano, halogen, nitro, acetyl, hydroxyl, amino, SCN, tri-(C1-C6)alkylsilyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl-(C3-C8)cycloalkyl, (C1-C6)alkyl-(C3-C8)cycloalkyl, halo(C3-C8)cycloalkyl, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)cyanoalkyl, (C1-C6)hydroxyalkyl, hydroxycarbonyl-(C1-C6)alkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkoxy. Petition 870210086398, of 20 / 09 / 2021, page 7 / 177 4 / 162 (Ci-Cs)alkyl, (C2-C6)alquenyl, (C2-C6)haloalquenyl,(C2C6)cyanoalquenyl, (C2-C6)alquinyl, (C2-C6)haloalquinyl,(C2C6)cyanoalquinyl, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)cyanoalkoxy, (Ci-C6)alkoxycarbonyl-(Ci-C6)alkoxy, (Ci-C6)alkoxy-(Ci-C6)alkoxy,(CiC6)alquilhydroxyimino, (Ci-C6)alkoxyimino, (Ci-C6)alquil-(Ci-C6)alkoxyimino, (Ci-C6)haloalquil-(Ci-C6)alkoxyimino, (Ci-C6)alquiltio, (Ci-C6)haloalquiltio, (Ci-C6)alkoxy-(Ci-C6)alquiltio, (Ci-C6)alquiltio-(Ci-C6)alquil, (CiC6)alquilsulfinyl, (Ci-C6)haloalquilsulfinyl, (Ci-C6)alkoxy-(CiC6)alquilsulfinyl, (Ci-C6)alquilsulfinyl-(Ci-C6)alquil, (Ci-C6)alquilsulfonyl, (Ci-C6)haloalquilsulfonyl, (Ci-C6)alkoxy-(Ci-C6)alquilsulfonyl,(CiC6)alquilsulfonyl-(Ci-C6)alquil, (Ci-C6)alquilsulfonyloxy,(CiC6)alquilcarbonyl, (Ci-C6)alkylaminothiocarbonyl, (Ci-C6)haloalkylcarbonyl, (Ci-C6)alkylaminocarbonyloxy, (Ci-C6)alkoxycarbonyl, (CiC6)haloalkoxycarbonyl, aminocarbonyl, (Ci-C6)alkylaminocarbonyl, (CiC6)alkylaminothiocarbonyl,di(C1-C6)alkylaminocarbonyl, di(C1-C6)alkylaminothiocarbonyl, (C2-C6)alkenylaminocarbonyl, di(C2-C6)alkenylaminocarbonyl, (C3-C8)cycloalkylaminocarbonyl,(C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di(C1-C6)alkylamino, aminosulfonyl, (C1-C6)alkylaminosulfonyl, di(C1-C6)alkylaminosulfonyl, (C1-C6)alkylsulfoximino, aminothiocarbonyl, (C1-C6)alkylaminothiocarbonyl, di(C1-C6)alkylaminothiocarbonyl, (C3-C8)cycloalkylamino,

[00016] is aryl or hetaryl, each of which is mono- or polysubstituted identically or differently, where (in the case of hetaryl) at least one carbonyl group may optionally be present and / or where possible substituents, in each case, are as follows: cyano, carboxyl, halogen, nitro, acetyl, hydroxyl, amino, SCN, tri-(C1-C6)alkylsilyl, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)cyanoalkyl, (C1-C6)hydroxyalkyl, hydroxycarbonyl-(C1-C6)alkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkyl, (C2-C6)alkenyl,(C2C6)haloalkenyl, (C2-C6)cyanoalkenyl, (C2-C6)alkynyl, (C2Petition 870210086398, dated 09 / 20 / 2021, page 8 / 177, 5 / 162 (Cs)haloalquinyla, (C2-C6)cyanoalquinyla, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)cyanoalkoxy, (Ci-C6)alkoxycarbonyl-(Ci-C6)alkoxy, (Ci-C6)alkoxy-(CiC6)alkoxy, (Ci-C6)alquilhydroxyimino, (Ci-C6)alkoxyimino, (Ci-C6)alquil-(CiC6)alkoxyimino, (Ci-C6)haloalquil-(Ci-C6)alkoxyimino, (Ci-C6)alquiltio, (CiC6)haloalquiltio, (Ci-C6)alkoxy-(Ci-C6)alquiltio, (Ci-C6)alquiltio-(CiC6)alquila, (Ci-C6)alquilsulfinyl, (Ci-C6)haloalquilsulfinyl, (Ci-C6)alkoxy(Ci-C6)alquilsulfinyl, (Ci-C6)alquilsulfinyl-(Ci-C6)alquil, (CiC6)alquilsulfonyl, (Ci-C6)haloalquilsulfonyl, (Ci-C6)alkoxy-(CiC6)alquilsulfonyl, (Ci-C6)alquilsulfonyl-(Ci-C6)alquil, (CiC6)alquilsulfonyloxy, (Ci-C6)alquilcarbonyla, (Ci-C6)haloalquilcarbonyla, (CiC6)alquilcarbonyloxy, (Ci-C6)alkoxycarbonyla, (CiC6)haloalkoxycarbonyla, aminocarbonyla, (Ci-C6)alkylaminocarbonyl, di(CiC6)alkylaminocarbonyl, (C2-C6)alquenylaminocarbonyl, di(C2-C6)alquenylaminocarbonyl, (C3-C8)cycloalkylaminocarbonyl, (CiC6)alkylaminocarbonyl,(Ci-C6)alquilamino, di(Ci-C6)alquilamino, aminosulfonyl, (Ci-C6)alquilaminosulfonyl, di(Ci-C6)alquilaminosulfonyl, (CiC6)alquilsulfoximino, aminothiocarbonyl, (Ci-C6)alquilaminothiocarbonyl, di(Ci-C6)alquilaminothiocarbonyl, (C3-C8)cycloalquilamino,

[00017] R5e (Ci-C6)alkyl, (Ci-C6)haloalkyl, (CiC6)cyanoalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)alkoxy-(Ci-C6)alkyl, (CiC6)haloalkoxy-(Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkenyloxy-(Ci-C6)alkyl, (C2-C6)haloalkenyl, (C2-C6)cyanoalkenyl, (C2-C6)alkynyl, (C2-C6)alkynyloxy-(Ci-C6)alkyl, (C2-C6)haloalkynyloxy-(Ci-C6)alkyl, (C2-C6)haloalkyl, (C2C6)cyanoalkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl-(C3C8)cycloalkyl, (Ci-C6)alkyl-(C3-C8)cycloalkyl, halo(C3-C8)cycloalkyl, (Ci-C6)alkylthio-(Ci-C6)alkyl, (Ci-C6)haloalkylthio-(Ci-C6)alkyl, (CiC6)alkylsulfinyl-(Ci-C6)alkyl, (Ci-C6)haloalkylsulfinyl-(Ci-C6)alkyl, (CiC6)alkylsulfonyl-(Ci-C6)alkyl, (Ci-C6)haloalkylsulfonyl-(Ci-C6)alkyl, (Ci-C6)alkoxy-(Ci-C6)alkylthio-(Ci-C6)alkyl, (Ci-C6)alkoxy-(CiPetição 870210086398, dated 09 / 20 / 2021, page 9 / 177 6 / 162 C6)alkylsulfinyl-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkylsulfonyl-(C1C6)alkyl, (C1-C6)alkylcarbonyl-(C1-C6)alkyl, (C1-C6)haloalkylcarbonyl(C1-C6)alkyl, or (C3C8)cycloalkylamino-(C1-C6)alkyl, n is 0, 1 or 2,

[00018] where, in the case where n = 2, the meanings of A3 may be the same or different.

[00019] It was further found that the compounds of Formula (I) have very good efficacy as pesticides, preferably as insecticides and / or acaricides, and furthermore generally have very good compatibility with plants, especially with regard to agricultural plants.

[00020] The compounds of the invention are defined in general terms by Formula (I). Preferred bands or substituents of the radicals given in the Formulas mentioned above and below are illustrated below in this document:

[00021] A1 is preferably nitrogen, =N+-O- or =C-R4,

[00022] A2 is preferably -N-R5, oxygen or sulfur,

[00023] A3 is preferably oxygen, =NH or =N-CN,

[00024] A4 is preferably nitrogen, =N+-O- or =C-R4,

[00025] A5 is preferably nitrogen, =N+-O- or =C-R4,

[00026] R1é preferentially (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)cyanoalkyl, (Ci-C4)alkoxy-(Ci-C4)alkyl, (Ci-C4)haloalkoxy-(Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkenyloxy-(Ci-C4)alkyl, (C2-C4)haloalkenyloxy-(Ci-C4)alkyl, (C2-C4)haloalkenyl, (C2C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)alkynyloxy-(Ci-C4)alkyl, (C2C4)haloalkynyloxy-(Ci-C4)alkyl, (C2-C4)haloalkyl, (C2C4)cyanoalkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl, Petition 870210086398, dated 09 / 20 / 2021, page. 10 / 177 7 / 162 (Ci-C4)alkyl-(C3-Cs)cycloalkyl, halo(C3-C6)cycloalkyl, (CiC4)alkylamino, di(Ci-C4)alkylamino, (C3-C6)cycloalkylamino, (CiC4)alkylcarbonylamino, (Ci-C4)alkylthio-(Ci-C4)alkyl, (CiC4)haloalkylthio-(Ci-C4)alkyl, (Ci-C4)alkylsulfinyl-(Ci-C4)alkyl, (CiC4)haloalkylsulfinyl-(Ci-C4)alkyl, (Ci-C4)alkylsulfonyl-(Ci-C4)alkyl, (CiC4)alkylcarbonyl-(Ci-C4)alkyl, (Ci-C4)haloalkylcarbonyl-(Ci-C4)alkyl, (Ci-C4)alkylsulfonylamino,

[00027] or is (C1-C4)alkyl, (C1-C4)alkoxy, (C2-C4)alkenyl, (C2C4)alkynyl, (C3-C6)cycloalkyl, each of which is optionally mono- or disubstituted identically or differently by aryl, heterocyclyl or heterocyclyl, where aryl, heterocyclyl and heterocyclyl may each optionally be mono- or disubstituted identically or differently by halogen, cyano, carbamoyl, aminosulfonyl, (C1-C4)alkyl, (C3-C4)cycloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)alkylsulfimino, or

[00028] Rié preferably aryl, heteroyl or heterocyclyl, each of which is optionally mono- or disubstituted identically or differently by halogen, cyano, carbamoyl, (C1-C4)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)alkylsulfimino, (C1-C4)alkylsulfoximino, (C1-C4)alkylcarbonyl, (C3-C4)trialkylsilyl, (=O) (only in the case of heterocyclyl) or (=O)2 (only in the case of heterocyclyl),

[00029] R2a, R2b, R3 and R4 are preferably each independently hydrogen, cyano, halogen, nitro, acetyl, hydroxyl, amino, SCN, tri(C1-C4)alkylsilyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C3-C6)cycloalkyl, (C1-C4)alkyl-(C3-C6)cycloalkyl, halo(C3-C6)cycloalkyl, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)cyanoalkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy-(C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2Petition 870210086398, of 20 / 09 / 2021, page 11 / 177 8 / 162 C4)cyanoalquinyl, (C2-C4)alquinyl, (C2-C4)haloalquinyl, (C2C4)cyanoalquinyl, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, (Ci-C4)cyanoalkoxy, (Ci-C4)alkoxy-(Ci-C4)alkoxy, (C1-C4)alquilhidroxyimino, (C1-C4)alkoxyimino, (C1-C4)alkyl-(C1-C4)alkoxyimino, (Ci-C4)haloalquil-(Ci-C4)alkoxyimino, (CiC4)alkylthio, (Ci-C4)haloalkylthio, (Ci-C4)alkylthio-(Ci-C4)alkoxyimino, (CiC4)alkylsulfinyl, (Ci-C4)haloalquilsulfinyl, (Ci-C4)alquilsulfinyl-(CiC4)alquil, (Ci-C4)alquilsulfonyl, (Ci-C4)haloalquilsulfonyl, (CiC4)alquilsulfonyl-(Ci-C4)alquil, (Ci-C4)alquilsulfonyloxy, (CiC4)alquilcarbonyla, (Ci-C4)haloalquilcarbonyla, aminocarbonyla, aminothiocarbonyla, (Ci-C4)alquilaminocarbonyla, di(Ci-C4)alquilaminocarbonyla, (Ci-C4)alquilsulfonylamine, (Ci-C4)alquilamino, di(Ci-C4)alquilamino, aminosulfonyl, (Ci-C4)alquilaminosulfonyla, di(Ci-C4)alquilaminosulfonyla, aminothiocarbonyl,

[00030] is phenyl or heteroyl, each of which is identically or differently mono- or disubstituted, wherein (in the case of heteroyl) at least one carbonyl group may optionally be present and / or wherein possible substituents, in each case, are as follows: cyano, halogen, nitro, acetyl, amino, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)cyanoalkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy-(C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2-C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkynyl, (C2-C4)cyanoalkynyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)cyanoalkoxy, (C1-C4)alkoxy-(C1-C4)alkoxy, (C1-C4)alkylhydroxyimino, (C1-C4)alkoxyimino, (C1-C4)alkyl-(C1-C4)alkoxyimino, (C1-C4)haloalkyl-(C1-C4)alkoxyimino, (C1-C4)alkylthio, (C1-C4)haloalkylthio, (C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)alkylsulfinyl, (C1-C4)haloalkylsulfinyl, (C1-C4)alkylsulfinyl-(C1-C4)alkyl,(C1-C4)alkylsulfonyl, (C1-C4)haloalkylsulfonyl, (C1-C4)alkylsulfonyl-(C1C4)alkyl,(Ci-C4)alquilsulfoniloxy, (Ci-C4)alquilcarbonyla,(CiC4)haloalquilcarbonyla, aminocarbonyla, (Ci-C4)alquilaminocarbonyla, di(Ci-C4)alquilaminocarbonyla, (Ci-C4)alquilsulfonilamino,(CiPetição 870210086398, de 20 / 09 / 2021, pág. 12 / 177, 9 / 162 C4)alquilamino, di(C1-C4)alquilamino, aminosulfonyl, (C1C4)alquilaminosulfonyl, di(C1-C4)alquilaminosulfonyl,

[00031] R5 is preferably (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)cyanoalkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy-(C1-C4)alkyl, (C1-C4)haloalkoxy-(C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkenyloxy-(C1-C4)alkyl, (C2-C4)haloalkenyloxy-(C1-C4)alkyl, (C2-C4)haloalkenyl, (C2-C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)alkynyloxy-(C1-C4)alkyl, (C2-C4)haloalkynyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C3C6)cycloalkyl, (C1-C4)alkyl-(C3-C6)cycloalkyl, halo(C3-C6)cycloalkyl, (C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)haloalkylthio-(C1-C4)alkyl, (C1C4)alkylsulfinyl-(C1-C4)alkyl, (C1-C4)haloalkylsulfinyl-(C1-C4)alkyl, (C1C4)alkylsulfonyl-(C1-C4)alkyl, (C1-C4)haloalkylsulfonyl-(C1-C4)alkyl, (C1-C4)alkoxy-(C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)alkylcarbonyl-(C1C4)alkyl,

[00032] is preferably not 0, 1 or 2,

[00033] where, regardless of the fact that n = 2, the meanings of A3 can be the same or different.

[00034] A1 is more preferably nitrogen or =C-R4,

[00035] A2 is more preferably -N-R5 or oxygen,

[00036] A3 is more preferably oxygen or =NH,

[00037] A4 is more preferably nitrogen or =C-R4,

[00038] A5 is more preferably nitrogen or =C-R4,

[00039] R1 is more preferably (C1-C4)alkyl, (CiC4)haloalkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkynyl, (C3-C6)cycloalkyl, (C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)alkylsulfinyl-(C1-C4)alkyl, (C1-C4)alkylsulfonyl-(C1-C4)alkyl,

[00040] or is (C1-C4)alkyl optionally monosubstituted by phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, pyrazinyl, triazolyl, thiazolyl, tetrazolyl, piperazinyl, tetrahydrofuryl or oxetanyl, where phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, pyrazolyl, triazolyl, thiazolyl, Petition 870210086398, dated 09 / 20 / 2021, page 13 / 177 10 / 162 tetrazolyl, piperazinyl, tetrahydrofuryl or oxetanyl may each optionally be mono- or disubstituted identically or differently with halogen, (C1-C4)alkyl or (C1-C4)haloalkyl, or

[00041] R1 is more preferably phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazyl, pyrazolyl, triazolyl, thiazolyl, tetrazolyl, piperazinyl, tetrahydrofuryl or oxetanyl, each of which is optionally mono- or disubstituted identically or differently by halogen, (C1-C4)alkyl or (C1-C4)haloalkyl,

[00042] R2a is more preferably hydrogen, halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)haloalkylthio, (C1-C4)haloalkylsulfinyl or (C1-C4)haloalkylsulfonyl,

[00043] R2b is more preferably hydrogen or halogen,

[00044] R3 is more preferably hydrogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)haloalkylthio, (C1-C4)haloalkylsulfinyl or (C1-C4)haloalkylsulfonyl,

[00045] R4 is most preferably hydrogen, halogen, cyano or (C1-C3)alkyl,

[00046] R5 is more preferably (C1-C4)alkyl or (C1C4)alkoxy-(C1-C4)alkyl,

[00047] n is most preferably 0, 1 or 2,

[00048] where, in the case where n = 2, the meanings of A3 may be the same or different.

[00049] A1 is even more preferably nitrogen or =C-R4,

[00050] A2 is even more preferably -N-R5 or oxygen,

[00051] A3

[00052] A4

[00053] A5

[00054] R1 is even more preferably oxygen, is even more preferably nitrogen or =CH, is even more preferably nitrogen or =CH, is even more preferably methyl, ethyl, n-propyl, Petition 870210086398, dated 09 / 20 / 2021, page 14 / 177 11 / 162 i-propyl, cyclopropyl, n-butyl, i-butyl, tert-butyl, cyclobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, -(CH2)2-S-C2H5, —\ / O

[00055] -(CH2)2-SO2-C2H5 or ,

[00056] R2a is even more preferably hydrogen, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, trifluoromethylthio, trifluoromethylsulfonyl, trifluoromethylsulfinyl, fluorine or chlorine, R2bé is even more preferably hydrogen, fluorine or chlorine,

[00057] R3 is even more preferably fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, trifluoromethylthio, trifluoromethylsulfonyl or trifluoromethylsulfinyl,

[00058] R4 is even more preferably hydrogen, fluorine, chlorine, bromine or cyano,

[00059] R5 is even more preferably methyl, ethyl, i-propyl, methoxymethyl or methoxyethyl,

[00060] n is even more preferably 0, 1 or 2.

[00061] A1 is specifically nitrogen (N) or =CH,

[00062] A2 is specifically -N-CH3 or oxygen (O),

[00063] A3 is specifically oxygen (O),

[00064] A4 is specifically nitrogen (N) or =CH,

[00065] A5 is specifically =CH,

[00066] R1 is specifically methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, -(CH2)2-S-C2H5,

[00067] -(CH2)2-SO2-C2H5 or

[00068] R2a is specifically hydrogen, trifluoromethyl, fluorine or chlorine, Petition 870210086398, dated 09 / 20 / 2021, p. 15 / 177 12 / 162

[00069] R2b is specifically hydrogen or chlorine.

[00070] R3 is specifically trifluoromethyl,

[00071] n is specifically 0, 1 or 2.

[00072] In a further preferred embodiment, the invention relates to compounds of Formula (IA)

[00073] In a further preferred embodiment, the invention relates to compounds of Formula (IB)

[00074] In a further preferred embodiment, the invention relates to compounds of Formula (IC)

[00075] In a further preferred embodiment, the invention relates to compounds of Formula (ID)

[00076] In a further preferred embodiment, the invention relates to compounds of Formula (IE) R1 CH3 Petition 870210086398, dated 09 / 20 / 2021, p. 16 / 177 13 / 162

[00077] In a further preferred embodiment, the invention relates to compounds of Formula (IF) R1(O)n=s' F3YYY^H-R2a nJ'n VAr· I CH

[00078] In a further preferred embodiment, the invention relates to compounds of Formula (IG)

[00079] In a further preferred embodiment, the invention relates to compounds of Formula (IH)

[00080] In a further preferred embodiment, the invention relates to compounds of Formula (II)

[00081] In a further preferred embodiment, the invention relates to compounds of Formula (IJ) Petition 870210086398, dated 09 / 20 / 2021, p. 17 / 177 14 / 162

[00082] In a further preferred embodiment, the invention relates to compounds of Formula (IK)

[00083] In a further preferred embodiment, the invention relates to compounds of Formula (IL)

[00084] In a further preferred embodiment, the invention relates to compounds of Formula (IM)

[00085] In a further preferred embodiment, the invention relates to compounds of Formula (IN)

[00086] In a further preferred embodiment, the invention relates to compounds of Formula (IO) Petition 870210086398, dated 09 / 20 / 2021, p. 18 / 177 15 / 162

[00087] In a further preferred embodiment, the invention relates to compounds of Formula (IP) R1

[00088] In a further preferred embodiment, the invention relates to compounds of Formula (IQ)

[00089] In a further preferred embodiment, the invention relates to compounds of Formula (IR)

[00090] In a further preferred embodiment, the invention relates to compounds of Formula (IS)

[00091] In a further preferred embodiment, the invention relates to compounds of Formula (IT)

[00092] In a further preferred embodiment, the invention relates to compounds of Formula (IU) Petition 870210086398, dated 09 / 20 / 2021, p. 19 / 177 16 / 162

[00093] In a further preferred embodiment, the invention relates to compounds of Formula (IV)

[00094] In a further preferred embodiment, the invention relates to compounds of Formula (IW)

[00095] In a further preferred embodiment, the invention relates to compounds of Formula (IX)

[00096] In Formulas (IA) to (IX), the radicals R1, R2a, R2b, R3, A1, A2, A3, A4, A5 and n are each as defined above.

[00097] In a further embodiment (Configuration 1), the invention relates to compounds of Formula (I)

[00098] where

[00099] A1 is nitrogen, =N+-O- or =C-R4, [000100] A2 is -N-R5, oxygen or sulfur, [000101] A3 is oxygen, [000102] A4 is nitrogen, =N+-O- or =C-R4, [000103] A5 is =CH, Petition 870210086398, dated 09 / 20 / 2021, page 20 / 177 17 / 162 [000104] R1 e (C1-C6)alkyl, (C1-C6)haloalkyl, (C1C6)cyanoalkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)haloalkoxy-(C1-C6)alkyl, (C2-C6)alkenyl, (C2C6)alkenyloxy-(C1-C6)alkyl, (C2-C6)haloalkenyloxy-(C1-C6)alkyl, (C2-C6)haloalkenyl, (C2-C6)cyanoalkenyl, (C2-C6)alkynyl, (C2C6)alkynyloxy-(C1-C6)alkyl, (C2-C6)haloalkynyloxy-(C1-C6)alkyl, (C2C6)haloalkyl, (C2-C6)cyanoalkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkyl-(C3-C8)cycloalkyl, (C1-C6)alkyl-(C3-C8)cycloalkyl, halo(C3-C8)cycloalkyl, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, (C3-C8)cycloalkylamino, (C1-C6)alkylcarbonylamino, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)haloalkylthio-(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)haloalkylsulfinyl-(C1-C6)alkyl, (C1C6)alkylsulfonyl-(C1-C6)alkyl, (C1-C6)haloalkylsulfonyl-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkylthio-(C1-C6)alkyl, (C1-C6)alkoxy-(C1C6)alkylsulfinyl-(C1-C6)alkyl,(C1-C6)alkoxy-(C1-C6)alkylsulfonyl-(C1C6)alkyl, (C1-C6)alkylcarbonyl-(C1-C6)alkyl, (C1C6)haloalkylcarbonyl-(C1-C6)alkyl, (C1-C6)alkoxycarbonyl-(C1C6)alkyl, (C1-C6)haloalkoxycarbonyl-(C1-C6)alkyl, (C1C6)alkylsulfonylamino, aminosulfonyl-(C1-C6)alkyl, (C1C6)alkylaminossulfonyl-(C1-C6)alkyl, di(C1-C6)alkylaminossulfonyl(C1-C6)alkyl, [000105] or is, in each case, (C1-C6)alkyl, (C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl identically or differently optionally mono- or poly-aryl-, -hetaryl- or -heterocyclyl-substituted, where aryl, heteroyl or heterocyclyl may each independently be mono- or polysubstituted identically or differently by halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, aminosulfonyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfimino, (C1Petition 870210086398, of 09 / 20 / 2021, page 21 / 177 18 / 162 C6)alkylsulphimino-(C1-C6)alkyl, (C1-C6)alkylsulphimino-(C2C6)alkylcarbonyl, (C1-C6)alkylsulfoximino, (C1-C6)alkylsulfoximino(C1-C6)alkyl, (C1-C6)alkylsulfoximino-(C2-C6)alkylcarbonyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C3-C6)trialkylsilyl or benzyl, or [000106] R1 is an aryl, heteroyl or heterocyclyl, each of which is optionally mono- or polysubstituted identically or differently by halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, (C1-C6)alkyl, (C3-C8)cycloalkyl, (C1-C6)-alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfimino, (C1-C6)alkylsulfimino-(C1-C6)alkyl, (C1-C6)alkylsulfimino-(C2-C6)alkylcarbonyl, (C1-C6)alkylsulfoximino, (C1-C6)alkylsulfoximino-(C1-C6)alkyl, (C1C6)alkylsulfoximino-(C2-C6)alkylcarbonyl, (C1-C6)alkoxycarbonyl, (C1C6)alkylcarbonyl, (C3-C6)trialkylsilyl, (=O) (only in the case of heterocyclyl) or (=O)2 (only in the case of heterocyclyl), [000107] R2a, R2b, R3 and R4 are each independently hydrogeneous, cyan, halogenous, nitro, acetylated, hydroxilated, amino, SCN, tri-(CiC6)alkylsilylated, (C3-C8)cycloalquilated, (C3-C8)cycloalquil-(C3-C8)cycloalquila, (Ci-C6)alquil-(C3-C8)cycloalquila, halo(C3-C8)cycloalquila, (Ci-C6)alquila, (Ci-C6)haloalquila, (Ci-C6)cyanoalquila, (Ci-C6)hidroxialquila, hidroxycarbonyl-(Ci-C6)-alkoxy, (Ci-C6)alkoxycarbonyl-(Ci-C6)alquila, (CiC6)alkoxy-(Ci-C6)alkyl, (C2-C6)alquenyl, (C2-C6)haloalquenyl, (C2C6)cyanoalquenyl, (C2-C6)alquinyl, (C2-C6)haloalquinyl, (C2C6)cyanoalquinyl, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)cyanoalkoxy, (Ci-C6)alkoxycarbonyl-(Ci-C6)alkoxy, (Ci-C6)alkoxy-(Ci-C6)alkoxy, (CiC6)alquilhydroxyimino, (Ci-C6)alkoxyimino, (Ci-C6)alquil-(CiC6)alkoxyimino, (Ci-C6)haloalquil-(CiC6)alkoxyimino, (Ci-C6)alquiltio, (Ci-C6)haloalquiltio, (Ci-C6)alkoxy-(Ci-C6)alquiltio, (Ci-C6)alkyltio-(CiC6)alquila, (Ci-C6)alquilsulfinila, (Ci-C6)haloalquilsulfinila,(Ci-C6)alcoxiPetition 870210086398, dated 09 / 20 / 2021, p. 22 / 177, 19 / 162 (Ci-C6)alquilsulfinyl, (Ci-C6)alquilsulfinyl-(Ci-C6)alquil,(CiC6)alquilsulfonyl, (Ci-C6)haloalquilsulfonyl, (Ci-C6)alkoxy-(CiC6)alquilsulfonyl, (Ci-C6)alquilsulfonyl-(Ci-C6)alquil,(CiC6)alquilsulfonyloxy, (Ci-C6)alquilcarbonyla, (Ci-C6)alquiltiocarbonyla, (Ci-C6)haloalquilcarbonyla, (Ci-C6)alquilcarbonyloxy,(CiC6)alkoxycarbonyla, (Ci-C6)haloalkoxycarbonyla, aminocarbonyla, (CiC6)alquilaminocarbonyla, (Ci-C6)alquilaminothiocarbonyl, di(CiC6)alquilaminocarbonyl, di(Ci-C6)alquilaminothiocarbonyl, (C2C6)alquenylaminocarbonyl, di(C2-C6)-alquenylaminocarbonyl, (C3C8)cycloalquilaminocarbonyl, (Ci-C6)alquilsulfonylamino, (CiC6)alquilamino, di(Ci-C6)alquilamino, aminosulfonyl, (CiC6)alquilaminosulfonyla, di(Ci-C6)alquilaminosulfonyla, (CiC6)alquilsulfoximino, aminothiocarbonyl, (Ci-C6)alquilaminothiocarbonyl, di(Ci-C6)alquilaminothiocarbonyl, (C3-C8)cycloalquilamino, NHCO-(CiC6)alquila ((Ci-C6)alkylcarbonylamino), [000108] is aryl or heteroyl, each of which is optionally mono- or polysubstituted identically or differently, wherein (in the case of heteroyl) at least one carbonyl group may optionally be present and / or where possible substituents, in each case, are as follows: cyano, carboxyl, halogen, nitro, acetyl, hydroxyl, amino, SCN, tri-(C1-C6)alkylsilyl, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)cyanoalkyl, (C1-C6)hydroxyalkyl, hydroxycarbonyl-(C1-C6)alkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)haloalkenyl, (C2C6)cyanoalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkynyl, (C2C6)cyanoalkynyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)cyanoalkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkoxy, (C1-C6)alkylhydroxyimino, (C1-C6)alkoxyimino, (C1-C6)alkyl-(C1C6)alkoxyimino, (C1-C6)haloalkyl-(C1-C6)alkoxyimino, (C1-C6)alkylthio, (C1-C6)haloalkylthio, (C1-C6)alkoxy-(C1-C6)alkylthio,(Ci-C6)alkylthio-(CiPetição 870210086398, dated 20 / 09 / 2021, p. 23 / 177, 20 / 162 Cs)alquila, (Ci-C6)alquilsulfinyl, (Ci-C6)haloalquilsulfinyl, (Ci-C6)alkoxy(Ci-C6)alquilsulfinyl, (Ci-C6)alquilsulfinyl-(Ci-C6)alquila,(CiC6)alquilsulfonyl, (Ci-C6)haloalquilsulfonyl, (Ci-C6)alkoxy-(CiC6)alquilsulfonyl, (Ci-C6)alquilsulfonyl-(Ci-C6)alquila,(CiC6)alquilsulfonyloxy, (Ci-C6)alquilcarbonyla, (Ci-C6)haloalquilcarbonyla, (Ci-C6)alquilcarbonyloxy, (Ci-C6)alkoxycarbonyla,(CiC6)haloalkoxycarbonyla, aminocarbonyla, (Ci-C6)alquilaminocarbonyla, di(Ci-C6)alquilaminocarbonyla, (C2-C6)alquenylaminocarbonyla, di(C2C6)-alquenylaminocarbonyla, (C3-C8)cycloalquilaminocarbonyla, (CiC6)alquilsulfonylamine, (Ci-C6)alquilamino, di(Ci-C6)alquilamino, aminosulfonyl, (Ci-C6)alquilaminosulfonyl, di(CiC6)alquilaminosulfonyl, (Ci-C6)alquilsulfoximino, aminothiocarbonyla, (Ci-C6)alquilaminothiocarbonyla, di(Ci-C6)alquilaminothiocarbonyla, (C3C8)cycloalquilamino, [000i09] R5é (Ci-C6)alquila, (Ci-C6)haloalkyl,(CiC6)cyanoalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)alkoxi-(Ci-C6)alkyl,(C6C6)haloalkoxy-(C6C6)alkyl, (C2C6)alkenyl, (C2C6)alkenyloxy-(C6C6)alkyl, (C2C6)haloalkenyloxy-(C6C6)alkyl, (C2C6)haloalkenyl, (C2C6)cyanoalkenyl, (C2C6)alkynyl, (C2C6)alkynyloxy-(C6C6)alkyl, (C2C6)haloalkynyloxy-(C6C6)alkyl, (C2C6)haloalkynyl, (C2C6)cyanoalkynyl, (C3C8)cycloalkyl, (C3C8)cycloalkyl-(C3C8)cycloalkyl, (C6C6)alkyl-(C3C8)cycloalkyl, halo(C3-C8)cycloalkyl, (Ci-C6)alkylthio-(Ci-C6)alkyl, (Ci-C6)haloalkylthio-(Ci-C6)alkyl, (CiC6)alkylsulfinyl-(Ci-C6)alkyl, (Ci-C6)haloalkylsulfinyl-(Ci-C6)alkyl, (Ci-C6)alkylsulfonyl-(Ci-C6)alkyl, (Ci-C6)haloalkylsulfonyl-(CiC6)alkyl, (Ci-C6)alkoxy-(Ci-C6)alkylthio-(Ci-C6)alkyl, (Ci-C6)alkoxy(Ci-C6)alkylsulfinyl-(Ci-C6)alkyl, (Ci-C6)alkoxy-(Ci-C6)alkylsulfonyl(Ci-C6)alkyl, (Ci-C6)alkylcarbonyl-(Ci-C6)alkyl, (CiC6)haloalkylcarbonyl-(Ci-C6)alkyl, (Ci-C6)alkoxycarbonyl-(CiC6)alkyl, (Ci-C6)haloalkoxycarbonyl-(Ci-C6)alkyl, aminocarbonyl-(CiPetição 870210086398,from 20 / 09 / 2021, page 24 / 177, 21 / 162 Cs)alkyl, (C1-C6)alkylamino-(C1-C6)alkyl, di(C1-C6)alkylamino-(C1C6)alkyl or (C3-C8)cycloalkylamino-(C1-C6)alkyl, n is 0, i or 2. [000ii0] Preference (Configuration 2) is given to compounds of Formula (I) wherein [000iii] Ai is nitrogen, =N+-O- or =C-R4, [000ii2] A2 is -N-R5, oxygen or sulfur, [000ii3] A3 is oxygen, [000ii4] A4 is nitrogen, =N+-O- or =C-R4, [000ii5] A5 is =CH, [000ii6] Ri is (C1-C4)alkyl, (C1-C4)hydroxyalkyl, (C1- C4)haloalkyl, (Ci-C4)cyanoalkyl, (Ci-C4)alkoxy-(Ci-C4)alkyl, (Ci-C4)haloalkoxy-(Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkenyloxy(Ci-C4)alkyl, (C2-C4)haloalkenyloxy-(Ci-C4)alkyl, (C2-C4)haloalkenyl, (C2-C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)alkynyloxy-(Ci-C4)alkyl, (C2-C4)haloalkynyloxy-(Ci-C4)alkyl, (C2-C4)haloalkynyl, (C2-C4)cyanoalkynyl, (C3-C6)cycloalkyl,(C3C6)cycloalkyl(C3-C6)cycloalkyl, (Ci-C4)alkyl-(C3-C6)cycloalkyl,halo(C3-C6)cycloalkyl, (Ci-C4)alkylamino, di(Ci-C4)alkylamino,(C3C6)cycloalkylamino, (Ci-C4)alkylcarbonylamino, (Ci-C4)alkylthio-(CiC4)alkyl, (Ci-C4)haloalkylthio-(Ci-C4)alkyl, (Ci-C4)alkylsulfinyl-(CiC4)alkyl, (Ci-C4)haloalkylsulfinyl-(Ci-C4)alkyl, (Ci-C4)alkylsulfonyl(Ci-C4)alkyl, (Ci-C4)alkylcarbonyl-(Ci-C4)alkyl,(Ci-C4)haloalkylcarbonyl-(Ci-C4)alkyl, (Ci-C4)alkylsulfonylamino, [000ii7] or (Ci-C4)alkyl, (Ci-C4)alkoxy, (C2-C4)alkenyl, (C2C4)alkynyl, (C3-C6)cycloalkyl,each of which is optionally mono- or disubstituted identically or differently by aryl, heterocyclyl or heterocyclyl, where aryl, heterocyclyl and heterocyclyl may each optionally be mono- or disubstituted identically or differently by halogen, cyano, carbamoyl, aminosulfonyl, (CiPetition 870210086398, of 09 / 20 / 2021, page 25 / 177, 22 / 162 or [000118] R1 is an aryl, heteroyl or heterocyclyl, each of which is optionally mono- or disubstituted identically or differently by halogen, cyano, carbamoyl, (C1-C4)alkyl, (C3C6)cycloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)alkylsulfimino, (C1-C4)alkylsulfoximino, (C1-C4)alkylcarbonyl, (C3C4)trialkylsilyl, (=O) (only in the case of heterocyclyl) or (=O)2 (only in the case of heterocyclyl), [000119] R2a, R2b, R3e R4são, cada um, independently hidrogênio, ciano, halogênio, nitro, acetila, hidroxila, amino, SCN, tri-(CiC4)alquilsila, (C3-C6)cicloalquila, (C3-C6)cicloalquila, (Ci-C4)alquil-(C3-C6)cicloalquila, halo(C3-C6)cicloalquila, (Ci-C4)alquila, (Ci-C4)haloalquila, (Ci-C4)cianoalquila, (Ci-C4)hidroxialquila, (CiC4)alcoxi-(Ci-C4)alquila, (C2-C4)alquenila, (C2-C4)haloalquenyla, (C2C4)cyanoalquenyla, (C2-C4)alquinyla, (C2-C4)haloalquinyla, (C2C4)cyanoalquinyla, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, (Ci-C4)cyanoalkoxy, (Ci-C4)alkoxy-(Ci-C4)alkoxy, (Ci-C4)alkylhidroxyimino, (CiC4)alkoxyimino, (Ci-C4)alquil-(Ci-C4)alkoxyimino, (Ci-C4)haloalquil-(CiC4)alkoxyimino, (Ci-C4)alkylthio, (Ci-C4)haloalkylthio, (Ci-C4)alkylthio(Ci-C4)alkoxyimino, (Ci-C4)alkylsulphinyl, (Ci-C4)haloalquilsulfonyl, (CiC4)alquilsulfonyl-(Ci-C4)alquila, (Ci-C4)alquilsulfonyl, (CiC4)haloalquilsulfonyl, (Ci-C4)alquilsulfonyl-(Ci-C4)alquila, (CiC4)alquilsulfonyloxy,(Ci-C4)alquilcarbonyla, (Ci-C4)haloalquilcarbonyla, aminocarbonyla, aminothiocarbonyla, (Ci-C4)alquilaminocarbonyla, di(CiC4)alquilaminocarbonyla, (Ci-C4)alquilsulfonylamine, (Ci-C4)alquilamino, di(Ci-C4)alquilamino, aminosulfonyl, (Ci-C4)alquilaminosulfonyl, di(Ci-C4)alquilaminosulfonyl, aminothiocarbonyla, NHCO-(Ci-C4)alquil, Petition 870210086398, 09 / 20 / 2021, pág. 26 / 177 23 / 162 ((Ci-C4)alquilcarbonylamino), [000120] is phenyl or heteroyl, each of which is identically or differently mono- or disubstituted, wherein (in the case of heteroyl) at least one carbonyl group may optionally be present and / or wherein possible substituents, in each case, are as follows: cyano, halogen, nitro, acetyl, amino, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)cyanoalkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy(C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkynyl, (C2C4)cyanoalkynyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)cyanoalkoxy, (C1-C4)alkoxy-(C1-C4)alkoxy, (C1-C4)alkylhydroxyimino,(C1C4)alkoxyimino, (C1-C4)alkyl-(C1-C4)alkoxyimino, (C1-C4)haloalkyl-(C1C4)alkoxyimino, (C1-C4)alkylthio, (C1-C4)haloalkylthio, (C1-C4)alkylthio(C1-C4)alkyl, (C1-C4)alkylsulfinyl, (C1-C4)haloalkylsulfinyl, (C1C4)alkylsulfinyl-(C1-C4)alkyl, (C1-C4)alkylsulfonyl, (C1C4)haloalkylsulfonyl, (C1-C4)alkylsulfonyl-(C1-C4)alkyl,(C1C4)alkylsulfonyloxy, (C1-C4)alkylcarbonyl, (C1-C4)haloalkylcarbonyl, aminocarbonyl, (C1-C4)alkylaminocarbonyl, di(C1C4)alkylaminocarbonyl, (C1-C4)alkylsulfonylamino, (C1-C4)alkylamino, di(C1-C4)alkylamino, aminossulfonyl, (C1-C4)alkylaminossulfonyl, di(C1-C4)alkylaminossulfonyl, [000121] R5 e (C1-C4)alkyl, (C1-C4)haloalkyl, (C1C4)cyanoalkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy-(C1-C4)alkyl, (C1C4)haloalkoxy-(C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkenyloxy-(C1C4)alkyl, (C2-C4)haloalkenyloxy-(C1-C4)alkyl, (C2-C4)haloalkenyl, (C2-C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)alkynyloxy-(C1C4)alkyl, (C2-C4)haloalkynyl, (C3-C6)cycloalkyl, (C3C6)cycloalkyl-(C3-C6)cycloalkyl, (C1-C4)alkyl-(C3-C6)cycloalkyl, halo(C3-C6)cycloalkyl, (C1-C4)alkylthio-(C1-C4)alkyl, (C1C4)haloalkylthio-(C1-C4)alkyl, (C1-C4)alkylsulfinyl-(C1-C4)alkyl, Petition 870210086398, dated 09 / 20 / 2021, page. 27 / 177 24 / 162 (C1-C4)haloalkylsulfinyl-(C1-C4)alkyl, (C1-C4)alkylsulfonyl-(C1C4)alkyl, (C1-C4)haloalkylsulfonyl-(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)alkylcarbonyl-(C1-C4)alkyl, [000122]n is 0, 1 or 2. [000123] Particular preference (Configuration 3) is given to compounds of Formula (I) wherein [000124] A1 is nitrogen or =C-R4, [000125] A2 is -N-R5 or oxygen, [000126] A3 is oxygen, [000127] A4 is nitrogen or =C-R4, [000128] A5 is =CH, [000129] R1 is (C1-C4)alkyl, (C1-C4)hydroxyalkyl, (C1- C4)haloalkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkynyl, (C3-C6)cycloalkyl, (C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)alkylsulfinyl-(C1-C4)alkyl, (C1-C4)alkylsulfonyl-(C1-C4)alkyl, [000130] or is (C1-C4)alkyl optionally monosubstituted by phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, pyrazolyl, triazolyl, thiazolyl, tetrazolyl, piperazinyl, tetrahydrofuryl or oxetanyl, where phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, pyrazolyl, triazolyl, thiazolyl, tetrazolyl, piperazinyl, tetrahydrofurila ou oxetanila podem, cada uma, opcionalmente ser mono- ou dissubstituídas identicamente ou diferentemente por halogênio, (C1-C4)alquila ou (C1-C4)haloalquila, ou [000131] R1é phenyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, pyrazolyl, triazolyl, thiazolyl, tetrazolyl, piperazinyl, tetrahydrofuryl ou oxetanyl,each of which is optionally mono- or disubstituted identically or differently by halogen, (C1-C4)alkyl or (C1-C4)haloalkyl, [000132] R2a is hydrogen, cyano, aminocarbonyl, halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)haloalkylthio, (C1Petition 870210086398, dated 09 / 20 / 2021, page 28 / 177 25 / 162 C4)haloalkylsulfinyl or (Ci-C4)haloalkylsulfonyl, [000133] R2bé hydrogen, (Ci-C4)alkoxy, (Ci-C4)haloalkyl, NHCO-(C1-C4)alkyl or halogen, [000134] R3 is hydrogen, halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)haloalkylthio, (C1-C4)haloalkylsulfinyl, (C1-C4)haloalkylsulfonyl, or is phenyl, pyrazolyl or imidazolyl, each of which is optionally monosubstituted by trifluoromethyl, [000135] R4 is hydrogen, halogen, cyano or (C1-C3)alkyl, [000136] R5 is (C1-C4)alkyl or (C1-C4)alkoxy-(C1-C4)alkyl, [000137] n is 0, 1 or 2. [000138] Very particular preference (Configuration 4) is given to compounds of Formula (I) wherein [000139] A1 is nitrogen or =C-R4, [000140] A2 is -N-R5 or oxygen, [000141] A3 is oxygen, [000142] A4 is nitrogen or =CH, [000143] A5 is =CH, [000144] R1 is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n- butyl, i-butyl, tert-butyl, cyclobutyl, hydroxyethyl (-CH2-CH2-OH), fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, -(CH2)2-S-C2H5, [000145] -(CH2)2-SO2-C2H5 or [000146] R2a is hydrogen, cyano, aminocarbonyl (CONH2), fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, trifluoromethoxy, difluorochloromethoxy, dichlorofluoromethoxy, trifluoromethylthio, trifluoromethylsulfonyl, trifluoromethylsulfinyl, fluorine or chlorine, Petition 870210086398, dated 09 / 20 / 2021, page 29 / 177 26 / 162 [000147] R2b is hydrogen, methoxy, ethoxy, trifluoromethyl, methylcarbonylamino (NHCO-methyl), fluorine or chlorine, [000148] R3 is fluorine, chlorine, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, trifluoromethoxy, difluorochloromethoxy, dichlorofluoromethoxy, trifluoromethylsulfonyl, trifluoromethylsulfinyl, or is phenyl, pyrazol-1-yl or imidazol-1-yl, each of which is optionally monosubstituted by trifluoromethyl, [000149] R4 is hydrogen, fluorine, chlorine, bromine or cyano, R5 is methyl, ethyl, i-propyl, methoxymethyl or methoxyethyl, [000150] n is 0, 1 or 2. [000151] Emphasis (Configuration 5) is given to compounds of Formula (I) where [000152]A1 [000153]A2 [000154]A3 [000155]A4 [000156]A5 [000157]R1 is nitrogen (N) or =CH, is -N-CH3 or oxygen (O), is oxygen (O), is nitrogen (N) or =CH, is =CH, is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl, tert-butyl, cyclobutyl, hydroxyethyl (-CH2-CH2-OH), fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, -(CH2)2-S-C2H5, [000158] -(CH2)2-SO2-C2H5 or (oxetan-3-ila), [000159] R2a is hydrogen, cyano, aminocarbonyl (CONH2), fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluororoethyl, tetrafluoroethyl, pentafluoroethyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulfonyl, trifluoromethylsulfinyl, fluorine or chlorine, [000160] R2b is hydrogen, methoxy, ethoxy, trifluoromethyl, methylcarbonylamino (NHCO-methyl), fluorine or chlorine, Petition 870210086398, dated 09 / 20 / 2021, page 30 / 177 27 / 162 [000161] R3 is fluorine, chlorine, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, trifluoromethoxy, trifluoromethylthio, trifluoromethylsulfonyl, trifluoromeN D NN tilsulfinyl, or is phenyl,1(pyrazol-1-yl) or1(imidazol-1-yl), each of which is optionally monosubstituted by trifluoromethyl, [000162] n is 0, 1 or 2. [000163] Particular emphasis (Configuration 6) is given to compounds of Formula (I) in which [000164] A1 is nitrogen (N) or =CH, [000165] A2 is -N-CH3 or oxygen (O), [000166] A3 is oxygen (O), [000167] A4 is nitrogen (N) or =CH, [000168] A5 is =CH, [000169] R1 is methyl, ethyl, n-propyl, i-propyl, trifluoromethyl, - CH2-CH2-F, -CH2-CH2-OH, [000170] -(CH2)2-S-C2H5, -(CH2)2-SO2-C2H5 or [000171] R2a is hydrogen, trifluoromethyl, cyano, CONH2, fluorine or chlorine, [000172] R2b is hydrogen, chlorine, trifluoromethyl, methoxy or NHCOCH3, [000173] R3 is pentafluoroethyl, trifluoromethyl, chloro, 4CF3(C6H4), 4-(CF3)pyrazol-1-yl, [000174] 3-(CF3)pyrazol-1-yl or 4-(CF3)imidazol-1-yl, [000175] n is 0, 1 or 2. [000176] In a further preferred embodiment, the invention relates to the compounds of Formula (I) where R1, R2a, R3, A1, A2, A3, A4, A5 en are, each one, as defined above, especially as defined in Configuration (1) or Configuration (2) or Configuration (3) or Petition 870210086398, dated 09 / 20 / 2021, page 31 / 177 28 / 162 Configuration (4) or Configuration (5) or Configuration (6), and [000177] R2b is acetyl, amino, SCN, tri-(C1-C6)alkylsilyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl-(C3-C8)cycloalkyl, (C1-C6)alkyl(C3-C8)cycloalkyl (where the linkage is via the cycloalkyl substituted by alkyl), halo(C3-C8)cycloalkyl, (C2-C6)alkenyl, (C2-C6)haloalkenyl, (C2-C6)cyanoalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkynyl, (C2-C6)cyanoalkynyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkoxy, (C1-C6)alkoxy-(C1C6)alkoxy, (C1-C6)alkylhydroxyimino, (C1-C6)alkoxyimino, (C1-C6)alkyl(C1-C6)alkoxyimino, (C1-C6)haloalkyl-(C1-C6)alkoxyimino, (C1C6)alkylthio, (C1-C6)haloalkylthio, (C1-C6)alkoxy-(C1-C6)alkylthio, (C1C6)alkylsulfinyl, (C1-C6)haloalkylsulfinyl, (C1-C6)alkoxy-(C1C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, (C1-C6)haloalkylsulfonyl, (C1-C6)alkoxy-(C1-C6)alkylsulfonyl, (C1-C6)alkylsulfonyloxy, (C1C6)alkylcarbonyl, (C1-C6)alkylthiocarbonyl,(C1C6)haloalkylcarbonyl,(C1-C6)alkylcarbonyloxy, (C1C6)alkoxycarbonyl, (C1-C6)haloalkoxycarbonyl, aminocarbonyl, (C1C6)alkylaminocarbonyl, (C1-C6)alkylaminothiocarbonyl, di-(C1C6)alkylaminocarbonyl, di-(C1-C6)alkylaminothiocarbonyl, (C2C6)alkenylaminocarbonyl, di-(C2-C6)-alkenylaminocarbonyl, (C3C8)cycloalkylaminocarbonyl, (C1-C6)alkylsulfonylamino, (C1C6)alkylamino, di-(C1-C6)alkylamino, aminosulfonyl, (C1C6)alkylaminossulfonyl, di-(C1-C6)alkylaminossulfonyl, (C1C6)alkylsulfoximino, aminothiocarbonyl, (C1C6)alkylaminothiocarbonyl, di-(C1-C6)alkylaminothiocarbonyl, (C3C8)cycloalkylamino, NHCO-(C1-C6)alkyla((C1C6)alkylcarbonylamino), [000178] is, in each case, hetaryl optionally individually or multiply, identically or differently substituted, where at least one carbonyl group may optionally be present e / ou, Petition 870210086398, dated 09 / 20 / 2021, page. 32 / 177 29 / 162 where substituents are possible, in each case, as follows: cyano, carboxyl, halogenium, nitro, acetyle, hydroxyl, amino, SCN, tri-(C1C6)alkylsilyl, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)cyanoalkyl, (C1-C6)hydroxyalkyl, hydroxycarbonyl-(C1-C6)-alkoxy, (C1C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkyl, (C2C6)alkenyl, (C2-C6)haloalkenyl, (C2-C6)cyanoalkenyl, (C2C6)alkynyla, (C2-C6)haloalkynyla, (C2-C6)cyanoalkynyl, (C1C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)cyanoalkoxy, (C1C6)alkoxycarbonyl-(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkoxy, (C1C6)alkylhydroxyimino, (C1-C6)alkoxyimino, (C1-C6)alkyl-(C1C6)alkoxyimino, (C1-C6)haloalkyl-(C1-C6)alkoxyimino, (C1-C6)alkylthio, (C1-C6)haloalkylthio, (C1-C6)alkoxy-(C1-C6)alkylthio, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl, (C1-C6)haloalkylsulfinyl, (C1C6)alkoxy-(C1-C6)alkylsulfinyl, (C1-C6)alkylsulfinyl-(C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C1-C6)haloalkylsulfonyl,(C1-C6)alkoxy-(C1C6)alkylsulfonyl, (C1-C6)alkylsulfonyl-(C1-C6)alkyl, (C1C6)alkylsulfonyloxy, (C1-C6)alkylcarbonyl, (C1-C6)haloalkylcarbonyl, (C1-C6)alkylcarbonyloxy, (C1-C6)alkoxycarbonyl, (C1-C6)haloalkoxycarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, di-(C1-C6)alkylaminocarbonyl, (C2-C6)alkenylaminocarbonyl, di-(C2C6)alkenylaminocarbonyl, (C3-C8)cycloalkylaminocarbonyl, (C1C6)alkylsulfonylamino, (C1-C6)alkylamino, di-(C1-C6)alkylamino, aminosulfonyl, (C1-C6)alkylaminosulfonyl, di-(C1C6)alkylaminosulfonyl, (C1-C6)alkylsulfoximino, aminothiocarbonyl, (C1-C6)alkylaminothiocarbonyl, di-(C1-C6)alkylaminothiocarbonyl, (C3C8)cycloalkylamino., [000179] In a further preferred embodiment, the invention relates to the compounds of Formula (I) where R1, R2a, R3, A1, A2, A3, A4, A5 and are each as defined above, especially as defined in Configuration (1) or Configuration (2) or Configuration (3) or Configuration Petition 870210086398, dated 09 / 20 / 2021, page 33 / 177 30 / 162 ration (4) or Configuration (5) or Configuration (6), and [000180] R2bé acetylate, amino, SCN, tri-(C1-C4)alkylsilyl, (C3C6)cycloalkyl, (C3-C6)cycloalkyl-(C3-C6)cycloalkyl, (C1-C4)alkyl(C3C6)cycloalkyl (where the ligation is via the cycloalkyl substituted by alkyl), halo(C3-C6)cycloalkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2C4)cyanoalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkynyl, (C2C4)cyanoalkynyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)alkoxy-(C1C4)alkoxy, (C1-C4)alkylhydroxyimino, (C1-C4)alkoxyimino, (C1-C4)alkyl(C1-C4)alkoxyimino, (C1-C4)haloalkyl-(C1-C4)alkoxyimino, (C1-C4)alkylthio, (C1-C4)haloalkylthio, (C1-C4)alkylsulfinyl, (C1-C4)haloalkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)haloalkylsulfonyl, (C1-C4)alkylsulfonyloxy, (C1-C4)alkylcarbonyl, (C1-C4)haloalkylcarbonyl, aminocarbonyl, (C1-C4)alkylaminocarbonyl, di(C1-C4)alkylaminocarbonyl, (C1-C4)alkylsulfonylamino, (C1-C4)alkylamino, di-(C1-C4)alkylaminocarbonyl, aminosulfonylamino, (C1C4)alkylaminosulfonyl, di-(C1-C4)alkylaminosulfonyl,aminothiocarbonyl, NHCO-(C1-C4)alkyl ((C1-C4)alkylcarbonylamino), [000181] is, in each case, individually or doubly substituted heteroyl, identically or differentially substituted, wherein at least one carbonyl group may optionally be present and / or wherein possible substituents, in each case, are as follows: cyano, halogen, nitro, acetyl, amino, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)cyanoalkyl, (C1-C4)hydroxyalkyl, (C1-C4)alkoxy-(C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)haloalkenyl, (C2-C4)cyanoalkenyl, (C2C4)alkynyl, (C2-C4)haloalkynyl, (C2-C4)cyanoalkynyl, (C1C4)alkoxy, (C1-C4)haloalkoxy, (C1-C4)cyanoalkoxy, (C1-C4)alkoxy-(C1C4)alkoxy, (C1-C4)alkylhydroxyimino, (C1-C4)alkoxyimino, (C1C4)alkyl-(C1-C4)alkoxyimino, (C1-C4)haloalkyl-(C1-C4)alkoxyimino, (C1-C4)alkylthio, (C1-C4)haloalkylthio, (C1-C4)alkylthio-(C1-C4)alkyl, (C1-C4)alkylsulfinyl, (C1-C4)haloalkylsulfinyl, (C1-C4)alkylsulfinylPetition 870210086398, of 09 / 20 / 2021, p. 34 / 177 31 / 162 (C1-C4)alkyl, (C1-C4)alkylsulfonyl, (C1-C4)haloalkylsulfonyl, (C1C4)alkylsulfonyl-(C1-C4)alkyl, (C1-C4)alkylsulfonyloxy, (C1C4)alkylcarbonyl, (C1-C4)haloalkylcarbonyl, aminocarbonyl, (C1C4)alkylaminocarbonyl, di-(C1-C4)alkylaminocarbonyl, (C1C4)alkylsulfonylamino, (C1-C4)alkylamino, di-(C1-C4)alkylamino, aminosulfonyl, (C1-C4)alkylaminosulfonyl, di-(C1C4)alkylaminosulfonyl. [000182] In a further preferred embodiment, the invention relates to the compounds of Formula (I) where R1, R2a, R3, A1, A2, A3, A4, A5 and are each as defined above, especially as defined in Configuration (1) or Configuration (2) or Configuration (3) or Configuration (4) or Configuration (5) or Configuration (6), and [000183] R2b is (C1-C4)alkoxy or NHCO-(C1-C4)alkyl. [000184] In a further preferred embodiment, the invention relates to the compounds of Formula (I) where R1, R2a, R3, A1, A2, A3, A4, A5 and are each as defined above, especially as defined in Configuration (1) or Configuration (2) or Configuration (3) or Configuration (4) or Configuration (5) or Configuration (6), and [000185] R2b is methoxy, ethoxy or NHCO-methyl. [000186] In a further preferred embodiment, the invention relates to the compounds of Formula (I) where R1, R2a, R3, A1, A2, A3, A4, A5 and are each as defined above, especially as defined in Configuration (1) or Configuration (2) or Configuration (3) or Configuration (4) or Configuration (5) or Configuration (6), and [000187] R2bé methoxy or NHCO-methyl. [000188] R2bé joined in position 3 or 5: Petition 870210086398, dated 09 / 20 / 2021, p. 35 / 177 32 / 162 [000189] In preferred settings, unless otherwise indicated, [000190] halogen is selected from the group of fluorine, chlorine, bromine and iodine, preferably, in turn, from the group of fluorine, chlorine and bromine, [000191] aryl (including as part of a larger unit, for example, arylalkyl) is selected from the phenyl, naphthyl, anthryl, phenanthrenyl group, and is preferably in turn phenyl, [000192] hetaryl (synonymous with heteroaryl, including as part of a larger unit, for example, hetarylalkyl) is selected from the group of furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5triazinyl, benzofuryl, benzisofuryl, benzothienyl, benzisothienyl, indolyl, isoindolyl, indazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, 2,1,3-benzoxadiazole, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, benzotriazinyl, purinyl, pteridinyl and indolizinyl, [000193] heterocyclyl is a saturated ring of 4, 5, or 6 members containing 1 or 2 nitrogen atoms and / or an oxygen atom and / or a sulfur atom, for example, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, thietanyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl and thiomorpholinyl. [000194] In the particularly preferred definitions, unless otherwise indicated, [000195] halogen is selected from the group of fluorine, chlorine, bromine and iodine, preferably, in turn, from the group of fluorine, Petition 870210086398, dated 09 / 20 / 2021, p. 36 / 177 33 / 162 chlorine and bromine, [000196] aryl (including as part of a larger unit, for example, arylalkyl) is selected from the phenyl, naphthyl, anthryl, phenanthrenyl group, and is preferably in turn phenyl, [000197] Hetaryl (including as part of a larger unit, for example, hetarylalkyl) is selected from the pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl and tetrazolyl groups. [000198] heterocyclyl is selected from the oxetanyl, tetrahydrofuryl and piperazinyl group. [000199] In the context of the present invention, unless defined differently elsewhere, the term “alkyl”, by itself or also in combination with additional terms, for example, haloalkyl, is understood to mean a radical of a saturated aliphatic hydrocarbon group having 1 to 12 carbon atoms and may be branched or unbranched. Examples of C1-C12-alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, hexyl, n-heptyl, n-octyl, n-nonyl, ndecyl, n-undecyl and n-dodecyl. Among these alkyl radicals, particular preference is given to C1-C6-alkyl radicals. Special preference is given to C1-C4-alkyl radicals. [000200] According to the invention, unless defined differently elsewhere, the term “alkenyl”, by itself or also in combination with additional terms, is understood to mean a linear or branched chain C2-C12-alkenyl radical having at least one double bond, for example, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5 Petition 870210086398, dated 09 / 20 / 2021, p. 37 / 177 34 / 162 hexenyl and 1,4-hexadienyl. Among these, preference is given to C2-C6-alkenyl radicals and particular preference to C2-C4-alkenyl radicals. [000201] According to the invention, unless defined differently elsewhere, the term "alkynyl," by itself or also in combination with additional terms, is understood to mean a linear or branched chain C2-C12-alkynyl radical having at least one triple bond, for example, ethinyl, 1-propynyl, and propargyl. Among these, preference is given to C3-C6-alkynyl radicals and particular preference to C3-C4-alkynyl radicals. The alkynyl radical may also contain at least one double bond. [000202] According to the invention, unless defined differently elsewhere, the term "cycloalkyl", by itself or also in combination with additional terms, is understood to mean a C3-C8-cycloalkyl radical, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Among these, preference is given to C3-C6-cycloalkyl radicals. The term "alkoxy," by itself or also in combination with additional terms, for example, haloalkoxy, is understood to mean an O-alkyl radical, where the term "alkyl" is as defined above. [000203] Halogen-substituted radicals, for example, haloalkyl, are mono- or polyhalogenated, up to the maximum number of possible substituents. In the case of polyhalogenation, the halogen atoms may be identical or different. In this case, halogen is fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine. [000204] Unless otherwise indicated, optionally substituted radicals may be mono- or polysubstituted, wherein the substituents in the case of polysubstitution may be the same or different. [000205] The definitions of radical or elucidations given above in Petition 870210086398, dated 09 / 20 / 2021, page 38 / 177 35 / 162 general terms or within preferred areas apply to final products and correspondingly to starting and intermediate materials. These radical definitions may be combined with one another as desired, i.e., including combinations between the respective preferred ranges. [000206] Preference is given according to the invention to use compounds of Formula (I) where a combination of the definitions listed above as preferred is present. [000207] Particular preference is given according to the invention to use compounds of Formula (I) where a combination of the definitions listed above as particularly preferred is present. [000208] Very particular preference is given according to the invention to use compounds of Formula (I) where a combination of the definitions listed above as very particularly preferred is present. [000209] Emphasis is given in accordance with the invention to using compounds of Formula (I) where a combination of the definitions listed above as specific is present. [000210] Particular emphasis is given according to the invention to using compounds of Formula (I) where a combination of the definitions listed above as very specific is present. [000211] Depending on the nature of the substituents, the compounds of Formula (I) may be in the form of mixtures of geometric and / or optically active isomers or corresponding isomeric mixtures in different compositions. These stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. The invention thus encompasses pure stereoisomers and any desired mixtures of these isomers. [000212] The compounds of the invention of Formula (I) can be obtained by the processes shown in the following schemes: Petition 870210086398, dated 09 / 20 / 2021, page 39 / 177 36 / 162 Process A (II) b) (I) [000213] The R1, R2a, R2b, R3, A1, A2, A3, A4, A5 and n radicals are each as defined above. [000214] Step a) [000215] The compounds of Formula (IV) can be prepared analogously to the process described in document US5576335 by reacting compounds of Formula (II) with carboxylic acids of Formula (III) in the presence of a condensing agent. [000216] The compounds of Formula (II) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in document US2003 / 69257 or document WO2006 / 65703. [000217] Carboxylic acids of Formula (III) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in document US2010 / 234604, document WO2012 / 61926 or Bioorganic and Medicinal Chemistry Letters, 18 (2008), 5023-5026. [000218] The reaction of compounds of Formula (II) with carboxylic acids of Formula (III) can be carried out with them in pure form or in Petition 870210086398, dated 09 / 20 / 2021, page 40 / 177 37 / 162 a solvent, preference being given to conducting the reaction in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000219] Suitable condensing agents are, for example, carbodiimides such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or 1,3-dicyclohexylcarbodiimide. [000220] The reaction can be carried out under reduced pressure, standard pressure or high pressure and at temperatures from 0 to 180 °C, preference being given to carrying out the reaction at standard pressure and temperatures from 20 to 140 °C. Step b) [000221] The compounds of Formula (I) can be prepared by condensation of the compounds of Formula (IV), for example, in a manner analogous to the processes described in document WO2012 / 86848. [000222] The conversion to the compounds of Formula (I) may be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from the usual solvents which are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; Petition 870210086398, dated 09 / 20 / 2021, page 41 / 177 38 / 162 nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000223] The reaction can be carried out in the presence of a condensing agent, an acid, a base, or a chlorinating agent. [000224] Examples of suitable condensing agents are carbodiimides such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or 1,3-dicyclohexylcarbodiimide; anhydrides such as acetic anhydride, trifluoroacetic anhydride; a mixture of triphenylphosphine, a base and carbon tetrachloride, or a mixture of triphenylphosphine and an azo diester, for example, diethylazodicarboxylic acid. [000225] Examples of suitable acids that can be used in the reaction described are sulfonic acids such as paratoluenesulfonic acid; carboxylic acids such as acetic acid, or polyphosphoric acids. [000226] Examples of suitable bases are nitrogen heterocycles such as pyridine, picoline, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]7-undecene (DBU); tertiary amines such as triethylamine and N,N-diisopropylethylamine; inorganic bases such as potassium phosphate, potassium carbonate and sodium hydride. [000227] An example of a suitable chlorinating agent is phosphorus oxychloride. [000228] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 200 °C. Process B Petition 870210086398, dated 09 / 20 / 2021, page 42 / 177 39 / 162 (II) + (V) (IV) b) (I) [000229] The R1, R2a, R2b, R3, A1, A2, A3, A4, A5 and n radicals are each as defined above. [000230] Step a) [000231] In a further embodiment of the invention, the compounds of Formula (IV) can be prepared by reacting compounds of Formula (II) with carbonyl chlorides of Formula (V) in the presence of a condensing agent. [000232] Carbonyl chlorides of Formula (V) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in document US2010 / 234603 or document US2010 / 234604. [000233] The reaction of the compounds of Formula (II) with carbonyl chlorides of Formula (V) can be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; hydrocarbon Petition 870210086398, dated 09 / 20 / 2021, page 43 / 177 40 / 162 aliphatic compounds such as hexane, heptane or octane; aromatic hydrocarbons, for example, toluene or xylene; nitriles, for example, acetonitrile or propionitrile; polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000234] The reaction is preferably carried out in the presence of a base. Suitable bases are those of the inorganic bases that are typically used in such reactions. Preference is given to using bases selected by way of example from the group consisting of acetates, phosphates, carbonates and hydrogen carbonates of alkali metals or alkaline earth metals. Particular preference is given to sodium acetate, sodium phosphate, potassium phosphate, cesium carbonate, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate. Additional suitable bases are tertiary amines such as triethylamine and N,N-diisopropylethylamine, and nitrogen heterocycles such as pyridine, picoline, 2,6-lutidine, 4-dimethylaminopyridine and 1,8-diazabicyclo[5.4.0]-7-undecene (DBU). [000235] The reaction can be carried out under reduced pressure, standard pressure or high pressure and at temperatures from -20 °C to 100 °C, preference being given to carrying out the reaction at standard pressure and temperatures from 0 °C to 80 °C. Step b) [000236] The further conversion of compounds of Formula (IV) to compounds of Formula (I) is carried out as in process A, step b). Process C R3x^a4nh2 -THE IH (II) HO R1(AW THE (III) R2a,2b THE (I) [000237] The R1, R2a, R2b, R3, A1, A2, A3, A4, A5e n radicals are each Petition 870210086398, dated 09 / 20 / 2021, page 44 / 177 41 / 162 one, as defined above. [000238] In a further embodiment of the invention, the compounds of Formula (I) can be prepared in a one-stage process from the intermediate compounds of Formulas (II) and (III) in the presence of a condensing agent. [000239] The conversion to the compounds of Formula (I) may be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from the usual solvents which are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; alcohols such as methanol, ethanol or isopropanol; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; Polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000240] Examples of suitable condensing agents are carbodiimides such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or 1,3-dicyclohexylcarbodiimide; anhydrides such as acetic anhydride, trifluoroacetic anhydride; a mixture of triphenylphosphine, a base and carbon tetrachloride, or a mixture of triphenylphosphine and an azo diester, for example, diethylazodicarboxylic acid. [000241] The reaction can be carried out in the presence of an acid or a base. [000242] Examples of an acid that can be used in the reaction described are sulfonic acids such as methanesulfonic acid or para-toluenesulfonic acid; carboxylic acids such as acetic acid, or polyphosphoric acids. [000243] Examples of suitable bases are nitro heterocycles Petition 870210086398, dated 09 / 20 / 2021, page 45 / 177 42 / 162 gens such as pyridine, picoline, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]-7undecene (DBU); tertiary amines such as triethylamine and N,N-diisopropylethylamine; inorganic bases such as potassium phosphate, potassium carbonate and sodium hydride. [000244] The reaction can be carried out in the presence of a suitable catalyst, for example, 1-hydroxybenzotriazole. [000245] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 200 °C. W. Process D + (II) (V) (I) [000246] The R1, R2a, R2b, R3, A1, A2, A3, A4, A5 and n radicals are each as defined above. [000247] In a further embodiment of the invention, the compounds of Formula (I) can be prepared in a one-stage process from the intermediate compounds of Formulas (II) and (V). [000248] The conversion to the compounds of Formula (I) may be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from the usual solvents which are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; alcohols such as methanol, ethanol or isopropanol; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide Petition 870210086398, dated 09 / 20 / 2021, page 46 / 177 43 / 162 or N-methylpyrrolidone, or nitrogen compounds, for example, pyridinium. [000249] The reaction is preferably carried out in the presence of a base. Suitable bases are inorganic bases that are typically used in such reactions. Preference is given to using bases selected by way of example from the group consisting of acetates, phosphates, hydroxides, carbonates and hydrogen carbonates of alkali metals or alkaline earth metals. Preference is given to cesium carbonate, sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide. Additional suitable bases are tertiary amines such as triethylamine and N,N-diisopropylethylamine, nitrogen heterocycles such as pyridine, picoline, 2,6-lutidine, 4-dimethylaminopyridine and 1,8-diazabicyclo[5.4.0]-7-undecene (DBU). [000250] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 200 °C. W. Process E + R2a 2b (II) (VI) (I) [000251] The radicals R1, R2a, R2b, R3, A1, A2, A3, A4, A5 and n are each as defined above. [000252] In a further embodiment of the invention, the compounds of Formula (I) can be prepared from the compounds of Formula (II) and the aldehydes of Formula (VI) in the presence of an oxidizing agent. [000253] Aldehydes of Formula (VI) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in the document. Petition 870210086398, dated 09 / 20 / 2021, p. 47 / 177 44 / 162 US2009 / 192195, document US2010 / 227894 or Angewandte Chemie, International Edition, 48 (2009), 7064-7068. [000254] The conversion to the compounds of Formula (I) may be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; alcohols such as methanol, ethanol or isopropanol; esters such as ethyl acetate; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000255] The reaction can be carried out in the presence of an acid. Examples of acids that can be used in the described reaction are sulfonic acids such as methanesulfonic acid or paratoluenesulfonic acid; carboxylic acids such as acetic acid, or polyphosphoric acids. [000256] The reaction can also be carried out in the presence of a sulfite. Examples of sulfites that can be used in the reaction described are sodium hydrogen sulfite or sodium sulfite. [000257] Examples of oxidizing agents that are useful in the reaction described are oxygen, copper(II) chloride, or DDQ. [000258] The reaction can be carried out under reduced pressure, standard pressure or high pressure and at temperatures from 0 to 200 °C, preference being given to carrying out the reaction at standard pressure and temperatures from 20 to 150 °C. Process F Petition 870210086398, dated 09 / 20 / 2021, page 48 / 177 45 / 162 the) (II) (VIIa): X2= -COOH (VIIb): X2= -COCI (VIII) b) R1-SH (X) w) (IX) d) (I) A3=O; n=1 (I) A3=O; n=2 [000259] The radicals R1, R2a, R2b, R3, A1, A2, A3, A4, A5 and n are each as defined above, and X1 is a halogen. Step a) [000260] The compounds of Formula (VIII) can be prepared analogously to the process described in document US5576335 by reacting compounds of Formula (II) with a carboxylic acid of Formula (VIIa) or with a carbonyl chloride of Formula (VIIb) in the presence of a condensing agent or a base. [000261] The compounds of Formula (II) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in document US2003 / 69257 or document WO2006 / 65703. [000262] Carboxylic acids of Formula (VIIa) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in the Petition 870210086398, dated 09 / 20 / 2021, page 49 / 177 46 / 162 document US2010 / 234604, document WO2012 / 61926 or Bioorganic and Medicinal Chemistry Letters, 18 (2008), 5023-5026. [000263] Carbonyl chlorides of Formula (VIIb) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in document US2010 / 234603 or document US2010 / 234604. [000264] The reaction of compounds of Formula (II) with carboxylic acids of Formula (VIIa) or carbonyl chlorides of Formula (VIIb) can be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000265] Suitable condensing agents are, for example, carbodiimides such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or 1,3-dicyclohexylcarbodiimide. [000266] Suitable bases are inorganic bases that are typically used in such reactions. Preference is given to using bases selected by way of example from the group consisting of acetates, phosphates, carbonates and hydrogen carbonates of alkali metals or alkaline earth metals. Particular preference is given to sodium acetate, sodium phosphate, potassium phosphate, cesium carbonate, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate. Petition 870210086398, dated 09 / 20 / 2021, page 50 / 177 47 / 162 [000267] The reaction can be carried out under reduced pressure, standard pressure or high pressure and at temperatures from 0 to 180 °C, preference being given to carrying out the reaction at standard pressure and temperatures from 20 to 140 °C. Step b) [000268] The compounds of Formula (IX) can be prepared by condensation of the intermediate compounds of Formula (VIII), for example, in a manner analogous to the processes described in document WO2012 / 86848. [000269] The conversion to the compounds of Formula (IX) may be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide or N-methylpyrrolidone, or nitrogen compounds, for example, pyridine. [000270] The reaction can be carried out in the presence of a condensing agent, an acid, a base, or a chlorinating agent. [000271] Examples of suitable condensing agents are carbodiimides such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) or 1,3-dicyclohexylcarbodiimide; anhydrides such as acetic anhydride, trifluoroacetic anhydride; a mixture of triphenylphosphine, a base and carbon tetrachloride, or a mixture of triphenylphosphine and an azo diester, for example, diethylazodicarboxylic acid. [000272] Examples of suitable acids that can be used in Petition 870210086398, dated 09 / 20 / 2021, page 51 / 177 48 / 162 The reaction described involves sulfonic acids such as paratoluenesulfonic acid; carboxylic acids such as acetic acid, or polyphosphoric acids. [000273] Examples of suitable bases are nitrogen heterocycles such as pyridine, picoline, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]-7-undecene (DBU); tertiary amines such as triethylamine and N,N-diisopropylethylamine; inorganic bases such as potassium phosphate, potassium carbonate and sodium hydride. [000274] An example of a suitable chlorinating agent is phosphorus oxychloride. [000275] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 200 °C. Step c) [000276] The compounds of Formula (I) where n is 0 can be prepared by reacting the intermediate compounds of Formula (IX) with the intermediate compounds of Formula (X) in the presence of a base. [000277] Derivatives of mercaptan of Formula (X), for example, methyl mercaptan, ethyl mercaptan or isopropyl mercaptan, are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in document US2006 / 25633, document US2006 / 111591, document US2820062, Chemical Communications, 13 (2000), 1163-1164 or Journal of the American Chemical Society, 44 (1922), p. 1329. [000278] The conversion to the compounds of Formula (I) where n is 0 can be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from the usual solvents that are inert under the prevailing reaction conditions. Petition 870210086398, dated 09 / 20 / 2021, page 52 / 177 49 / 162 tes. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; nitriles, for example, acetonitrile or propionitrile; aromatic hydrocarbons, for example, toluene or xylene; polar aprotic solvents, for example, N,N-dimethylformamide, N-methylpyrrolidone or dimethyl sulfoxide. [000279] Examples of suitable bases are inorganic bases from the group consisting of acetates, phosphates, and carbonates of alkali metals or alkaline earth metals. Preference is given to cesium carbonate, sodium carbonate, and potassium carbonate. Additional suitable bases are alkali metal hydrides, for example, sodium hydride. [000280] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 200 °C. [000281] or chlorine. Step d) [000282] In the reaction described, X1 is preferably a fluorine atom. The compounds of Formula (I) where A3 is oxygen and n is 1 can be prepared by oxidation of the compounds of Formula (I) where n is 0. The oxidation is generally carried out in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; alcohols such as methanol or ethanol; formic acid, acetic acid, propionic acid or water. [000283] Examples of suitable oxidizing agents are hydrogen peroxide, meta-chloroperbenzoic acid, or sodium periodate. [000284] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from -20 °C to 120 °C. Petition 870210086398, dated 09 / 20 / 2021, page 53 / 177 50 / 162 [000285] Stage e) [000286] The compounds of Formula (I) where A3 is oxygen and en is 2 can be prepared by oxidation of the compounds of Formula (I) where A3 is oxygen and en is 1. The oxidation is generally carried out in a solvent. Preference is given to halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; alcohols such as methanol or ethanol; formic acid, acetic acid, propionic acid or water. [000287] Examples of suitable oxidizing agents are hydrogen peroxide and meta-chloroperbenzoic acid. [000288] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from -20 °C to 120 °C. Step f) [000289] The compounds of Formula (I) where A3 is oxygen and n is 2 can also be prepared in a one-stage process by oxidation of the compounds of Formula (I) where n is 0. The oxidation is generally carried out in a solvent. Preference is given to halogenated hydrocarbons, for example, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane or chlorobenzene; alcohols such as methanol or ethanol; formic acid, acetic acid, propionic acid or water. [000290] Examples of suitable oxidizing agents are hydrogen peroxide and meta-chloroperbenzoic acid. [000291] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from -20 °C to 120 °C. Process G [000292] The compounds of Formula (I) for which R3 = halogen can be converted to other compounds of Formula (I) for the Petition 870210086398, dated 09 / 20 / 2021, page 54 / 177 51 / 162 which R3 is another radical according to the definition. [000293] The compounds of Formula (I) for which R3 is a C-bonded radical of the aryl or heteroaryl group according to the definition can be prepared, for example, from the compounds of Formula (I) for which R3 is preferably a halogen of the chlorine or bromine group by commonly known methods (cf. Chem. Rev. 1995, 95, 2457-2483; Tetrahedron 2002, 58, 9633-9695; MetalCatalyzed Cross-Coupling Reactions (eds.: A. de Meijere, F. Diederich), 2nd ed., Wiley-VCH, Weinheim, 2004). [000294] For example, compounds in which R3 is preferably chlorine or bromine can be reacted with suitable arylboronic acids or esters thereof by known methods (cf. WO2010071819) in the presence of suitable catalysts from the transition metal salt group to give compounds of Formula (I) in which R3 is an aryl radical. Examples of preferred coupling catalysts include palladium catalysts such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) or tetrakis(triphenylphosphine)palladium. Suitable basic reaction auxiliaries used to conduct the processes are preferably sodium or potassium carbonates. [000295] Some of the required (hetero)arylboronic acids or (hetero)arylboronic esters are known and / or commercially available, for example, prepared by commonly known methods (cf. Boronic Acids (eds.: DG Hall), 2nd ed., Wiley-VCH, Weinheim, 2011). [000296] The preparation of compounds of Formula (I) in which R3 is an N-linked heteroyl, for example, imidazol-1-yl and pyrazol-1-yl can be carried out by methods known from the literature (see, for example, Journal of Organic Chemistry (2010), 69, 5578), preferably in the presence of copper(I) iodide and basic reaction aids, by Petition 870210086398, dated 09 / 20 / 2021, p. 55 / 177 52 / 162 For example, trans-N,N'-dimethylcyclohexane-1,2-diamine and potassium carbonate, in a suitable solvent or diluent. Useful solvents or diluents include all inert organic solvents, for example, aliphatic or aromatic hydrocarbons. Preference is given to using toluene. [000297] Some of the compounds in Formula (II) are new. [000298] New compounds are those of Formula (IIa) CH3(IIa) [000299] where R3 is as defined above, although R3 need not be chlorine, bromine or CHO. [000300] The present invention also provides compounds of Formula (IIa) in which R3 is (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C1-C4)haloalkylthio, (C1-C4)haloalkylsulfinyl or (C1-C4)haloalkylsulfonyl, where R3 is not CF3 or CHF2. [000301] Preferably, R3 is CH2F, C2H4F, C2H3F2, C2H2F3, C2HF4, C2F5, n-C3F7, i-C3F7, OCH2F, SCH2F, SOCH2F, SO2CH2F, OCHF2, SCHF2, SOCHF2, SO2CHF2, OCF3, OCF2Cl, OCFCl2, SCF3, SOCF3, SO2CF3, OC2H4F, SC2H4F, SOC2H4F, SO2C2H4F, OC2H3F2, SC2H3F2, SOC2H3F2, SO2C2H3F2, OC2H2F3, SC2H2F3, SOC2H2F3, SO2C2H2F3, OC2HF4, SC2HF4, SOC2HF4, SO2C2HF4, OC2F5, SC2F5, SOC2F5, SO2C2F5, n-OC3F7, n-SC3F7, n-SOC3F7, n-SO2C3F7, i-OC3F7, i-SC3F7, iSOC3F7 or i-SO2C3F7. [000302] More preferably, R3 is CH2F, OCF3, C2H4F, C2H3F2, C2H2F3, C2HF4, C2F5, SCF3, SOCF3 or SO2CF3. [000303] The most preferable, R3é C2F5. Process H Petition 870210086398, dated 09 / 20 / 2021, page 56 / 177 53 / 162 XI Cl XII the) b) [000304] The R3radical is as defined above. Step a) [000305] The compounds of Formula (XIII) can be prepared in analogy to the process described in document WO2005 / 55928 or Journal of Medicinal Chemistry, 48 (2005), p. 6128-6139, by reacting compounds of Formula (XI) with benzyl chlorocarbonate (benzyl chloroformate) of Formula (XII), for example, in the presence of a base. [000306] The compounds of Formula (XI) are commercially available or can be prepared by known methods, for example, in a manner analogous to the processes described in WO2012 / 3576, WO2007 / 47793 or WO2006 / 65703. [000307] The conversion to the compounds of Formula (XIII) may be carried out in substance or in a solvent, preference being given to conducting the reaction in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, tert-butyl methyl ether; nitriles, for example, acetonitrile or propionitrile; or aromatic hydrocarbons, for example, toluene or xylene. [000308] Examples of suitable bases are inorganic bases from the group consisting of acetates, phosphates, and carbonates of alkali metals. Petition 870210086398, dated 09 / 20 / 2021, page 57 / 177 54 / 162 or alkaline earth metals. Preference is given to cesium carbonate, sodium carbonate and potassium carbonate. [000309] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 120 °C. [000310] Step b) [000311] Compounds of Formula (IIa) can be prepared by reducing compounds of Formula (XIII), for example, in a manner analogous to the processes described in Journal of Heterocyclic Chemistry, 22 (1985), p. 313-318. [000312] An example of a suitable reducing agent is lithium aluminum hydride. [000313] The conversion to the compounds of Formula (IIa) may be carried out with them in pure form or in a solvent, preference being given to conducting the reaction in a solvent selected from usual solvents that are inert under the prevailing reaction conditions. Preference is given to ethers, for example, diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane or tert-butyl methyl ether. [000314] The reaction can be carried out under reduced pressure, standard pressure or high pressure, and at temperatures from 0 °C to 100 °C. [000315] Also new is the compound of Formula (II-02) Methods and Uses [000316] The invention also relates to methods for controlling animal pests, in which the compounds of Formula (I) are left to act on the animal pests and / or their habitat. Animal pest control is preferably carried out in agriculture and forestry and in material protection. Preferably, methods for Petition 870210086398, dated 09 / 20 / 2021, page 58 / 177 55 / 162 ra surgical or therapeutic treatment of the human body or of an animal and diagnostic methods performed on the human body or of an animal. [000317] The invention also relates to the use of the compounds of Formula (I) as pesticides, especially agricultural protection agents. [000318] In the context of this application, the term pesticide, in each case, also always includes the term “agricultural protection agent”. [000319] The compounds of Formula (I), given their good plant tolerance, favorable homeothermic toxicity, and good environmental compatibility, are suitable for protecting plants and plant organs against biotic and abiotic stress factors, increasing crop yields, improving the quality of harvested material, and combating animal parasites, especially insects, arachnids, helminths, nematodes, and mollusks, which are found in agriculture, horticulture, animal husbandry, aquatic crops, forests, gardens and recreational facilities, in the protection of stored products and materials, and in the hygiene sector. They can preferably be used as pesticides. They are effective against normally sensitive and resistant species and against all or some developmental stages. The pests mentioned above include: [000320] pests of the phylum Arthropoda, especially of the class Arachnida, for example, Acarus spp., for example, Acarus siro, Aceria kuko, Aceria sheldoni, Aculops spp., Aculus spp., for example, Aculus fockeui, Aculus schlechtendali, Amblyomma spp., Amphitetranychus viennensis, Argas spp., Boophilus spp., Brevipalpus spp., for example, Brevipalpus phoenicis, Bryobia graminum, Bryobia praetiosa, Centruroides spp., Chorioptes spp., Dermanyssus gallinae, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Dermacentor spp., Eotetranychus spp., for example, Eotetranychus hicoriae, Epitrimerus Petition 870210086398, dated 20 / 09 / 2021, p. 59 / 177 56 / 162 pyri, Eutetranychus spp., for example, Eutetranychus banksi, Eriophyes spp., for example, Eriophyes pyri, Glycyphagus domesticus, Halotydeus destructor, Hemitarsonemus spp., for example, Hemitarsonemus latus (=Polyphagotarsonemus latus), Hyalomma spp., Ixodes spp., Latrodectus spp., Loxosceles spp., Neutrombicula autumnalis, Nuphersa spp., Oligonychus spp., for example, Oligonychus coniferarum, Oligonychus ilicis, Oligonychus indicus, Oligonychus mangiferus, Oligonychus pratensis, Oligonychus punicae , Oligonychus yothersi, ounithodorus spp., ounithonyssus spp., Panonychus spp., for example, Panonychus citri (=Metatetranychus citri), Panonychus ulmi (=Metatetranychus ulmi), Phyllocoptruta oleivora, Platytetranychus multidigituli, Polyphagotarsonemus latus, Psoroptes spp., Rhipicephalus spp., Rhizoglyphus spp., Sarcoptes spp., Scorpio maurus, Steneotarsonemus spp., Steneotarsonemus spinki, Tarsonemus spp., for example, Tarsonemus confusus, Tarsonemus pallidus, Tetranychus spp., e.g., Tetranychus canadensis, Tetranychus cinnabarinus, Tetranychus turkestani, Tetranychus urticae, Trombicula alfreddugesi, Vaejovis spp., Vasates lycopersici;. [000321] of the class Chilopoda, for example, Geophilus spp., Scutigera spp.; [000322] of the order or class of Collembola, for example, Onychiurus armatus; Sminthurus viridis; [000323] of the class Diplopoda, for example, Blaniulus guttulatus; [000324] of the class Insecta, for example, of the order Blattodea, for example, Blatta orientalis, Blattella asahinai, Blattella germanica, Leucophaea maderae, Panchlora spp., Parcoblatta spp., Periplaneta spp., for example, Periplaneta americana, Periplaneta australasiae, Supella longipalpa; [000325] of the order Coleoptera, for example, Acalymma vittatum, Acanthoscelides obtectus, Adoretus spp., Agelastica alni, Agriotes Petition 870210086398, dated 09 / 20 / 2021, page 60 / 177 57 / 162 spp., for example, Agriotes linneatus, Agriotes mancus, Alphitobius diaperinus, Amphimallon solstitialis, Anobium punctatum, Anoplophora spp., Anthonomus spp., for example, Anthonomus grandis, Anthrenus spp., Apion spp., Apogonia spp., Atomaria spp., for example, Atomaria linearis, Attagenus spp., Baris caerulescens, Bruchidius obtectus, Bruchus spp., for example, Bruchus pisorum, Bruchus rufimanus, Cassida spp., Cerotoma trifurcata, Ceutorrhynchus spp., for example, Ceutorrhynchus assimilis, Ceutorrhynchus quadridens, Ceutorrhynchus rapae, Chaetocnema spp., for example, Chaetocnema confinis, Chaetocnema denticulata, Chaetocnema ectypa, Cleonus mendicus, Conoderus spp., Cosmopolites spp. , for example, Cosmopolites sordidus, Costelytra zealandica, Ctenicera spp. , Curculio spp., for example, Curculio caryae, Curculio caryatrypes, Curculio obtusus, Curculio sayi, Cryptolestes ferrugineus, Cryptolestes pusillus, Cryptorhynchus lapathi, Cryptorhynchus mangiferae, Cylindrocopturus spp., Cylindrocopturus adspersus, Cylindrocopturus furnissi, Dermestes spp., Diabrotica spp., for example, Diabrotica balteata, Diabrotica barberi, Diabrotica undecimpunctata howardi, Diabrotica undecimpunctata undecimpunctata, Diabrotica virgifera virgifera, Diabrotica virgifera zeae, Dichocrocis spp., Dicladispa armigera, Diloboderus spp., Epilachna spp., for example, Epilachna borealis, Epilachna varivestis, Epitrix spp., for example, Epitrix cucumeris, Epitrix fuscula, Epitrix hirtipennis, Epitrix subcrinita, Epitrix tuberis, Faustinus spp., Gibbium psylloides, Gnathocerus cornutus, Hellula undalis, Heteronychus arator, Heteronyx spp., Hylamorpha elegans, Hylotrupes bajulus, Hypera postica, Hypomeces squamosus, Hypothenemus spp., for example, Hypothenemus hampei, Hypothenemus obscurus, Hypothenemus pubescens, Lachnosterna consanguinea, Lasioderma serricorne, Latheticus oryzae, Lathridius spp., Lema spp., Leptinotarsa ​​decemLineata, Leucoptera spp., for example, Leucoptera coffeella, Lissorhoptrus oryzophilus, Lixus spp.,. Petition 870210086398, dated 20 / 09 / 2021, p. 61 / 177 58 / 162 Luperomorpha xanthodera, Luperodes spp., Lyctus spp., Megascelis spp., Melanotus spp., e.g., Melanotus longulus oregonensis, Meligethes aeneus, Melolontha spp., e.g., Melolontha melolontha, Migdolus spp., Monochamus spp., Naupactus xanthographus, Necrobia spp., Niptus hololeucus, Oryctes rhinoceros, Oryzaephilus surinamensis, Oryzaphagus oryzae, Otiorhynchus spp., e.g., Otiorhynchus cribricollis, Otiorhynchus ligustici, Otiorhynchus ovatus, Otiorhynchus rugosostriarus, Otiorhynchus sulcatus, Oxycetonia jucunda, Phaedon cochleariae, Phyllophaga spp., Phyllophaga helleri, Phyllotreta spp., e.g., Phyllotreta armoraciae, Phyllotreta pusilla, Phyllotreta ramosa, Phyllotreta striolata, Popillia japonica, Premnotrypes spp., Prostephanus truncatus, Psylliodes spp., for example, Psylliodes affinis, Psylliodes chrysocephala, Psylliodes punctulata, Ptinus spp., Rhizobius ventralis, Rhizopertha dominica, Sitophilus spp., for example, Sitophilus granarius, Sitophilus linearis, Sitophilus oryzae, Sitophilus zeamais, Sphenophorus spp., Stegobium paniceum, Sternechus spp., for example, Sternechus paludatus, Symphyletes spp., Tanymecus spp., for example, Tanymecus dilaticollis, Tanymecus indicus, Tanymecus palliatus, Tenebrio molitor, Tenebrioides mauretanicus, Tribolium spp., for example, Tribolium audax, Tribolium castaneum, Tribolium confusum, Trogoderma spp., Tychius spp., Xylotrechus spp., Zabrus spp., for example, Zabrus tenebrioides;. [000326] of the order Diptera, for example, Aedes spp., for example, Aedes aegypti, Aedes albopictus, Aedes sticticus, Aedes vexans, Agromyza spp., for example, Agromyza frontella, Agromyza parvicornis, Anastrepha spp., Anopheles spp., for example, Anopheles quadrimaculatus, Anopheles gambiae, Asphondylia spp., Bactrocera spp., for example, Bactrocera cucurbitae, Bactrocera dorsalis, Bactrocera oleae, Bibio hortulanus, Calliphora erythrocephala, Calliphora vicina, Ceratitis capitata, Chironomus spp., Chrysomya spp., Chrysops spp., Petition 870210086398, dated 20 / 09 / 2021, p. 62 / 177 59 / 162 Chrysozona pluvialis, Cochliomya spp., Contarinia spp., for example, Contarinia johnsoni, Contarinia nasturtii, Contarinia pyrivora, Contarinia schulzi, Contarinia sorghicola, Contarinia tritici, Cordylobia anthropophaga, Cricotopus sylvestris, Culex spp., for example, Culex pipiens, Culex quinquefasciatus, Culicoides spp., Culiseta spp., Cuterebra spp., Dacus oleae, Dasineura spp., for example, Dasineura brassicae, Delia spp., for example, Delia antiqua, Delia coarctata, Delia florilega, Delia platura, Delia radicum, Dermatobia hominis, Drosophila spp., for example, Drosphila melanogaster, Drosophila suzukii, Echinocnemus spp., Fannia spp., Gasterophilus spp., Glossina spp., Haematopota spp., Hydrellia spp., Hydrellia griseola, Hylemya spp., Hippobosca spp., Hypoderma spp., Liriomyza spp., for example, Liriomyza brassicae, Liriomyza huidobrensis, Liriomyza sativae, Lucilia spp., for example, Lucilia cuprina, Lutzomyia spp., Mansonia spp., Musca spp., for example, Musca domestica, Musca domestica vicina, Oestrus spp., Oscinella frit, Paratanytarsus spp., Paralauterborniella subcincta, Pegomya spp., for example, Pegomya betae, Pegomya hyoscyami, Pegomya rubivora, Phlebotomus spp., Phorbia spp., Phormia spp., Piophila casei, Prodiplosis spp., Psila rosae, Rhagoletis spp., for example, Rhagoletis cingulata, Rhagoletis completa, Rhagoletis fausta, Rhagoletis indifferens, Rhagoletis mendax, Rhagoletis pomonella, Sarcophaga spp., Simulium spp., for example, Simulium meridionale, Stomoxys spp., Tabanus spp., Tetanops spp., Tipula spp., for example, Tipula paludosa, Tipula simplex;. [000327] of the order Hemiptera, for example, Acizzia acaciaebaileyanae, Acizzia dodonaeae, Acizzia uncatoides, Acrida turrita, Acyrthosipon spp., for example, Acyrthosiphon pisum, Acrogonia spp., Aeneolamia spp., Agonoscena spp., Aleyrodes proletella, Aleurolobus barodensis, Aleurothrixus floccosus, Allocaridara malayensis, Amrasca spp., for example, Amrasca bigutulla, Amrasca devastans, Anuraphis Petition 870210086398, dated 09 / 20 / 2021, page 63 / 177 60 / 162 cardui, Aonidiella spp., for example, Aonidiella aurantii, Aonidiella citrina , Aonidiella inornata, Aphanostigma piri, Aphis spp., for example, Aphis citricola, Aphis craccivora, Aphis fabae, Aphis forbesi, Aphis glycines, Aphis gossypii, Aphis hederae, Aphis illinoisensis, Aphis middletoni, Aphis nasturtii, Aphis nerii, Aphis pomi, Aphis spiraecola, Aphis viburniphila, Arboridia apicalis, Arytainilla spp., Aspidiella spp., Aspidiotus spp., for example, Aspidiotus nerii, Atanus spp., Aulacorthum solani, Bemisia tabaci, Blastopsylla occidentalis, Boreioglycaspis melaleucae, Brachycaudus helichrysi, Brachycolus spp., Brevicoryne brassicae, Cacopsylla spp., for example, Cacopsylla pyricola, Calligypona marginata, Carneocephala fulgida, Ceratovacuna lanigera, Cercopidae, Ceroplastes spp., Chaetosiphon fragaefolii, Chionaspis tegalensis, Chlorita onukii, Chondracris rosea, Chromaphis juglandicola, Chrysomphalus ficus, Cicadulina mbila, Coccomytilus halli, Coccos spp., for example, Coccus hesperidum, Coccus longulus, Coccus pseudomagnoliarum, Coccus viridis, Cryptomyzus ribis, Cryptoneossa spp., Ctenarytaina spp., Dalbulus spp., Dialeurodes citri, Diaphorina citri, Diaspis spp., Drosicha spp., Dysaphis spp., for example, Dysaphis apiifolia, Dysaphis plantaginea, Dysaphis tulipae, Dysmicoccus spp., Empoasca spp., for example, Empoasca abrupta, Empoasca fabae, Empoasca maligna, Empoasca solana, Empoasca stevensi, Eriosoma spp., for example, Eriosoma americanum, Eriosoma lanigerum, Eriosoma pyricola, Erythroneura spp., Eucalyptolima spp., Euphyllura spp., Euscelis bilobatus, Ferrisia spp., Geococcus coffeae, Glycaspis spp., Heteropsylla cubana, Heteropsylla spinulosa, Homalodisca coagulata, Hyalopterus arundinis, Hyalopterus pruni, Icerya spp., for example, Icerya purchasi, Idiocerus spp., Idioscopus spp., Laodelphax striatellus, Lecanium spp., for example, Lecanium corni (=Parthenolecanium corn), Lepidosaphes spp., e.g., Lepidosaphes ulmi, Lipaphis erysimi, Macrosiphum spp., e.g., Ma. Petition 870210086398, dated 09 / 20 / 2021, page 64 / 177 61 / 162 crosiphum euphorbiae, Macrosiphum lilii, Macrosiphum rosae, Macrosteles facifrons, Mahanarva spp., Melanaphis sacchari, Metcalfiella spp., Metcalfa pruinosa, Metopolophium dirhodum, Monellia costalis, Monelliopsis pecanis, Myzus spp., for example, Myzus ascalonicus, Myzus cerasi, Myzus ligustri, Myzus ornatus, Myzus persicae,. Myzus nicotianae, Nasonovia ribisnigri, Nephotettix spp., for example, Nephotettix cincticeps,, Nephotettix nigropictus, Nilaparvata lugens, Oncometopia spp., Orthezia praelonga, Oxya chinensis, Pachypsylla spp., Parabemisia myricae, Paratrioza spp., for example, Paratrioza cockerelli, Parlatoria spp., Pemphigus spp., for example, Pemphigus bursarius, Pemphigus populivenae, Peregrinus maidis, Phenacoccus spp., for example, Phenacoccus madeirensis, Phloeomyzus passerinii, Phorodon humuli, Phylloxera spp., for example, Phylloxera devastatrix, Phylloxera notabilis, Pinnaspis aspidistrae, Planococcus spp., for example, Planococcus citri, Prosopidopsylla flava, Protopulvinaria pyriformis, Pseudaulacaspis pentagona, Pseudococcus spp., for example, Pseudococcus calceolariae, Pseudococcus comstocki, Pseudococcus longispinus, Pseudococcus maritimus , Pseudococcus viburni, Psyllopsis spp., Psylla spp., for example, Psylla buxi, Psylla mali, Psylla pyri, Pteromalus spp., Pyrilla spp., Quadraspidiotus spp., for example, Quadraspidiotus juglansregiae, Quadraspidiotus ostreaeformis, Quadraspidiotus perniciosus, Quesada gigas, Rastroccus spp., Rhopalosiphum spp., for example, Rhopalosiphum maidis, Rhopalosiphum oxyacanthae, Rhopalosiphum padi, Rhopalosiphum rufiabdominale, Saissetia spp., for example, Saissetia coffeae, Saissetia miranda, Saissetia neglecta, Saissetia oleae, Scaphoideus titanus , Schizaphis graminum, Selenaspidus articulatus, Sitobion avenae, Sogata spp., Sogatella furcifera, Sogatodes spp., Stictocephala festina, Siphoninus phillyreae, Tenalaphara malayensis, Tetragonocephela spp., Tinocallis caryaefoliae, Tomaspis spp., Toxoptera spp., etc. Petition 870210086398, dated 20 / 09 / 2021, p. 65 / 177 62 / 162 example, Toxoptera aurantii, Toxoptera citricidus, Trialeurodes vaporariorum, Trioza spp., for example, Trioza diospyri, Typhlocyba spp., Unaspis spp., Viteus vitifolii, Zygina spp.; [000328] of the suborder Heteroptera, for example, Anasa tristis, Antestiopsis spp., Boisea spp., Blissus spp., Calocoris spp., Campylomma livida, Cavelerius spp., Cimex spp., for example, Cimex adjunctus, Cimex hemipterus, Cimex lectularius, Cimex pilosellus, Collaria spp., Creontiades dilutus, Dasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus spp., Euschistus spp., for example, Euschistus heros, Euschistus servus, Euschistus tristigmus, Euschistus variolarius, Eurygaster spp., Halyomorpha halys, Heliopeltis spp., Horcias nobilellus, Leptocorisa spp., Leptocorisa varicornis, Leptoglossus occidentalis, Leptoglossus phyllopus, Lygocoris spp., for example, Lygocoris pabulinus, Lygus spp., for example, Lygus elisus, Lygus hesperus, Lygus lineolaris, Macropes excavatus, Monalonion atratum, Nezara spp., for example, Nezara viridula, Oebalus spp., Piesma quadrata, Piezodorus spp., for example, Piezodorus guildinii, Psallus spp., Pseudacysta persea, Rhodnius spp., Sahlbergella singularis, Scaptocoris castanea, Scotinophora spp., Stephanitis nashi, Tibraca spp., Triatoma spp.;. [000329] of the order Hymenoptera, for example, Acromyrmex spp., Athalia spp., for example, Athalia rosae, Atta spp., Diprion spp., for example, Diprion similis, Hoplocampa spp., for example, Hoplocampa cookei, Hoplocampa testudinea, Lasius spp., Linepithema humile, Monomorium pharaonis, Sirex spp., Solenopsis invicta, Tapinoma spp., Urocerus spp., Vespa spp., for example, Vespa crabro, Xeris spp.; [000330] of the order Isopoda, for example, Armadillidium vulgare, Oniscus asellus, Porcellio scaber; [000331] give the order of Isoptera, for example, Coptotermes spp., por Petition 870210086398, dated 20 / 09 / 2021, p. 66 / 177 63 / 162 example, Coptotermes formosanus, Cornitermes cumulans, Cryptotermes spp., Incisitermes spp., Microtermes obesi, Odontotermes spp., Reticulitermes spp., for example, Reticulitermes flavipes, Reticulitermes hesperus; [000332] of the order Lepidoptera, for example, Achroia grisella, Acronicta major, Adoxophyes spp., for example, Adoxophyes orana, Aedia leucomelas, Agrotis spp., for example, Agrotis segetum, Agrotis ipsilon, Alabama spp., for example, Alabama argillacea, Amyelois transitella, Anarsia spp., Anticarsia spp., for example, Anticarsia gemmatalis, Argyroploce spp., Barathra brassicae, Borbo cinnara, Bucculatrix thurberiella, Bupalus piniarius, Busseola spp., Cacoecia spp., Caloptilia theivora, Capua reticulana, Carpocapsa pomonella, Carposina niponensis, Cheimatobia brumata, Chilo spp., for example, Chilo plejadellus, Chilo suppressalis, Choristoneura spp., Clysia ambiguella, Cnaphalocerus spp., Cnaphalocrocis medinalis, Cnephasia spp., Conopomorpha spp., Conotrachelus spp., Copitarsia spp., Cydia spp., for example, Cydia nigricana, Cydia pomonella, Dalaca noctuides, Diaphania spp., Diatraea saccharalis, Earias spp., Ecdytolopha aurantium, Elasmopalpus lignosellus, Eldana saccharina, Ephestia spp., for example, Ephestia elutella, Ephestia kuehniella, Epinotia spp., Epiphyas postvittana, Etiella spp., Eulia spp., Eupoecilia ambiguella, Euproctis spp., for example, Euproctis chrysorrhoea, Euxoa spp., Feltia spp., Galleria mellonella, Gracillaria spp., Grapholitha spp., for example, Grapholita molesta, Grapholita prunivora, Hedylepta spp., Helicoverpa spp., for example, Helicoverpa armigera, Helicoverpa zea, Heliothis spp., for example, Heliothis virescens Hofmannophila pseudospretella, Homoeosoma spp., Homona spp., Hyponomeuta padella, Kakivoria flavofasciata, Laphygma spp., Leucinodes orbonalis, Leucoptera spp., for example, Leucoptera coffeella, Lithocolletis spp., for example, Lithocolletis blancardella, Lithophane antennata, Lobesia. Petition 870210086398, dated 20 / 09 / 2021, p. 67 / 177 64 / 162 spp., for example, Lobesia botrana, Loxagrotis albicosta, Lymantria spp., for example, Lymantria dispar, Lyonetia spp., for example, Lyonetia clerkella, Malacosoma neustria, Maruca testulalis, Mamestra brassicae, Melanitis leda, Mocis spp., Monopis obviella, Mythimna separata , Nemapogon cloacellus, Nymphula spp., Oiketicus spp., Oria spp., Orthaga spp., Ostrinia spp., for example, Ostrinia nubilalis, Orlema ​​melanopus, Orlema ​​oryzae, Panolis flammea, Parnara spp., Pectinophora spp., for example, Pectinophora gossypiella, Perileucoptera spp., Phthorimaea spp., for example, Phthorimaea operculella, Phyllocnistis citrella, Phyllonorycter spp., for example, Phyllonorycter blancardella, Phyllonorycter crataegella, Pieris spp., for example, Pieris rapae, Platynota stultana, Plodia interpunctella, Plusia spp., Plutella xylostella (=Plutella maculipennis), Prays spp., Prodenia spp., Protoparce spp., Pseudaletia spp., for example, Pseudaletia unipuncta, Pseudoplusia includens, Pyrausta nubilalis, Rachiplusia nu, Schoenobius spp., for example, Schoenobius bipunctifer, Scirpophaga spp., for example, Scirpophaga innotata, Scotia segetum, Sesamia spp., for example, Sesamia inferens, Sparganothis spp., Spodoptera spp., for example, Spodoptera eradiana, Spodoptera exigua, Spodoptera frugiperda, Spodoptera praefica, Stathmopoda spp., Stomopteryx subsecivella, Synanthedon spp., Tecia solanivora, Thermesia gemmatalis, Tinea cloacella, Tinea pellionella, Tineola bisselliella, Tortrix spp., Trichophaga tapetzella, Trichoplusia spp., for example, Trichoplusia ni, Tryporyza incertulas, Tuta absoluta, Virachola spp.;. [000333] of the order Orthoptera or Saltatoria, for example, Acheta domesticus, Dichroplus spp., Gryllotalpa spp., for example, Gryllotalpa gryllotalpa, Hieroglyphus spp., Locusta spp., for example, Locusta migratoria, Melanoplus spp., for example, Melanoplus devastator, Paratlanticus ussuriensis, Schistocerca gregaria; [000334] of the order Phthiraptera, for example, Damalinia spp., Petition 870210086398, dated 09 / 20 / 2021, page 68 / 177 65 / 162 Haematopinus spp., Linognathus spp., Pediculus spp., Phylloxera uvatrix, Phthirus pubis, Trichodectes spp.; [000335] of the order Psocoptera, for example, Lepinotus spp., Liposcelis spp.; [000336] of the order Siphonaptera, for example, Ceratophyllus spp., Ctenocephalides spp., for example, Ctenocephalides canis, Ctenocephalides felis, Pulex irritans, Tunga penetrans, Xenopsylla cheopis; [000337] of the order Thysanoptera, for example, Anaphothrips obscurus, Baliothrips biformis, Drepanothrips reuteri, Enneothrips flavens, Frankliniella spp., for example, Frankliniella fusca, Frankliniella occidentalis, Frankliniella schultzei, Frankliniella tritici, Frankliniella vaccinii, Frankliniella williamsi, Heliothrips spp., Hercinothrips femoralis, Rhipiphorothrips cruentatus, Scirtothrips spp., Taeniothrips cardamomi, Thrips spp., for example, Thrips palmi, Thrips tabaci; [000338] give the order of Zygentoma (= Thysanura), for example, Ctenolepisma spp., Lepisma saccharina, Lepismodes inquilinus, Thermobia domestica; [000339] give the class Symphyla, for example, Scutigerella spp., for example, Scutigerella immaculata; [000340] pragas do filo dos Mollusca, for example, give class dos Bivalvia, for example, Dreissena spp., [000341] and also of the class Gastropoda, for example, Arion spp., for example, Arion ater rufus, Biomphalaria spp., Bulinus spp., Deroceras spp., for example, Deroceras laeve, Galba spp., Lymnaea spp., Oncomelania spp., Pomacea spp., Succinea spp.; [000342] animal and human parasites of the phyla Platyhelminthes and Nematoda, for example, Aelurostrongylus spp., Amidostomum spp., Ancylostoma spp., Angiostrongylus spp., Anisakis spp., Anoplocephala spp., Ascaris spp., Ascaridia spp., Baylisascaris spp., Brugia spp., Bu Petition 870210086398, dated 09 / 20 / 2021, page 69 / 177 66 / 162 nostomum spp., Capillaria spp., Chabertia spp., Clonorchis spp., Cooperia spp., Crenosoma spp., Cyathostoma spp., Dicrocoelium spp., Dictyocaulus spp., Diphyllobothrium spp., Dipylidium spp., Dirofilaria spp., Dracunculus spp., Echinococcus spp., Echinostoma spp., Enterobius spp., Eucoleus spp., Fasciola spp., Fascioloides spp., Fasciolopsis spp., Filaroides spp., Gongylonema spp., Gyrodactylus spp., Habronema spp., Haemonchus spp., Heligmosomoides spp., Heterakis spp., Hymenolepis spp., Hyostrongylus spp., Litomosoides spp., Loa spp., Metastrongylus spp., Metorchis spp., Mesocestoides spp., Moniezia spp., Muellerius spp., Necator spp., Nematodirus spp., Nippostrongylus spp., Oesophagostomum spp., Ollulanus spp., Onchocerca spp., Opisthorchis spp., Oslerus spp., Ostertagia spp., Oxyuris spp., Paracapillaria spp., Parafilaria spp., Paragonimus spp., Paramphistomum spp., Paranoplocephala spp., Parascaris spp., Passalurus spp., Protostrongylus spp., Schistosoma spp., Setaria spp., Spirocerca spp., Stephanofilaria spp., Stephanurus spp., Strongyloides spp., Strongylus spp., Syngamus spp., Taenia spp., Teladorsagia spp., Thelazia spp., Toxascaris spp., Toxocara spp., Trichinella spp., Trichobilharzia spp., Trichostrongylus spp., Trichuris spp., Uncinaria spp., Wuchereria spp.;. [000343] plant pests of the phylum Nematoda, i.e., phytoparasitic nematodes, especially Aglenchus spp., e.g., Aglenchus agricola, Anguina spp., e.g., Anguina tritici, Aphelenchoides spp., e.g., Aphelenchoides arachidis, Aphelenchoides fragariae, Belonolaimus spp., e.g., Belonolaimus gracilis, Belonolaimus longicaudatus, Belonolaimus nortoni, Bursaphelenchus spp., e.g., Bursaphelenchus cocophilus, Bursaphelenchus eremus, Bursaphelenchus xylophilus, Cacopaurus spp., e.g., Cacopaurus pestis, Criconemella spp., e.g., Criconemella curvata, Criconemella onoensis, Criconemella ornata, Criconemella rusium, Criconemella xenoplax (= Mesocriconema xenoplax), Criconemoides spp., Petition 870210086398, dated 20 / 09 / 2021, p. 70 / 177 67 / 162 for example, Criconemoides ferniae, Criconemoides onoense, Criconemoides ornatum, Ditylenchus spp., for example, Ditylenchus dipsaci, Dolichodorus spp., Globodera spp., for example, Globodera pallida, Globodera rostochiensis, Helicotylenchus spp., for example, Helicotylenchus dihystera, Hemicriconemoides spp., Hemicycliophora spp., Heterodera spp., for example, Heterodera avenae, Heterodera glycines, Heterodera schachtii, Hoplolaimus spp., Longidorus spp., for example, Longidorus africanus, Meloidogyne spp., for example, Meloidogyne chitwoodi, Meloidogyne fallax, Meloidogyne hapla, Meloidogyne incognita, Meloinema spp., Nacobbus spp., Neotylenchus spp., Paraphelenchus spp., Paratrichodorus spp., for example, Paratrichodorus minor, Pratylenchus spp., for example, Pratylenchus penetrans, Pseudohalenchus spp., Psilenchus spp., Punctodera spp., Quinisulcius spp., Radopholus spp., for example, Radopholus citrophilus, Radopholus similis, Rotylenchulus spp., Rotylenchus spp., Scutellonema spp., Subanguina spp., Trichodorus spp., for example, Trichodorus obtusus, Trichodorus primitivus, Tylenchorhynchus spp., for example, Tylenchorhynchus annulatus, Tylenchulus spp., for example, Tylenchulus semipenetrans, Xiphinema spp., for example, Xiphinema index. [000344] In addition, it is possible to control, from the subkingdom Protozoa, the order Coccidia, for example, Eimeria spp. [000345] The compounds of Formula (I) may optionally, at certain concentrations or application rates, be used as herbicides, phytotoxicity protectants, growth regulators or agents to improve plant properties, such as microbicides or gametocides, for example, as fungicides, antifungals, bactericides, virucides (including agents against viroids) or as agents against MLO (mycoplasma-like organisms) and RLO (rickettsia-like organisms). If appropriate, they may also be used as intermediates or precursors for the synthesis of other Petition 870210086398, dated 09 / 20 / 2021, page 71 / 177 68 / 162 active ingredients. Formulations [000346] The present invention also relates to formulations and forms of use prepared from them as pesticides, for example, liquids for soaking, immersion and spraying, comprising at least one compound of Formula (I).In some cases, the forms of use include other pesticides and / or adjuvants that enhance the action, such as penetration agents, for example, vegetable oils, for example, rapeseed oil, sunflower oil, mineral oils, for example, paraffin oils, alkyl esters of vegetable fatty acids, for example, rapeseed oil methyl ester or soybean oil methyl ester, or alkanol alkoxylates, and / or dispersing agents, for example, alkylsiloxanes and / or salts, for example, inorganic or organic ammonium or phosphonium salts, for example, ammonium sulfate or diammonium hydrogen phosphate, and / or retention promoters, for example, dioctyl sulfosuccinate, or hydroxypropyl guar polymers and / or humectants, for example, glycerol, and / or fertilizers, for example, fertilizers containing ammonium, potassium or phosphorus. [000347] Common formulations are, for example, water-soluble liquids (SL), emulsified concentrates (EC), water-emulsified concentrates (EW), suspension concentrates (SC, SE, FS, OD), water-dispersible granules (WG), granules (GR) and capsule concentrates (CS); these and other possible formulation types are described, for example, by Crop Life International and in Pesticide Specifications, Manual on Development and Use of FAO and the WHO specifications for pesticides, FAO Plant Production and Protection Papers - 173, prepared by the FAO / WHO Joint Meeting on Pesticide Specifications, 2004, ISBN: 9251048576. The formulations, in addition to one or more compounds of Formula (I), may optionally also comprise agrochemically active ingredients. Petition 870210086398, dated 09 / 20 / 2021, page 72 / 177 69 / 162 [000348] These are preferably formulations or forms of use which include auxiliaries, for example, diluents, solvents, spontaneity promoters, vehicles, emulsifiers, dispersants, frost protectors, biocides, thickeners and / or other auxiliaries, for example, adjuvants. An adjuvant in this context is a component that improves the biological activity of the formulation without having biological activity itself. Examples of adjuvants are agents that promote retention, spreading characteristics, adhesion to the leaf surface or penetration. [000349] These formulations are prepared in a known manner, for example, by mixing the compounds of Formula (I) with auxiliaries, for example, diluents, solvents and / or solid carriers and / or other auxiliaries, for example, surfactants. The formulations are produced in suitable facilities or even before or during application. [000350] The auxiliaries used may be such substances suitable for imparting special properties, such as certain physical, technical and / or biological properties, to the formulation of the compounds of Formula (I) or to the forms of use prepared from these formulations (for example, ready-to-use pesticides, such as spray liquors or seed treatment products). [000351] Suitable extending agents are, for example, water, polar and non-polar organic liquid chemicals, for example, from the class of aromatic and non-aromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes and chlorobenzenes), alcohols and polyols (which, if appropriate, may also be substituted, etherified and / or esterified), ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, substituted and unsubstituted amines, amides, lactams, such as N-(alkylpyrrolidones) and lactones, sulfones and sulfoxides (such as dimethyl sulfoxide). Petition 870210086398, dated 09 / 20 / 2021, p. 73 / 177 70 / 162 If the extending agent used is water, it is also possible to use, for example, organic solvents as auxiliary solvents. Useful liquid solvents essentially include: aromatic compounds, such as xylene, toluene or alkylnaphthalenes; chlorinated aromatic compounds or chlorinated aliphatic hydrocarbons, such as chlorobenzenes, chloroethylenes or methylene chloride; aliphatic hydrocarbons, such as cyclohexane or paraffins, for example, fractions of mineral oils, mineral and vegetable oils; alcohols, such as butanol or glycol and their ethers and esters; ketones, such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone; strongly polar solvents, such as dimethylformamide and dimethyl sulfoxide; or also water. [000352] In principle, any suitable solvents can be used. Examples of suitable solvents are aromatic hydrocarbons, such as xylene, toluene or alkylnaphthalenes, aromatic or chlorinated aliphatic hydrocarbons, such as chlorobenzene, chloroethylene or methylene chloride, aliphatic hydrocarbons, such as cyclohexane, paraffins, petroleum fractions, mineral and vegetable oils, alcohols, such as methanol, ethanol, isopropanol, butanol or glycol and their ethers and esters, ketones, such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents, such as dimethyl sulfoxide, and also water. [000353] In principle, it is possible to use all suitable carriers. Useful carriers include especially: for example, ammonium salts and ground natural minerals such as kaolin, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals such as finely divided silica, alumina and natural or synthetic silicates, resins, waxes and / or solid fertilizers. Mixtures of such carriers may also be used. Useful carriers for granules include: for example, crushed and fractionated natural rocks, such as co Petition 870210086398, dated 09 / 20 / 2021, page 74 / 177 71 / 162 mo calcite, marble, pumice, sepiolite, dolomite, and synthetic granules of inorganic and organic flours, and also granules of organic materials such as sawdust, paper, coconut husks, corn cobs and tobacco stalks. [000354] It is also possible to use liquefied gaseous extenders or solvents. Particularly suitable extenders or vehicles are those that are gaseous at standard temperature and under standard pressure, for example, aerosol propellants such as halogenated hydrocarbons, or also butane, propane, nitrogen and carbon dioxide. [000355] Examples of emulsifiers and / or foam formers, dispersants or wetting agents with ionic or non-ionic properties, or mixtures of these surfactants, are polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic acid or naphthalenesulfonic acid salts, ethylene oxide polycondensates with fatty alcohols or with fatty acids or with fatty amines, with substituted phenols (preferably alkylphenols or arylphenols), sulfosuccinic ester salts, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty acid esters of polyols and derivatives of compounds containing sulfates, sulfonates and phosphates, for example, polyglycol alkylaryl ethers, alkylsulfonates, alkylsulfates, aryl sulfonates, protein hydrolysates, residual liquors of lignosulfite and methylcellulose.The presence of a surfactant is advantageous if one of the compounds in Formula (I) and / or one of the inert vehicles is insoluble in water and when the application occurs in water. [000356] Additional auxiliaries that may be present in the formulations and the forms of use derived from them are colorants such as inorganic pigments, for example, iron oxide, titanium oxide and Prussian Blue, and organic colorants, such as coran Petition 870210086398, dated 09 / 20 / 2021, pp. 75 / 177 72 / 162 contains alizarin, azo dyes and metal phthalocyanine dyes, and nutrients and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc. [000357] In addition, stabilizers, such as low-temperature stabilizers, preservatives, antioxidants, light stabilizers, or other agents that improve chemical and / or physical stability, may be present. Additionally, foaming agents or anti-foaming agents may be present. [000358] In addition, the formulations and forms of use derived from them may also include, as additional auxiliaries, viscosity agents such as carboxymethyl cellulose and natural and synthetic polymers in the form of powders, granules or latex, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or even natural phospholipids, such as cephalins and lecithins, and synthetic phospholipids. Other possible auxiliaries are mineral and vegetable oils. [000359] Optionally, additional auxiliaries may be present in the formulations and forms of use derived from them. Examples of such additives are fragrances, protective colloids, binders, adhesives, thickeners, thixotropic agents, penetration agents, retention promoters, stabilizers, sequestrants, complex-forming agents, humectants, dispersing agents. In general, the compounds of Formula (I) may be combined with any solid or liquid additive commonly used for formulation purposes. [000360] Useful retention promoters include all those substances which reduce dynamic surface tension, for example, dioctyl sulfosuccinate, or increase viscoelasticity, for example, hydroxypropyl guar polymers. [000361] Useful penetrants in the present context are all substances which are typically used to improve penetration. Petition 870210086398, dated 09 / 20 / 2021, pp. 76 / 177 73 / 162 of agrochemical active ingredients in plants. Penetrants are defined, in this context, by their ability to penetrate the application liquor (usually aqueous) and / or the spray coating into the plant cuticle and thus increase the mobility of the active ingredients in the cuticle. The method described in the literature (Baur et al., 1997, Pesticide Science 51, 131-152) can be used to determine this property. Examples include alcohol alkoxylates, such as coconut fatty ethoxylate (10) or isotridecyl ethoxylate (12), fatty acid esters, for example, rapeseed oil methyl ester or soybean oil methyl ester, fatty amine alkoxylates, for example, tallow amine ethoxylate (15), or ammonium and / or phosphonium salts, for example, ammonium sulfate or diammonium hydrogen phosphate. [000362] The formulations preferably comprise between 0.00000001% and 98% by weight of the compound of Formula (I), with particular preference between 0.01% and 95% by weight of the compound of Formula (I), more preferably between 0.5% and 90% by weight of the compound of Formula (I), based on the weight of the formulation. [000363] The content of the compound of Formula (I) in the forms of use prepared from the formulations (in particular, pesticides) may vary within wide ranges. The concentration of the compound of Formula (I) in the forms of use may typically be between 0.00000001% and 95% by weight of the compound of Formula (I), preferably between 0.00001% and 1% by weight, based on the weight of the form of use. Application is achieved in a usual manner appropriate to the forms of use. Mixtures [000364] The compounds of Formula (I) may also be used in a mixture with one or more fungicides, bactericides, acaricides, molluscicides, nematicides, insecticides, microbiological agents, beneficial organisms, herbicides, fertilizers, bird repellents, phytotoni Petition 870210086398, dated 09 / 20 / 2021, pp. 77 / 177 74 / 162 cos, sterilizing agents, phytotoxicity protectants, semiochemicals and / or plant growth regulators suitable for, for example, broadening the spectrum of action, prolonging the period of action, increasing the speed of action, preventing repellency or preventing the evolution of resistance. In addition, combinations of active ingredients of this type can improve plant growth and / or tolerance to abiotic factors, for example, high or low temperatures, drought or high water content or soil salinity. It is also possible to improve flowering and fruiting performance, optimize germination capacity and root development, facilitate harvesting and improve yields, influence ripening, improve the quality and / or nutritional value of harvested products, extend storage life and / or improve the processability of harvested products. [000365] In addition, the compounds of Formula (I) may be present in a mixture with other active ingredients or semiochemicals, such as bird attractants and / or repellents and / or plant activators and / or growth regulators and / or fertilizers. Similarly, the compounds of Formula (I) may be used in mixtures with agents to improve plant properties, for example, growth, production and quality of harvested material. [000366] In a particular embodiment of the invention, the compounds of Formula (I) are in the form of formulations or application forms prepared from these formulations in mixture with other compounds, preferably those as described below. [000367] If one of the compounds mentioned below can occur in several tautomeric forms, these forms are also included, even if not explicitly indicated in each case. Insecticides / acaricides / nematicides [000368] The active ingredients specified here by their names Petition 870210086398, dated 09 / 20 / 2021, pp. 78 / 177 75 / 162 common pesticides are known and described, for example, in The Pesticide Manual, 16th ed., British Crop Protection Council 2012, or can be found on the Internet (e.g., http: / / www.alanwood.net / pesticides). (1) Acetylcholinesterase (AChE) inhibitors, for example, carbamates, for example, alanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, etiofencarb, fenobucarb, formetanate, furatiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimetacarb, XMC and xylylcarb;or organophosphates, for example, acephate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusaphos, chloroxyphos, chlorfenvinphos, chlormephos, chlorpyrifos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfotom, EPN, ethione, etoprofos, famphur, fenamifos, fenitrothione, fenthione, fosthiazate, heptenofos, imiciaphos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl) salicylate, isoxathione, malathion, mecarban, methamidophos, methidathione, mevinphos, monocrotophos, naled, omethoate, oxidemetom-methyl, parathion, parathion-methyl, fenthoate, phorate, phosalone, phosmet, phosphamidon, phoshima, pirimiphos-methyl, profenofos, propetanphos, prothiophos, pyraclophos, pyridafenthion, quinalfos, sulfotepe, tebupirinphos, temephos, terbufos, tetrachlorvinphos, thiometom, triazophos, trichlorfon and vamidothion. (2) GABA-activated chloride channel antagonists, for example, cyclodiene-organochlorines, for example, chlordane and endosulfan or phenylpyrazoles (fiprols), for example, etiprol and fipronil. (3) Sodium channel modulators / voltage-activated sodium channel blockers, for example, pyrethroids, for example, acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, s-cyclopentenyl isomer of bioallethrin, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma Petition 870210086398, dated 09 / 20 / 2021, pp. 79 / 177 76 / 162 cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, tetracypermethrin, zeta-cypermethrin, cyfenothrin [trans isomers (1R)], deltamethrin, empentrin [EZ-(1R) isomer (1R)], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucitrinate, flumethrin, taufluvalinate, halfenprox, imiprothrin, cadetrin, permethrin, phenothrin [trans isomers (1R)], prallethrin, pyrethrins (pyrethrum), resmethrin, silafluophen, tefluthrin, tetramethrin, tetramethrin [1R isomers (1R)], tralomethrin and transfluthrin or DDT or methoxychlor. (4) Nicotinergic acetylcholine receptor (nAChR) agonists, for example, neonicotinoids, for example, acetamipride, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam or nicotine or sulfoxaflor. (5) Allosteric activators of the nicotinergic acetylcholine receptor (nAChR), for example, spinosyns, for example, spinetoram and spinosad. (6) Chloride channel activators, for example, avermectins / milbemycins, for example, abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Mimics of juvenile hormone, for example, juvenile hormone analogues, for example, hydroprene, quinoprene and methoprene or fenoxycarb or pyriproxyfen. (8) Active ingredients with unknown or nonspecific mechanisms of action, for example, alkyl halides, for example, methyl bromide and other alkyl halides; or chloropicrin or sulfuryl fluoride or borax or tartar emetic. (9) Compounds with selective antifeedant activity, for example, pimetrozine or flonicamide. (10) Inhibitors of mite growth, for example, clofentezine, hexthiazine and diflovidazine or ethoxazole. (11) Microbial agents that disrupt the membrane of the Petition 870210086398, dated 09 / 20 / 2021, page 80 / 177 77 / 162 insect testis, for example, Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis and plant BT protein: CrylAb, CrylAc, CrylFa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34 / 35Ab1. (12) Inhibitors of oxidative phosphorylation, ATP-disrupting agents, for example, diafenthiuron or organotin compounds, for example, azocyclotin, ci-hexatin and fenbutatin oxide or propargite or tetradifon; (13) Uncouplers of oxidative phosphorylation that interrupt the H proton gradient, for example, chlorfenapyr, DNOC and sulfluramide. (14) Nicotinergic acetylcholine receptor antagonists, for example, bensultap, cartap hydrochloride, thiocyclam and thioultapesodium. (15) Type 0 chitin biosynthesis inhibitors, for example, bistriflurom, chlorfluazurom, diflubenzurom, flucicloxurom, flufenoxurom, hexaflumurom, lufenurom, novalurom, noviflumurom, teflubenzurom and triflumurom. (16) Inhibitors of type 1 chitin biosynthesis, for example, buprofezin. (17) Molting inhibitors (especially for Diptera, i.e., dipterans), for example, cyromazine. (18) Ecdyszone receptor agonists, for example, chromafenozide, halofenozide, methoxyfenozide and tebufenozide. (19) Octopaminergic agonists, for example, amitraz. (20) Electron transport inhibitors of complex-III, for example, hydramethylnon or acequinocil or fluacripyrim. (21) Electron transport inhibitors of complex-I, for example, of the METI acaricide group, for example, phenazaquin, Petition 870210086398, dated 09 / 20 / 2021, page 81 / 177 78 / 162 fenpyroximate, pirimidifen, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris). (22) Voltage-activated sodium channel blockers, for example, indoxacarb or metaflumizone. (23) Acetyl-CoA carboxylase inhibitors, for example, tetronic and tetramic acid derivatives, for example, spirodiclofen, spiromesifen and spirotetramate. (24) Complex IV electron transport inhibitors, for example, phosphines, for example, aluminum phosphide, calcium phosphide, phosphine and zinc phosphide or cyanide. (25) Complex II electron transport inhibitors, for example, cyanopyrafene and cyflumethophene. (28) Agents affecting the ryanodine receptor, for example, diamides, for example, chlorantraniliprole, cyantraniliprole and flubendiamide, [000369] Other active ingredients, for example, afidopyropene, azadirachtin, benclotiaz, benzoximate, bifenazate, bromopropylate, quinomethionate, cryolite, [000370] dicofol, diflovidazine, fluensulfone, flomethoquine, flufenerim, flufenoxystrobin, flufiprol, fluopiram, flupiradifurone, fufenozide, heptafluthrin, imidaclotiaz, iprodione, meperfluthrin, paichongding, piflubumide, pirifluquinazone, piriminostrobin, tetramethylfluthrin and iodomethane;and also preparations based on Bacillus firmus (I-1582, BioNeem, Votivo) and also the following compounds: 3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-carboxamide (known from document WO2005 / 077934) and 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl}-3-(trifluoromethyl)1H-1,2,4-triazol-5-amine (known from document WO2006 / 043635), {1'-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indol-3,4'-piperidin]1(2H)-yl}(2-chloropyridin-4-yl)methanone (known from the document; Petition 870210086398, dated 09 / 20 / 2021, page 82 / 177 79 / 162 WO2003 / 106457), 2-chloro-N-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl}-4-(trifluoromethyl)phenyl]isonicotinamide (known from document WO2006 / 003494), 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from document WO2009 / 049851), 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo1,8-diazaspiro[4.5]dec-3-en-4-yl-ethyl carbonate (known from document WO2009 / 049851), 4-(but-2-in-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from document WO2004 / 099160), 4-(but-2in-1-yloxy)-6-(3-chlorophenyl)pyrimidine (known from document WO2003 / 076415), PF1364 (CAS Reg. No. 1204776-60-2), 4-[5-(3,5dichlorophenyl)-5-(trifluoromethyl)-4,5-di-hidro-1,2-oxazol-3-yl]-2-methyl-N-{2oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}benzamide (conhecida do documento WO2005 / 085216), 4-{5-[3-chloro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4,5-di-hidro-1,2-oxazol-3-yl}-N-{2-oxo-2-[(2,2,2trifluoroethyl)amino]ethyl}-1-naftamida (conhecida do documento WO2009 / 002809), 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5yl]carbonyl}amino)-5-chloro-3-methylbenzoyl]-2-methyl-hydrazinacarboxylate methyl (conhecido do documento WO2005 / 085216), 2-[2-({[3bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3methylbenzoyl]-2-ethyl-hydrazinacarboxylate methyl (conhecido do documento WO2005 / 085216), 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1Hpirazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-methylhidrazinecarboxylate de methyl (according to document WO2005 / 085216), 2-[3,methyl 5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethylhydrazinecarboxylate (known from WO2005 / 085216), 1-(3-chloropyridin-2yl)-N-[4-cyano-2-methyl-6-(methylcarbamoyl)phenyl]-3-{[5-(trifluoromethyl)-2Htetrazol-2-yl]methyl}-1H-pyrazol-5-carboxamide (known from WO2010 / 069502), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6methylphenyl]-3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-carboxamide, Petition 870210086398, dated 09 / 20 / 2021, page 83 / 177 80 / 162 (known from document CN102057925), 3-chloro-N-(2-cyanopropan-2-yl)-N-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-methylphenyl]phthalamide (known from document WO2012 / 034472), 8-chloro-N-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide (known from document WO2010 / 129500), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-(1-oxythiethan-3-yl)benzamide (known from document WO2009 / 080250), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-di-hydro- 1,2-oxazol-3-yl]-2-methyl-N-(1-oxidotietan-3-yl)benzamida (referred to in document WO2012 / 029672), 1-[(2-chloro-1,3-thiazol-5-yl)methyl]-4-oxo-3- phenyl-4H-pyrido[1,2-a]pyrimidin-1-ío-2-olate (according to document WO2009 / 099929), 1-[(6-chloropyridin-3-yl)methyl]-4-oxo-3-phenyl-4Hpirido[1,2-a]pyrimidin-1-ío-2-olate (according to document WO2009 / 099929), (5S,8R)-1-[(6-chloropyridin-3-yl)methyl]-9-nitro-2,3,5,6,7,8-hexahydro-1H-5,8-epoxyimidazo[1,2-a]azepine (known from document WO2010 / 069266), (2E)-1-[(6-chloropyridin-3-yl)methyl]-N'-nitro-2-pentylidene-hydrazinecarboximidamide (known from document WO2010 / 060231), 4-(3-{2,6-dichloro-4-[(3,3-dichloroprop-2-en-1yl)oxy]phenoxy}propoxy)-2-methoxy-6-(trifluoromethyl)pyrimidine (known from document CN101337940), N-[2-(tert-butylcarbamoyl)-4-chloro-6-methylphenyl]-1-(3-chloropyridin-2-yl)-3-(fluoromethoxy)-1H-pyrazol-5-carboxamide (known from document WO2008 / 134969). Fungicides [000371] The active ingredients specified here by their common name are known and described, for example, in Pesticide Manuals or on the Internet (e.g., http: / / www.alanwood.net / pesticides). (1) Inhibitors of ergosterol biosynthesis, for example, (1.1) aldimorph, (1.2) azaconazole, (1.3) bitertanol, (1.4) bromuconazole, (1.5) cyproconazole, (1.6) diclobutrazole, (1.7) difenoconazole, (1.8) diniconazole, (1.9) diniconazole-M, (1.10) dodemorph, (1.11) dode- acetate Petition 870210086398, dated 09 / 20 / 2021, page 84 / 177 81 / 162 morfe, (1.12) epoxiconazol, (1.13) etaconazol, (1.14) fenarimol, (1.15) fenbuconazol, (1.16) fenexamida, (1.17) fenpropidina, (1.18) fenpropimorfe, (1.19) fluquinconazol, (1.20) flurprimidol, (1.21) flusilazol, (1.22) flutriafol, (1.23) furconazol, (1.24) furconazol-cis, (1.25) hexaconazol, (1.26) imazalil, (1.27) sulfato de imazalil, (1.28) imibenconazol, (1.29) ipconazol, (1.30) metconazol, (1.31) miclobutanil, (1.32) naftifina, (1.33) nuarimol, (1.34) oxpoconazol, (1.35) paclobutrazol, (1.36) pefurazoato, (1.37) penconazol, (1.38) piperalin, (1.39) procloraz, (1.40) propiconazol, (1.41) protioconazol, (1.42) piributicarbe, (1.43) pirifenox, (1.44) quinconazol, (1.45) simeconazol, (1.46) espiroxamina, (1.47) tebuconazol, (1.48) terbinafim, (1.49) tetraconazol, (1.50) triadimefom, (1.51) triadimenol, (1.52) tridemorfe, (1.53) triflumizol, (1.54) triforim, (1.55) triticonazol, (1.56) uniconazol, (1.57) uniconazol-P, (1.58) viniconazol, (1.59) voriconazol, (1.60) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1yl)cycloheptanol, (1.61) 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1Himidazole-5-carboxylate of methyl, (1.62) N'-{5-(difluoromethyl)-2-methyl-4[3-(trimethylsilyl)propoxy]phenyl}-N-ethyl-N-methylimidoformamide, (1.63) N-ethylN-methyl-N'-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}imidoformamide and (1.64) O-[1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl]-1Himidazole-1-carbothioate, (1.65) pyrisoxazole. (2) Respiratory inhibitors (respiratory chain inhibitors), for example, (2.1) bixaphene, (2.2) boscalid, (2.3) carboxin, (2.4) diflumetorim, (2.5) fenfuran, (2.6) fluopyram, (2.7) flutolanil, (2.8) fluxapyroxad, (2.9) furomethpyr, (2.10) furmeciclox, (2.11) isopyrazam mixture of the syn-epimeric racemate 1RS,4SR,9RS and the anti-epimeric racemate 1RS,4SR,9SR, (2.12) isopyrazam (anti-epimeric racemate), (2.13) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.14) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (2.15) isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), (2.16) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (2.17) isopyrazam (syn-epimeric enantiomer Petition 870210086398, dated 09 / 20 / 2021, p. 85 / 177 82 / 162 1S,4R,9S), (2.18) mepronil, (2.19) oxicarboxina, (2.20) penflufeno, (2.21) pentiopirade, (2.22) sedaxano, (2.23) tifluzamida, (2.24) 1-metilN-[2-(1,1,2,2-tetrafluoroetoxi)fenil]-3-(trifluorometil)-1H-pirazol-4carboxamida, (2.25) 3-(difluorometil)-1-metil-N-[2-(1,1,2,2tetrafluoroetoxi)fenil]-1H-pirazol-4-carboxamida, (2.26) 3(difluorometil)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxi)fenil]-1metil-1H-pirazol-4-carboxamida, (2.27) N-[1-(2,4-diclorofenil)-1metoxipropan-2-il]-3-(difluorometil)-1-metil-1H-pirazol-4-carboxamida, (2.28) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluorometil)piridin-2il]oxi}fenil)etil]quinazolina-4-amina, (2.29) benzovindiflupir, (2.30) N[(1S,4R)-9-(diclorometileno)-1,2,3,4-tetra-hidro-1,4-metanonaftalen-5il]-3-(difluorometil)-1-metil-1H-pirazol-4-carboxamida e (2.31) N[(1R,4S)-9-(diclorometileno)-1,2,3,4-tetra-hidro-1,4-metanonaftalen-5il]-3-(difluorometil)-1-metil-1H-pirazol-4-carboxamida, (2.32) 3(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl)-1Hpyrazol-4-carboxamide, (2.33) 1,3,5-trimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.34) 1 -methyl-3(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl)-1H-pyrazole-4carboxamide, (2.35) 1-methyl-3-(trifluoromethyl)-N-[(3R)-1,1,3-trimethyl-2,3di-hydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.36) 1 -methyl-3(trifluoromethyl)-N-[(3C)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1Hpyrazol-4-carboxamide, (2.37) 3-(difluoromethyl)-1-methyl-N-[(3C)-1,1,3trimethyl-2,3-di-hydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.38) 3(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]1H-pyrazole-4-carboxamide, (2.39) 1,3,5-trimethyl-N-[(3R)-1,1,3-trimethyl2,3-di-hydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (2.40) 1,3,5trimethyl-N-[(3C)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1H-pyrazole-4carboxamide, (2.41) benodanil, (2.42) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridine-3-carboxamide, (2.43) isofetamide. (3) Respiratory inhibitors (respiratory chain inhibitors) Petition 870210086398, dated 09 / 20 / 2021, p. 86 / 177 83 / 162 ria) that act on complex III of the respiratory chain, for example, (3.1) ametoctradine, (3.2) amisulbrom, (3.3) azoxystrobin, (3.4) ciazofamide, (3.5) cumetoxystrobin, (3.6) cumoxystrobin, (3.5) dimoxystrobin, (3.8) enstroburin, (3.9) famoxadone, (3.10) fenamidone, (3.11) flufenoxystrobin, (3.12) fluoxastrobin, (3.13) cresoxim-methyl, (3.14) metominostrobin, (3.15) orisastrobin, (3.16) picoxystrobin, (3.17) pyraclostrobin, (3.18) pyrametostrobin, (3.19) pyroxystrobin, (3.20) piribencarb, (3.21) triclopiricarb, (3.22) trifloxystrobin, (3.23) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-2(methoxy-imino)-N-methylethanamide, (3.24) (2E)-2-(methoxy-imino)-N-methyl2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)ethamide, (3.25) (2E)-2-(methoxy-imino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoro methyl)phenyl]ethoxy}imino)methyl]phenyl}ethamide, (3.26) (2E)-2-{2-[({[(1E)-1(3-{[(E)-1-fluoro-2-phenylethenyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2(methoxyimino)-N-methylethanamide, (3.27) (2E)-2-{2-[({[(2E,3E)-4-(2,6dichlorophenyl)but-3-en-2-ylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide, (3.28) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4yl)pyridine-3-carboxamide, (3.29) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)-2,4-dihydro-3H-1,2,4triazol-3-one, (3.30) (2E)-2-{2-[({cyclopropyl[(4-methoxyphenyl)imino]methyl} sulfanyl)methyl]phenyl}-3-methoxyprop-2-enoate of methyl, (3.31) N-(3-ethyl3,5,5-trimethylcyclohexyl)-3-(formylamino)-2-hydroxybenzamide, (3.32) 2{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide. (4) Inhibitors of mitosis and cell division, for example, (4.1) benomyl, (4.2) carbendazim, (4.3) chlorphenazole, (4.4) dietofencarb, (4.5) etaboxam, (4.6) fluopicolide, (4.7) fuberidazole, (4.8) pencicuron, (4.9) thiabendazole, (4.10) thiophanate-methyl, (4.11) thiophanate, (4.12) zoxamide, (4.13) 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine and (4.14) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4(2,4,6-trifluorophenyl)pyridazine. Petition 870210086398, dated 09 / 20 / 2021, page 87 / 177 84 / 162 (5) Compounds having activity at multiple sites, for example, (5.1) Bordeaux mixture, (5.2) captafol, (5.3) captan, (5.4) chlorothalonil, (5.5) copper preparations, such as copper hydroxide, (5.6) copper naphthenate, (5.7) copper oxide, (5.8) copper oxychloride, (5.9) copper sulfate, (5.10) diclofluanide, (5.11) dithianon, (5.12) dodine, (5.13) dodine free base, (5.14) ferbam, (5.15) fluorofolpet, (5.16) folpet, (5.17) guazatine, (5.18) guazatine acetate, (5.19) iminoctadine, (5.20) iminoctadine albesylate, (5.21) iminoctadine triacetate, (5.22) mancopper, (5.23) mancozeb, (5.24) maneb, (5.25) metiram, (5.26) zinc metiram, (5.27) copper oxine, (5.28) propamidine, (5.29) propineb, (5.30) sulfur and sulfur preparations, for example, calcium polysulfide, (5.31) thiram, (5.32) tolylfluanide, (5.33) zineb, (5.34) ziram and (5.35) anilazine. (6) Resistance inducers, for example, (6.1) acibenzolarS-methyl, (6.2) isotianil, (6.3) probenazole, (6.4) thiadinil and (6.5) laminarin. (7) Amino acid and protein biosynthesis inhibitors, for example, (7.1), (7.2) blasticidin-S, (7.3) ciprodinil, (7.4) kasugamycin, (7.5) kasugamycin hydrochloride hydrate, (7.6) mepanipirim, (7.7) pyrimethanil, (7.8) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline and (7.9) oxytetracycline and (7.10) streptomycin. (8) Inhibitors of ATP production, for example, (8.1) fentin acetate, (8.2) fentin chloride, (8.3) fentin hydroxide and (8.4) silthiofam. (9) Cell wall synthesis inhibitors, for example, (9.1) bentiavalicarb, (9.2) dimethomorph, (9.3) flumorph, (9.4) iprovalicarb, (9.5) mandipropamide, (9.6) polyoxins, (9.7) polioxorim, (9.8) validamycin A, (9.9) valifenalate and (9.10) polyoxin B. (10) Lipid and membrane synthesis inhibitors, for example, (10.1) biphenyl, (10.2) chlorneb, (10.3) dichloram, (10.4) edifen Petition 870210086398, dated 09 / 20 / 2021, page 88 / 177 85 / 162 phos, (10.5) etridiazole, (10.6) iodocarb, (10.7) iprobenphos, (10.8) isoprothiolane, (10.9) propamocarb, (10.10) propamocarb hydrochloride, (10.11) prothiocarb, (10.12) pyrazophos, (10.13) quintozene, (10.14) tecnazene and (10.15) tolclophos-methyl. (11) Inhibitors of melanin biosynthesis, for example, (11.1) carpropamide, (11.2) diclocimet, (11.3) fenoxanil, (11.4) phthalide, (11.5) piroquilon, (11.6) tricyclazole and (11.7) 2,2,2-trifluoroethyl {3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl}carbamate. (12) Nucleic acid synthesis inhibitors, for example, (12.1) benalaxyl, (12.2) benalaxyl-M (quiralaxyl), (12.3) bupirimate, (12.4) clozilacon, (12.5) dimethirimol, (12.6) etirimol, (12.7) furalaxyl, (12.8) himexazole, (12.9) metalaxyl, (12.10) metalaxyl-M (mefenoxam), (12.11) ofurace, (12.12) oxadixyl, (12.13) oxolinic acid and (12.14) octilinone. (13) Signal transduction inhibitors, for example, (13.1) clozolinate, (13.2) fenpiclonil, (13.3) fludioxonil, (13.4) iprodione, (13.5) procymidone, (13.6) quinoxifene, (13.7) vinclozolin and (13.8) proquinazide. (14) Uncouplers, for example, (14.1) binapacryl, (14.2) dinocap, (14.3) ferinzone, (14.4) fluazinam and (14.5) meptildinocap. (15) Other compounds, for example, (15.1) bentiazole, (15.2) betoxazine, (15.3) capsimycin, (15.4) carvone, (15.5) quinomethionate, (15.6) pyriophenone (clazafenone), (15.7) cufraneb, (15.8) ciflufenamide, (15.9) cymoxanil, (15.10) cyprosulfamide, (15.11) dazomet, (15.12) debacarb, (15.13) dichlorophen, (15.14) diclomezine, (15.15) difenzoquat, (15.16) difenzoquat methyl sulfate, (15.17) diphenylamine, (15.18) EcoMate, (15.19) fenpyrazamine, (15.20) flumetover, (15.21) fluorimide, (15.22) flusulfamide, (15.23) flutianil, (15.24) aluminum fosetyl, (15.25) calcium fosetyl, (15.26) sodium fosetyl, (15.27) hexachlorobenzene, (15.28) irumamycin, (15.29) metasulfocarb, (15.30) methyl isothiocyanate, (15.31) metrafenone, (15.32) mildiomycin, Petition 870210086398, dated 09 / 20 / 2021, page 89 / 177 86 / 162 (15.33) natamycin, (15.34) dimethyldithiocarbamato de níquel, (15.35) nitrotal-isopropila, (15.36) octilinona, (15.37) oxamocarbe, (15.38) oxyfentine, (15.39) pentachlorophenol e seus sais, (15.40) phenothrin, (15.41) phosphoric acid and other substances, (15.42) propamocarbe-fosetilato, (15.43) propanosine-sodium, (15.44) pirimorphe, (15.45) (2E)-3-(4-tert-butylphenyl)3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (15.46) (2Z)-3-(4tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (15.47) pyrrolnitrin, (15.48) tebufloquine, (15.49) tecloftalam, (15.50) tolnifanide, (15.51) triazoxide, (15.52) trichlamide, (15.53) zarilamide, (15.54) 2-methylpropanoate (3S,6S,7R,8R)-8-benzyl-3-[({3[(isobutyryloxy)methoxy]-4-methoxipyridin-2-yl}carbonyl)amino]-6-methyl-4,9dioxo-1,5-dioxonan-7-yl, (15.55) 1 -(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5di-hidro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3(trifluoromethyl)-1H-pyrazol-1-yl]ethanona, (15.56) 1 -(4-{4-[(5S)-5-(2,6-difluorofenil)-4,5-di-hidro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]etanone, (15.57) 1 -(4-{4-[5(2,6-difluorofenil)-4,5-di-hidro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]etanone, (15.58) 1Himidazol-1-carboxylate de 1 -(4-methoxyfenoxy)-3,3-dimethylbutan-2-yl, (15.59) 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, (15.60) 2,3-dibutyl-6chlorothieno[2,3-d]pyrimidin-4(3H)-ona, (15.61) 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrol-1,3,5,7(2H,6H)-tetrona, (15.62) 2-[5-methyl-3(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-di-hidro-1,2oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.63) 2-[5-methyl-3(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-di-hidro-1,2oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (15.64) 2-[5-methyl-3(trifluoromethyl)-1H-pyrazol-1-yl]-1-{4-[4-(5-phenyl-4,5-di-hydro-1,2-oxazol-3yl)-1,3-thiazol-2-yl]piperidine-1-yl}ethanone65,) 2-butoxy-6-iodo-3-propyl4H-chromen-4-one, (15.66) 2-chloro-5-[2-chloro-1-(2,6-difluoro-4methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15-phenyl.67) Petition 870210086398, dated 20 / 09 / 2021, p. 90 / 177 87 / 162 (15.68) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinolina, (15.69) 3,4,5-trichloropyridine-2,6-dicarbonitrila, (15.70) 3-chloro-5-(4chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (15.71) 4-(4-chlorophenyl)5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (15.72) 5-amino-1,3,4-thiadiazol-2-thiol, (15.73) 5-Chloro-N'-phenyl-N'-(prop-2-ylene-1-yl)thiophene-2-sulfonhydrazide, (15.74) 5-fluoro-2-[(4-fluorobenzyl)oxi]pyrimidine-4-amine, (15.75) 5-fluoro-2-[(4-methylbenzyl)oxi]pyrimidine-4-amine, (15.76) 5-methyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidine-7-amine, (15.77) ethyl (2Z)-3amino-2-cyano-3-phenylacrylate, (15.78) N'-(4-{[3-(4-chlorobenzyl)-1,2,4thiadiazol-5-yl]oxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamida, (15.79) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-in-1-yloxy)phenyl]propanamida, (15.80) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-in-1-yloxy)phenyl]propanamida, (15.81) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4dichloronicotinamide, (15.82) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4dichloronicotinamida, (15.83) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2fluoro-4-iodonicotinamida, (15.84) N-{(E)-[(cyclopropylmethoxy)imino][6(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamida, (15.85) N-{(Z)[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamida, (15.86) N'-{4-[(3-terc-butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2chloro-5-methylphenyl}-N-ethyl-N-methylimidoformamida, (15.87) N-methyl-2-(1 {[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4tetra-hidronaphthalene-1-yl)-1,3-thiazol-4-carboxamida, (15.88) N-methyl-2-(1 {[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)1,2,3,4-tetra-hidronaphthalene-1-yl]-1,3-thiazol-4-carboxamida, (15.89) Nmethyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)N-[(1S)-1,2,3,4-tetra-hidronaphthalene-1-yl]-1,3-thiazol-4-carboxamida, (15.90) {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl] pyridine-2-yl}pentyl carbamate, (15.91) phenazine-1-carboxylic acid, (15.92.9-deol) quinoline quinolin-8-ol (2:1), (15.94) {6[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridine-2Petition 870210086398, dated 20 / 09 / 2021, p. 91 / 177. 88 / 162 terc-butyl il}carbamate, (15.95) 1-methyl-3-(trifluoromethyl)-N-[2'(trifluoromethyl)biphenyl-2-yl]-1H-pyrazol-4-carboxamida, (15.96) N-(4'chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazol-4-carboxamida, (15.97) N-(2',4'-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazol-4carboxamida, (15.98) 3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)bife nyl-2-yl]-1H-pyrazol-4-carboxamida, (15.99) N-(2',5'-difluorobiphenyl-2-yl)-1 methyl-3-(trifluoromethyl)-1H-pyrazol-4-carboxamida, (15,100) 3-(difluoro methyl)-1-methyl-N-[4'-(prop-1-in-1-yl)biphenyl-2-yl]-1H-pyrazol-4-carboxamida, (15.101) 5-fluoro-1,3-dimethyl-N-[4'-(prop-1-in-1-yl)biphenyl-2-yl]-1H-pyrazol4-carboxamida, (15.102) 2-chloro-N-[4'-(prop-1-in-1-yl)biphenyl-2-yl]nicotine midida, (15.103) 3-(difluoromethyl)-N-[4'-(3,3-dimethylbut-1-in-1-yl)biphenyl-2yl]-1-methyl-1H-pyrazol-4-carboxamida, (15.104) N-[4'-(3,3-dimethylbut-1-in1 -yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazol-4-carboxamida, (15.105) 3-(difluoromethyl)-N-(4'-ethynylbiphenyl-2-yl)-1-methyl-1H-pyrazole-4carboxamide, (15.106) N-(4'-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1Hpyrazole-4-carboxamide, (15.107) 2-chloro-N-(4'-ethynylbiphenyl-2-yl)nicotinamide, (15.108) 2-chloro-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (15.109) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]1,3-thiazole-5-carboxamide, (15.110) 5-fluoro-N-[4'-(3-hydroxy-3-methylbut1 -yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (15.111) 2chloro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (15.112) 3-(difluoromethyl)-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]1-methyl-1H-pyrazole-4-carboxamide, (15.113) 5-fluoro-N-[4'-(3-methoxy-3methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (15,114) 2-chloro-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (15.115) (5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6methylphenyl)methanone, (15.116) N-[2-(4-{[3-(4-chlorophenyl)prop-2-in-1yl]oxi}-3-methoxyphenyl)ethyl]-N2-(methylsulfonyl)valinamida, (15.117) 4oxo-4-[(2-phenylethyl)amino]butanoic acid, (15.118) {6-[({[(Z)-(1-methyl-1Htetrazol-5-yl)(phenyl)methylene]amino}oxi)methyl]pyridin-2-yl}carbamate de. Petition 870210086398, 09 / 20 / 2021, pág. 92 / 177 89 / 162 but-3-in-1-ila, (15,119) 4-amino-5-fluoropyrimidine-2-ol (tautomeric form: 4-amino-5-fluoropyrimidine-2(1H)-one), (15,120) 3,4,5-trihydroxy de.125, ()1 benzoate 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-di-hydro-1Hinden-4-yl)-1H-pyrazol-4-carboxamide, (15,122) 1,3-dimethyl-N-[(3R)1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1H-pyrazol-4-carboxamide, (15,123) 1,3-dimethyl-N-[(3S)-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]1H-pyrazol-4-carboxamide, (15,124) [3-(4-chloro-2-fluorophenyl)-5-(2,4difluorophenyl)-1,2-oxazol-4-yl](pyridine-3-yl)methanol, (15.125) (S)-[3-(4chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridine-3yl)methanol, (15.126) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)1,2-oxazol-4-yl](pyridine-3-yl)methanol, (15.127) 2-{[[3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-2,4-di-hydro-3H-1,2,4-triazol-3-thione, (15,128) thiocyanate of 1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2yl]methyl}-1H-1,2,4-triazol-5-yl, (15.129) 5-(allylsulfanyl)-1-{[3-(2chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (15.130) 2-[1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4di-hydro-3H-1,2,4-triazole-3-thione, (15.131) 2-{[rel(2R,3S)-3-(2chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-di-hydro-3H-1,2,4triazole-3-thione, (15.132) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-2,4-di-hydro-3H-1,2,4-triazole-3-thione, (15,133) thiocyanate of 1-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl, (15,134) thiocyanate of 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}1H-1,2,4-triazol-5-yla, (15.135) 5-(allylsulfanyl)-1-{[rel(2R,3S)-3-(2chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (15.136) 5-(allylsulfanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (15.137) 2-[(2S,4S,5S)-1(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H1,2,4-triazole-3-thione, (15,138) 2-[(2R,4S,5S)-1-(2,4-dichlorophenyl)-5hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazole-3-thiona,. Petition 870210086398, of 20 / 09 / 2021, p. 93 / 177 90 / 162 (15.139) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazole-3-thione, (15.14) 2[(2S,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4di-hydro-3H-1,2,4-triazole-3-thione, (15,141) 2-[(2S,4S,5R)-1-(2,4dichlorophenyl)-5-hydroxy-2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4triazole-3-thione, (15,142) 2-[(2R,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy2,6,6-trimethyl-heptan-4-yl]-2,4-di-hydro-3H-1,2,4-triazole-3-thione, (15,143) 2-[(2R,4R,5S)-1-(2,4-dichlorofenil)-5-hydroxy-2,6,6-trimetil-heptan-4-yl]2,4-di-hidro-3H-1,2,4-triazol-3-thiona, (15.144) 2-[(2S,4R,5S)-1-(2,4dichlorofenil)-5-hydroxy-2,6,6-trimetil-heptan-4-yl]-2,4-di-hidro-3H-1,2,4triazol-3-thiona, (15.145) 2-fluoro-6-(trifluorometil)-N-(1,1,3-trimetil-2,3di-hidro-1H-inden-4-yl)benzamide, (15.146) 2-(6-benzylpyridin-2yl)quinazolina, (15.147) 2-[6-(3-fluoro-4-methoxyphenyl)-5-metilpyridin-2yl]quinazolina, (15.148) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinolina, (15.149) ácido abscísico, (15.150) 3(difluorometil)-N-methoxy-1-metil-N-[1-(2,4,6-trichlorofenil)propan-2-yl]-1Hpyrazole-4-carboxamide, (15.151) N'-[5-bromo-6-(2,3-di-hidro-1H-inden2-yloxy)-2-metilpyridin-3-yl]-N-ethyl-N-methylimidoformamide, (15.152) N'-{5bromo-6-[1-(3,5-difluorofenil)ethoxy]-2-metilpyridin-3-yl}-N-ethyl-Nmethylimidoformamide, (15.153) N'-{5-bromo-6-[(1R)-1-(3,5difluorofenil)ethoxy]-2-metilpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.153)154) N'-{5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3yl}-N-ethyl-N-methylimidoformamide, (15.155) N'-{5-bromo-6-[(cis-4isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidoformamide, (15.156) N'-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin3-yl}-N-ethyl-N-methylimidoformamide, (15.157) N-cyclopropyl-3(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.158) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.159) N(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (15.159) N(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-Petição 870210086398, of 20 / 09 / 2021, pág. 94 / 177. 91 / 162 pirazol-4-carboxamida, (15.160) N-(5-cloro-2-etilbenzil)-N-ciclopropil-3(difluorometil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (15.161) N(5-cloro-2-isopropilbenzil)-N-ciclopropil-3-(difluorometil)-5-fluoro-1metil-1H-pirazol-4-carboxamida, (15.162) N-ciclopropil-3(difluorometil)-N-(2-etil-5-fluorobenzil)-5-fluoro-1-metil-1H-pirazol-4carboxamida, (15.163) N-ciclopropil-3-(difluorometil)-5-fluoro-N-(5fluoro-2-isopropilbenzil)-1-metil-1H-pirazol-4-carboxamida, (15.164) Nciclopropil-N-(2-ciclopropil-5-fluorobenzil)-3-(difluorometil)-5-fluoro-1metil-1H-pirazol-4-carboxamida, (15.165) N-(2-ciclopentil-5fluorobenzil)-N-ciclopropil-3-(difluorometil)-5-fluoro-1-metil-1H-pirazol4-carboxamida, (15.166) N-ciclopropil-3-(difluorometil)-5-fluoro-N-(2fluoro-6-isopropilbenzil)-1-metil-1H-pirazol-4-carboxamida, (15.167) Nciclopropil-3-(difluorometil)-N-(2-etil-5-metilbenzil)-5-fluoro-1-metil-1Hpirazol-4-carboxamida, (15.168) N-ciclopropil-3-(difluorometil)-5-fluoroN-(2-isopropil-5-metilbenzil)-1-metil-1H-pirazol-4-carboxamida, (15.169) N-ciclopropil-N-(2-ciclopropil-5-metilbenzil)-3-(difluorometil)-5fluoro-1-metil-1H-pirazol-4-carboxamida, (15.170) N-(2-terc-butil-5metilbenzil)-N-ciclopropil-3-(difluorometil)-5-fluoro-1-metil-1H-pirazol-4carboxamida, (15.171) N-[5-cloro-2-(trifluorometil)benzil]-N-ciclopropil3-(difluorometil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (15.172) Nciclopropil-3-(difluorometil)-5-fluoro-1-metil-N-[5-metil-2(trifluorometil)benzil]-1H-pirazol-4-carboxamida, (15.173) N-[2-cloro-6(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)-5-fluoro-1-metil-1Hpirazol-4-carboxamida, (15.174) N-[3-cloro-2-fluoro-6(trifluorometil)benzil]-N-ciclopropil-3-(difluorometil)-5-fluoro-1-metil-1Hpirazol-4-carboxamida, (15.175) N-ciclopropil-3-(difluorometil)-N-(2-etil4,5-dimetilbenzil)-5-fluoro-1-metil-1H-pirazol-4-carboxamida, (15.176). N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1Hpyrazol-4-carbothiamide, (15,177) 3-(difluoromethyl)-N-(7-fluoro-1,1,3trimethyl-2,3-di-hydro-1H-inden-4-yl)-1-methyl-1H-pyrazol-4-carboxamide, Petition 870210086398, dated 20 / 09 / 2021, p. 95 / 177 92 / 162 (15,178) 3-(difluoromethyl)-N-[(3R)-7-fluoro-1,1,3-trimethyl-2,3-di-hydro-1Hinden-4-yl]-1-methyl-1H-pyrazol-4-carboxamide, (15,179) 3-(difluoromethyl)N-[(3S)-7-fluoro-1,1,3-trimethyl-2,3-di-hydro-1H-inden-4-yl]-1-methyl-1Hpyrazol-4-carboxamide, (15,180) N'-(2,5-Nthylimimethylformyl-4-phene (15,181) N'-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5dimethylphenyl}-N-ethyl-N-methylimidoformamide, (15,182) N-(4-chloro-2,6difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine. All mixture components mentioned in classes (1) to (15), as the case may be, can form salts with suitable bases or acids, if they are capable of doing so based on their functional groups. Biological Pesticides as Mixture Components [000372] The compounds of Formula (I) can be combined with biological pesticides. [000373] Biological pesticides include, in particular, bacteria, fungi, yeasts, plant extracts and products formed by microorganisms, including proteins and secondary metabolites. [000374] Biological pesticides include bacteria, such as spore-forming bacteria, root-colonizing bacteria, and bacteria that act as biological insecticides, fungicides, or nematicides. [000375] Examples of such bacteria that are used or can be used as biological pesticides are: [000376] Bacillus amyloliquefaciens, strain FZB42 (DSM 231179) or Bacillus cereus, especially B. cereus, strain CNCM I-1562 or Bacillus firmus, strain I-1582 (CNCM Accession Number I-1582) or Bacillus pumilus, especially strain GB34 (ATCC Accession Number 700814) and strain QST2808 (NRRL Accession Number B-30087) or Bacillus subtilis, especially strain GB03 (ATCC Accession Number SD-1397) or Bacillus subtilis, strain QST713 (NRRL Accession Number B-21661) or Bacillus subtilis, strain OST 30002 (Accession Number Petition 870210086398, dated 09 / 20 / 2021, page 96 / 177 93 / 162 NRRL B-50421) Bacillus thuringiensis, especially, B. thuringiensis subspecies israelensis (serotype H-14), strain AM65-52 (ATCC Accession Number 1276) or B. thuringiensis subsp. aizawai, especially strain ABTS-1857 (SD-1372) or B. thuringiensis subsp. kurstaki, strain HD-1 or B. thuringiensis subsp. tenebrionis, strain NB 176 (SD5428), Pasteuria penetrans, Pasteuria spp. (nematode Rotylenchulus reniformis)-PR3 (ATCC Accession Number SD-5834), Streptomyces microflavus, strain AQ6121 (= QRD 31.013, NRRL B-50550), Streptomyces galbus, strain AQ 6047 (NRRL Accession Number 30232). [000377] Examples of fungi and yeasts that are used or can be used as biological pesticides are: [000378] Beauveria bassiana, especially strain ATCC 74040, Coniothyrium minitans, especially strain CON / M / 91-8 (DSM Accession Number 9660), Lecanicillium spp., especially strain HRO LEC 12, Lecanicillium lecanii (formerly known as Verticillium lecanii), especially strain KV01, Metarhizium anisopliae, especially strain F52 (DSM 3884 / ATCC 90448), Metschnikowia fructicola, especially strain NRRL Y-30752, Paecilomyces fumosoroseus (now: Isaria fumosorosea), especially strain IFPC 200613 or strain Apopka 97 (ATCC Accession Number 20874), Paecilomyces lilacinus, especially P. lilacinus, strain 251 (AGAL 89 / 030550), Talaromyces flavus, especially strain V117b, Trichoderma atroviride, especially strain SC1 (CBS Accession Number 122089), Trichoderma harzianum, especially T. harzianum rifai T39. (CNCM Accession Number I-952) [000379] Examples of viruses that are used or can be used as biological pesticides are: [000380] Adoxophyes orana granulosis virus (GV) (fruit tortricid), Cidia pomonella granulosis virus (GV) (apple moth) (GV), Helicoverpa nuclear polyhedrosis virus (NPV) Petition 870210086398, dated 09 / 20 / 2021, page 97 / 177 94 / 162 armigera (cotton earworm), mNPV of Spodoptera exigua (beetroot fall armyworm), mNPV of Spodoptera frugiperda (fall armyworm), NPV of Spodoptera littoralis (African cotton bollworm). [000381] Also included are bacteria and fungi that are added as an 'inoculant' to plants or plant parts or plant organs and which, by virtue of their particular properties, promote plant growth and health. Examples include: [000382] Agrobacterium spp., Azorhizobium caulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., especially, Burkholderia cepacia (formally known as Pseudomonas cepacia), Gigaspora spp. or Gigaspora monosporum, Glomus spp., Laccaria spp., Lactobacillus buchneri, Paraglomus spp., Pisolithus tinctorus, Pseudomonas spp., Rhizobium spp., especially, Rhizobium trifolii, Rhizopogon spp., Scleroderma spp., Suillus spp., Streptomyces spp. [000383] Examples of plant extracts and products formed by microorganisms, including proteins and secondary metabolites, that are used or can be used as biological pesticides are: [000384] Allium sativum, Artemisia absinthium, azadiratin, Biokeeper WP, Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum, chitin, Armor-Zen, Dryopteris filixmas, Equisetum arvense, Fortune Aza, Fungastop, Heads Up (Chenopodium quinoa saponin extract), Pyrethrum / pyrethrins, Quassia amara, Quercus, Quillaja, Regalia, Requiem™ Insecticide, rotenone, ryania / ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, Triact 70, Tricon, Tropaeulum majus, Urtica dioica, Veratrina, Viscum album, extract Brassicaceae, especially rapeseed powder or mustard powder. Plant protection agents as mixture components. [000385] The compounds of Formula (I) can be combined with Petition 870210086398, dated 09 / 20 / 2021, page 98 / 177 95 / 162 phytoprotectors, for example, benoxacor, cloquintocet (-mexyl), cyometrinil, dichlormide, cyprosulfamide, fenchlorazole (-ethyl), fenchlorim, flurazole, fluxofenim, furilazole, isoxadifen (-ethyl), mefenpyr (-diethyl), naphthalic anhydride, oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl}sulfonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyl)-1-oxa-4-azaspiro[4.5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3oxazolidine (CAS 52836-31-4). Plants and Parts of Plants [000386] All plants and plant parts can be treated according to the invention. Herein, plants should be understood in this document as meaning all plants and plant populations, such as desired and undesired wild plants or cultivated plants (including naturally occurring crop plants), for example, cereals (wheat, rice, triticale, barley, rye, oats), maize, soybeans, potatoes, sugar beets, sugarcane, tomatoes, peas and other vegetable species, cotton, tobacco, rapeseed, and also fruit plants (with the fruits apples, pears, citrus fruits and grapevines). Cultivated plants may be plants that can be obtained through conventional breeding and optimization methods or through biotechnological and genetic methods or combinations of these methods, including transgenic plants and including plant cultivars that may or may not be protected by property rights over cultivars.Plant parts should be understood to mean all parts and organs of plants above and below ground, such as stems, leaves, flowers, and roots, examples being leaves, needles, stalks, stems, flowers, fruit bodies, fruits, and seeds, as well as tubers, roots, and rhizomes. Plant parts also include harvested plants and vegetative and generative propagation material, for example, seedlings, tubers, rhizomes, cuttings, and seeds. [000387] The treatment, according to the invention, of plants and par Petition 870210086398, dated 09 / 20 / 2021, page 99 / 177 96 / 162 plant tests with the compounds of Formula (I) is carried out directly or by allowing the compounds to act on their surroundings, environment or storage space through usual treatment methods, for example, by immersion, spraying, evaporation, nebulization, dispersion, painting, injection and, in the case of propagation material, especially in the case of seeds, also by applying one or more coating layers. [000388] As mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars or those obtained through conventional biological breeding, such as protoplast crossing or fusion, and their parts are treated. In another preferred embodiment, transgenic plants and plant cultivars obtained through genetic engineering methods, possibly in combination with conventional methods (genetically modified organisms), and their parts are treated. The term plant parts or plant parts has been explained above. Particular preference is given according to the invention to treating plants of the respective commercially usual cultivars or those that are in use.Plant cultivars should be understood as plants that have new properties (traits) and that have been obtained through conventional breeding, mutagenesis, or recombinant DNA techniques. They can be cultivars, growers, varieties, bio- or genotypes. Transgenic plants, seed treatment and integration events [000389] The preferred transgenic plants or plant cultivars (those obtained by genetic engineering) which are to be treated according to the invention include all plants which, through genetic modification, have received genetic material that confers Petition 870210086398, dated 09 / 20 / 2021, pp. 100 / 177 97 / 162 completed useful advantageous properties (traits) of these plants. Examples of such properties are improved plant growth, greater tolerance to high or low temperatures, greater tolerance to drought or soil water or salinity levels, enhanced flowering performance, easier harvesting, accelerated maturation, higher yields, higher quality and / or higher nutritional value of harvested products, improved storage and / or processing life of harvested products.Additional and particularly emphasized examples of such properties are increased plant resistance against microbial pests, such as insects, arachnids, nematodes, mites, slugs and snails, caused, for example, by toxins formed in plants, especially those formed in plants by the genetic material of Bacillus thuringiensis (e.g., by the genes CryIA(a), CryIA(b), CryIA(c), CryIIA, CryIIIA, CryIIIB2, Cry9c, Cry2Ab, Cry3Bb and CryIF, as well as combinations thereof), in addition to increased plant resistance against phytopathogenic fungi, bacteria and / or viruses due, for example, to systemic acquired resistance (SAR), systemin, phytoalexins, stimulators and also resistance genes and correspondingly expressed proteins and toxins, and a greater tolerance of plants to certain herbicidally active ingredients, e.g., imidazolinones, sulfonylureas, glyphosates or phosphinothricin (e.g., the PAT gene).The genes that confer the desired properties (“traits”) in question may also be present in combination with one another in transgenic plants. Examples of transgenic plants include important crops such as cereals (wheat, rice, triticale, barley, rye, oats), corn, soybeans, potatoes, sugar beets, sugarcane, tomatoes, peas and other types of vegetables, cotton, tobacco, rapeseed, and also fruit plants (with fruits such as apples, pears, citrus fruits and grapes), with particular emphasis being placed on this. Petition 870210086398, dated 09 / 20 / 2021, pp. 101 / 177 98 / 162 given to corn, soybeans, wheat, rice, potatoes, cotton, sugarcane, tobacco, and rapeseed. The properties (“traits”) that are particularly emphasized are the increased resistance of the plants to insects, arachnids and nematodes, slugs, and snails. Crop Protection - Types of Treatment [000390] The treatment of plants and plant parts with the compounds of Formula (I) is carried out directly or through action on their environment, habitat or storage space by means of usual treatment methods, for example, by immersion, spraying, atomizing, watering, evaporation, dusting, misting, dispersion, foaming, painting, spreading, injection, wetting (soaking), drip irrigation and, in the case of propagation material, especially in the case of seeds, also as a powder for dry seed treatment, a solution for liquid seed treatment, a water-soluble powder for treatment as a paste, by encrustation, by coating with one or more layers of coating, etc. In addition, it is possible to apply the compounds of Formula (I) by the ultra-low volume method or inject the application form or the compound of Formula (I) itself into the soil. [000391] A preferred direct treatment of plants is foliar application, i.e., the compounds of Formula (I) are applied to the foliage, where the frequency of treatment and the application rate should be adjusted according to the level of infestation with the pest in question. [000392] In the case of systemically active compounds, the compounds of Formula (I) also access the plants through the root system. The plants are then treated by the action of the compounds of Formula (I) in the plant's habitat. This can be achieved, for example, by immersion or mixing in the soil or nutrient solution, meaning that the plant's location (e.g., soil or hydroponic systems) Petition 870210086398, dated 20 / 09 / 2021, page 102 / 177 99 / 162 nicos) is impregnated with a liquid form of the compounds of Formula (I), or by application to the soil, meaning that the compounds of Formula (I) according to the invention are introduced in solid form (e.g., in the form of granules) to the plant site. In the case of hydroponic rice crops, this can also be achieved by dosing the compound of Formula (I) in a solid application form (e.g., as granules) in a flooded hydroponic field. Seed Treatment [000393] The control of animal pests through seed treatment has been known for a long time and is the subject of continuous improvements. However, seed treatment involves a number of problems that cannot always be satisfactorily resolved. Thus, it is desirable to develop methods to protect the seed and the germinating plant that eliminate, or at least considerably reduce, the additional application of pesticides during storage, after planting, or after plant emergence. Furthermore, it is desirable to optimize the amount of active ingredient used in order to provide ideal protection for the seed and the germinating plant against attack by animal pests, but without damaging the plant itself due to the active ingredient used.In particular, seed treatment methods should also take into account the intrinsic insecticidal or nematicidal properties of transgenic plants resistant or tolerant to pests, in order to achieve optimal protection of the seeds and the germinating plant with a minimum of pesticides being used. [000394] Therefore, in particular, the present invention also relates to a method for protecting seeds and germinating plants against pest attack by treating the seed with one of the compounds of Formula (I). The method according to the invention Petition 870210086398, dated 09 / 20 / 2021, pp. 103 / 177 100 / 162 treatment for the protection of seeds and germinating plants against pest attack further comprises a method in which the seed is treated simultaneously in a single operation or sequentially with a compound of Formula (I) and a mixing component. It also further comprises a method where the seed is treated at different times with a compound of Formula (I) and a mixing component. [000395] The invention also relates to the use of the compounds of Formula (I) for seed treatment to protect the seeds and the resulting plant against animal pests. [000396] The invention further relates to a seed that has been treated with a compound of Formula (I) for protection against animal pests. The invention also relates to a seed that has been treated simultaneously with a compound of Formula (I) and a mixing component. The invention further relates to seeds that have been treated at different times with a compound of Formula (I) and a mixing component. In the case of seeds that have been treated at different times with a compound of Formula (I) and a mixing component, individual substances may be present on the seed in different layers. In this case, the layers comprising a compound of Formula (I) and the mixing components may optionally be separated by an intermediate layer.The invention also relates to a seed where a compound of Formula (I) and a mixing component have been applied as part of a coating or as another layer or additional layers, in addition to a coating. [000397] The invention further relates to a seed which, after treatment with a compound of Formula (I), is subjected to a film coating process to prevent dust abrasion on the seed. Petition 870210086398, dated 09 / 20 / 2021, pp. 104 / 177 101 / 162 [000398] One of the advantages found with a systemically acting compound of Formula (I) is the fact that, through seed treatment, not only the seed but also the plants that result from it after emergence are protected against animal pests. In this way, immediate treatment of the crop at planting time or soon after can be dispensed with. [000399] It should be considered as an additional advantage that, by treating the seed with a compound of Formula (I), the germination and emergence of the treated seeds can be increased. [000400] Similarly, it will be considered advantageous that the compounds of Formula (I) can be used, in particular, also for transgenic seeds. [000401] Furthermore, the compounds of Formula (I) can be used in combination with signaling technology compositions, leading to improved colonization by symbionts, for example, rhizobia, mycorrhizae and / or endophytic bacteria or fungi, and / or optimized nitrogen fixation. [000402] The compounds of Formula (I) are suitable for protecting seeds of a plant cultivar that is used in agriculture, in greenhouses, in viticulture or in horticulture. More particularly, this includes seeds of cereals (e.g., wheat, barley, rye, millet and oats), maize, cotton, soybeans, rice, potatoes, sunflowers, coffee, tobacco, canola, rapeseed, beet (e.g., sugar beet and fodder beet), peanuts, vegetables (e.g., tomatoes, cucumbers, beans, cruciferous vegetables, onions and lettuce), fruit trees, lawns and ornamental plants. The treatment of seeds of cereals (such as wheat, barley, rye and oats), maize, soybeans, cotton, canola, rapeseed and rice is of particular importance. [000403] As mentioned above, semen treatment Petition 870210086398, dated 09 / 20 / 2021, pp. 105 / 177 102 / 162 transgenic seed with a compound of Formula (I) is also of particular importance. This involves plant seeds that generally contain at least one heterologous gene regulating the expression of a polypeptide that has insecticidal and / or nematicidal properties, in particular. The heterologous genes in transgenic seed may originate from microorganisms such as Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus or Gliocladium. The present invention is particularly suitable for the treatment of transgenic seed containing at least one heterologous gene originating from Bacillus sp. It is, particularly preferably, a heterologous gene derived from Bacillus thuringiensis. [000404] In the context of the present invention, the compound of Formula (I) is applied to the seed. Preferably, the seed is treated in a state in which it is sufficiently stable to avoid damage during treatment. In general, the seed can be treated at any point in time between harvest and planting. The seed commonly used has been separated from the plant and freed from ears, husks, stems, coverings, hairs or fruit pulp. For example, it is possible to use seed that has been harvested, cleaned and dried to a moisture content that allows storage. Alternatively, it is also possible to use seed which, after drying, has been treated, for example, with water and then dried again, for example, by applying a base coat. In the case of rice seed, it is also possible to use seed which, for example, has been pre-swollen in water to a particular stage (sternum protrusion stage), which leads to better germination and more homogeneous emergence. [000405] When treating the seed, care should generally be taken to ensure that the amount of compound of Formula (I) applied to the seed and / or the amount of other additives is chosen in such a way that seed germination is not impaired or the plant Petition 870210086398, dated 09 / 20 / 2021, pp. 106 / 177 103 / 162 resulting is not damaged. This must be ensured, in particular, in the case of active ingredients that may exhibit phytotoxic effects at certain application rates. [000406] In general, the compounds of Formula (I) are applied to the seed in the form of a suitable formulation. Suitable formulations and processes for seed treatment are known to those skilled in the art. [000407] The compounds of Formula (I) can be converted into usual seed coating formulations, such as solutions, emulsions, suspensions, powders, foams, pastes or other seed coating compositions, and also ULV formulations. [000408] These formulations are produced in a known manner by mixing the compounds of Formula (I) with usual additives, for example, usual diluents and solvents or diluents, colorants, wetting agents, dispersants, emulsifiers, antifoaming agents, preservatives, secondary thickeners, adhesives, gibberellins and also water. [000409] Dyes that may be present in seed coating formulations that can be used according to the invention are all dyes that are usual for such purposes. It is possible to use pigments that are poorly soluble in water, or dyes that are soluble in water. Examples include dyes known by the names Rhodamine B, CI Pigment Red 112 and CI Solvent Red 1. [000410] Useful wetting agents that may be present in seed coating formulations usable according to the invention are all substances which promote wetting and which are conventionally used for the formulation of active agrochemical ingredients. Preference is given to the use of alkyl naphthalene sulfonates, such as di-isopropyl- or di Petition 870210086398, dated 09 / 20 / 2021, pp. 107 / 177 104 / 162 isobutylnaphthalenesulfonates. [000411] Suitable dispersants and / or emulsifiers which may be present in seed coating formulations usable according to the invention are all non-ionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Preference is given to the use of non-ionic or anionic dispersants or mixtures of non-ionic or anionic dispersants. Suitable non-ionic dispersants include, in particular, ethylene oxide / propylene oxide block polymers, alkylphenol polyglycol ethers and triestyrylphenol polyglycol ethers, and phosphate or sulfate derivatives thereof. Suitable anionic dispersants are especially lignosulfonates, polyacrylic acid salts and arylsulfonate / formaldehyde condensates. [000412] Antifoaming agents that may be present in seed coating formulations usable according to the invention are all substances for inhibiting foam conventionally used for the formulation of agrochemical active ingredients. Preference is given to the use of silicone and magnesium stearate antifoaming agents. [000413] Preservatives that may be present in seed coating formulations usable according to the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and benzyl alcohol hemiformal. [000414] Secondary thickeners which may be present in seed coating formulations usable according to the invention are all substances that can be used for such purposes in agrochemical compositions. Cellulose derivatives, acrylic acid derivatives, xanthan gum, modified clays and finely divided silica are preferred. Petition 870210086398, dated 09 / 20 / 2021, pp. 108 / 177 105 / 162 [000415] Suitable adhesives which may be present in seed coating formulations usable according to the invention are all binders usable in seed treatment products. Polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose may be mentioned as being preferred. [000416] Gibberellins that may be present in seed coating formulations that can be used according to the invention are preferably gibberellins A1, A3 (= gibberellic acid), A4 and A7; gibberellic acid is particularly preferably used. Gibberellins are known (cf. R. Wegler Chemie der Pflanzenschutz- und Schadlingsbekampfungsmittel, vol. 2, Springer Verlag, 1970, pages 401-412). [000417] The seed coating formulations usable according to the invention can be used to treat a wide variety of different types of seeds, either directly or after prior dilution with water. For example, the concentrates or preparations obtainable by dilution with water can be used to coat cereal seeds such as wheat, barley, rye, oats, and triticale, as well as maize, rice, rapeseed, peas, beans, cotton, sunflowers, soybeans, and beets, or a wide variety of different vegetable seeds. The seed coating formulations usable according to the invention, or diluted forms thereof, can also be used to coat transgenic plant seeds. [000418] For treating seeds with seed coating formulations usable according to the invention, or application forms prepared from them, all mixing units commonly used for seed treatment are useful. Specifically, the procedure in seed treatment is to place the seed in a mixer, operated in a manner Petition 870210086398, dated 09 / 20 / 2021, pp. 109 / 177 106 / 162 discontinuous or continuous, add the desired quantity of seed treatment formulations, as is or after prior dilution with water, and mix until the formulation is evenly distributed over the seed. If appropriate, this is followed by a drying operation. [000419] The application rate of the seed coating formulations usable according to the invention can be varied within a relatively wide range. It is guided by the content, especially, of the compounds of Formula (I) in the formulations and by the seed. The application rates of the compound of Formula (I) are generally between 0.001 and 50 g per kilogram of seed, preferably between 0.01 and 15 g per kilogram of seed. Animal Health [000420] In the field of animal health, that is, in the field of veterinary medicine, the compounds of Formula (I) are active against parasites in animals, especially ectoparasites or endoparasites. The term endoparasites includes, in particular, helminths and protozoa, such as coccidia. Ectoparasites are typically and preferably arthropods, especially insects and mites. [000421] In the field of veterinary medicine, the compounds of Formula (I) are suitable, with favorable homeothermic toxicity, for the control of parasites that occur in animal reproduction and animal husbandry in livestock, zoo animals, laboratory animals, experimental animals and domestic animals. They are active against all or specific developmental stages of the parasites. [000422] Agricultural livestock include, for example, mammals such as sheep, goats, horses, donkeys, camels, buffalo, rabbits, reindeer, fallow deer and, in particular, cattle and pigs; or domestic birds such as turkeys, ducks, geese, in particular, chickens Petition 870210086398, dated 09 / 20 / 2021, pp. 110 / 177 107 / 162 nhas; fish and crustaceans, for example, in aquaculture; and also insects, such as bees. [000423] Domestic animals include, for example, mammals such as hamsters, guinea pigs, rats, mice, chinchillas, ferrets and, in particular, dogs, cats, caged birds, reptiles, amphibians and aquarium fish. [000424] In a preferred embodiment, the compounds of Formula (I) are administered to mammals. [000425] In another preferred embodiment, the compounds of Formula (I) are administered to birds, primarily caged birds and, in particular, farm birds. [000426] The use of compounds of Formula (I) for the control of animal parasites is intended to reduce or prevent disease, deaths and reduced performance (in the case of meat, milk, wool, hides, eggs, honey and so forth), so that more economical and simpler animal maintenance is possible and better animal welfare is attainable. [000427] In relation to the field of animal health, the term control or control means that the compounds of Formula (I) are effective in reducing the incidence of the particular parasite in an animal infected with such parasites to harmless levels. More specifically, control in the present context means that the compound of Formula (I) can kill the respective parasite, inhibit its growth, or inhibit its proliferation. [000428] Arthropods include: [000429] of the order Anoplurida, for example, Haematopinus spp., Linognathus spp., Pediculus spp., Phtirus spp., Solenopotes spp.; of the order Mallophagida and the suborders Amblycerina and Ischnocerina, for example, Trimenopon spp., Menopon spp., Trinoton spp., Bovicola spp., Werneckiella spp., Lepikentron spp., Damalina spp., Trichodectes Petition 870210086398, dated 09 / 20 / 2021, pp. 111 / 177 108 / 162 spp., Felicola spp.; of the order Diptera and the suborders Nematocerina and Brachycerina, for example, Aedes spp., Anopheles spp., Culex spp., Simulium spp., Eusimulium spp., Phlebotomus spp., Lutzomyia spp., Culicoides spp., Chrysops spp., Odagmia spp., Wilhelmia spp., Hybomitra spp., Atylotus spp., Tabanus spp., Haematopota spp., Philipomyia spp., Braula spp., Musca spp., Hydrotaea spp., Stomoxis spp., Haematobia spp., Morellia spp., Fannia spp., Glossina spp., Calliphora spp., Lucilia spp., Chrysomyia spp., Wohlfahrtia spp., Sarcophaga spp., Oestrus spp., Hypoderma spp., Gasterophilus spp., Hippobosca spp., Lipoptena spp., Melophagus spp., Rhinoestrus spp., Tipula spp.; of the order Siphonapterida, for example, Pulex spp., Ctenocephalides spp., Tunga spp., Xenopsylla spp., Ceratophyllus spp.; [000430] of the order Heteropterida, for example, Cimex spp., Triatoma spp., Rhodnius spp., Panstrongylus spp.; as well as pests that cause nuisance and sanitary problems of the order Blattarida. [000431] In addition, Arthropods include: [000432] of the subclass Acari (Acarina) and of the order Metastigmata, for example, of the family Argasidae, such as Argas spp., Ornithodorus spp., Otobius spp., of the family Ixodidae, such as Ixodes spp., Amblyomma spp., Rhipicephalus (Boophilus) spp., Dermacentor spp., Haemophysalis spp., Hyalomma spp., Rhipicephalus spp. (the original genus of multi-host ticks); of the order Mesostigmata, such as Dermanyssus spp., Ornithonyssus spp., Pneumonyssus spp., Raillietia spp., Pneumonyssus spp., Sternostoma spp., Varroa spp., Acarapis spp.; from the order Actinedida (Prostigmata), for example, Acarapis spp., Cheyletiella spp., Ornithocheyletia spp., Myobia spp., Psorergates spp., Demodex spp., Trombicula spp., Neotrombiculla spp., Listrophorus spp.; and from the order Acaridida (Astigmata), for example, Acarus spp., Tyrophagus spp., Caloglyphus spp., Hypodectes spp., Pterolichus spp., Psoroptes spp., Chorioptes Petition 870210086398, dated 09 / 20 / 2021, pp. 112 / 177 109 / 162 spp., Otodectes spp., Sarcoptes spp., Notoedres spp., Knemidocoptes spp., Cytodites spp., Laminosioptes spp. [000433] Parasitic protozoa include: [000434] Mastigophora (Flagellata), e.g., Trypanosomatidae, e.g., Trypanosoma b. brucei, Tb gambiense, Tb rhodesiense, T. congolense, T. cruzi, T. evansi, T. equinum, T. lewisi, T.percae, T. simiae, T. vivax, Leishmania brasiliensis, L. donovani, L. tropica, e.g., Trichomonadidae, e.g., Giardia lamblia, G. canis; [000435] Sarcomastigophora (Rhizopoda), such as Entamoebidae, for example, Entamoeba histolytica, Hartmanellidae, for example, Acanthamoeba sp., Harmanella sp.; [000436] Apicomplexa (Sporozoa), tais as Eimeridae, for example, Eimeria acervulina, E. adenoides, E. alabamensis, E. anatis, E. anserina, E. arloingi, E. ashata, E. auburnensis, E. bovis, E. chin canillapetti, E. chin brunetti, E. columbae, E. contorta, E. crandalis, E. debliecki, E. dispersa, E. ellipsoidales, E. falciformis, E. faurei, E. flavescens, E. gallopavonis, E. hagani, E. intestinalis, E. iroquoina, E. lexiucarbenati, E. laubbesidua, E. lau. E. media, E. meleagridis, E. meleagrimitis, E. mitis, E. Necatrix, E. ninakohlyakimovae, E. ovis, E. parva, E. pavonis, E. perforans, E. phasani, E. piriformis, E. praecox, E., sudua, E. speciis scabra., E. ten. E. truncata, E. truttae, E. zuernii, Globidium spec., Isospora belli, I. canis, I. felis, I. ohioensis, I. rivolta, I. spec., I. suis, Cystisospora spec., Cryptosporidium spec., especially, C .parvum; such as Toxoplasmadidae, for example, Toxoplasma gondii, Hammondia heydornii, Neospora caninum, Besnoitia besnoitii; as Sarcocistidae, e.g., Sarcocistis bovicanis, S. bovihominis, S. ovicanis, S. ovifelis, S. neurona, S. spec., S. suihominis, as Leucozoidae, e.g., Leucozytozoon simondi, as Plasmodiidae, e.g., Plasmodium berghei, P. falciparum, P. malariae, P. ovale, P. Petition 870210086398, dated 09 / 20 / 2021, pp. 113 / 177 110 / 162 vivax, P. spec., such as Piroplasmea, for example, Babesia argentina, B. bovis, B. canis, B. spec., Theileria parva, Theileria spec., such as Adeleina, for example, Hepatozoon canis, H. spec. [000437] Pathogenic endoparasites, which are helminths, include Platyhelmintha (e.g., Monogenea, cestodes, and trematodes), nematodes, Acanthocephala, and Pentastoma. These include: [000438] Monogenea: for example: Gyrodactylus spp., Dactylogyrus spp., Polystoma spp. [000439] Cestoides: from the order of the Pseudophyllidea, for example: Diphyllobothrium spp., Spirometra spp., Schistocephalus spp., Ligula spp., Bothridium spp., Diplogonoporus spp.; [000440] da ordem dos Cyclophyllida, por exemplo: Mesocestoides spp., Anoplocephala spp., Paranoplocephala spp., Moniezia spp., Thysanosoma spp., Thysaniezia spp., Avitellina spp., Stilesia spp., Cittotaenia spp., Eyra spp., Bertiella spp., Taenia spp., Echinococcus spp., Hydatigera spp., Davainea spp., Raillietina spp., Hymenolepis spp., Echinolepis spp., Echinocotyle spp., Diorchis spp., Dipylidium spp., Joyeuxiella spp., Diplopylidium spp.; [000441] Trematoides: from the class of Digenea, for example: Diplostomum spp., Posthodiplostomum spp., Schistosoma spp., Trichobilharzia spp., Ornithobilharzia spp., Austrobilharzia spp., Gigantobilharzia spp., Leucochloridium spp., Brachylaima spp., Echinostoma spp., Echinoparyphium spp., Echinochasmus spp., Hypoderaeum spp., Fasciola spp., Fascioloides spp., Fasciolopsis spp., Cyclocoelum spp., Typhlocoelum spp., Paramphistomum spp., Calicophoron spp., Cotylophoron spp., Gigantocotyle spp., Fischoederius spp., Gastrothylacus spp., Notocotylus spp., Catatropis spp., Plagiorchis spp., Prosthogonimus spp., Dicrocoelium spp., Eurytrema spp., Troglotrema spp., Paragonimus spp., Collyriclum spp., Nanophyetus spp., Opisthorchis spp., Clonorchis spp. Metorchis spp., Heterophyes spp., Metago Petition 870210086398, dated 20 / 09 / 2021, p. 114 / 177 111 / 162 nimus spp.; [000442] nematodes: Trichinellida, for example: Trichuris spp., Capillaria spp., Paracapillaria spp., Eucoleus spp., Trichomosoides spp., Trichinella spp.; [000443] of the order Tylenchida, for example: Micronema spp., Strongyloides spp.; [000444] da ordem dos Rhabditida, por exemplo: Strongylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonema spp., Gyalocephalus spp., Cilindropharynx spp., Poteriostomum spp., Ciclococercus spp., Cilicostephanus spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., Ancilostoma spp., Uncinaria spp., Necator spp., Bunostomum spp., Globocephalus spp., Syngamus spp., Ciathostoma spp., Metastrongylus spp., Dictyocaulus spp., Muellerius spp., Protostrongylus spp., Neostrongylus spp., Cistocaulus spp., Pneumostrongylus spp., Spicocaulus spp., Elaphostrongylus spp. Parelaphostrongylus spp., Crenosoma spp., Paracrenosoma spp., Oslerus spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Teladorsagia spp., Marshallagia spp., Cooperia spp., Nippostrongylus spp., Heligmosomoides spp., Nematodirus spp., Hyostrongylus spp., Obeliscoides spp., Amidostomum spp., Ollulanus spp.; [000445] of the Spirurida order, for example: Oxiuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Aspiculuris spp., Heterakis spp.; Ascaris spp., Toxascaris spp., Toxocara spp., Baylisascaris spp., Parascaris spp., Anisakis spp., Ascaridia spp.; Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp.; Stephanofilaria spp., Parafilaria spp., Setaria spp., Loa spp., Dirofilaria spp., Litomosoides spp., Brugia spp., Wuchereria spp., Onchocerca spp., Spirocerca spp.; Petition 870210086398, dated 09 / 20 / 2021, pp. 115 / 177 112 / 162 [000446] Acanthocephala: of the order Oligacanthorhynchida, for example: Macracanthorhynchus spp., Prosthenorchis spp.; of the order Polymorphida, for example: Filicollis spp.; of the order Moniliformida, for example: Moniliformis spp.; [000447] of the order Echinorhynchida, for example, Acanthocephalus spp., Echinorhynchus spp., Leptorhynchoides spp.; [000448] Pentastoma: from the order Porocephalida, for example, Linguatula spp. [000449] In the veterinary field and in animal breeding, the administration of the compounds of Formula (I) is carried out by means of methods generally known in the art, such as by enteral, parenteral, dermal or nasal routes in the form of suitable preparations. Administration may be carried out therapeutically or prophylactically. [000450] Thus, one embodiment of the present invention relates to the use of a compound of Formula (I) as a medicine. [000451] Another aspect relates to the use of a compound of Formula (I) as an anti-endoparasitic agent, in particular, a helminthicide or antiprotozoal agent. The compounds of Formula (I) are suitable for use as an anti-endoparasitic agent, especially a helminthicide or antiprotozoal agent, for example, in animal reproduction, in animal breeding, in animal housing and in the hygiene sector. [000452] Another aspect, in turn, refers to the use of a compound of Formula (I) in the form of an antiectoparasitic agent, especially an arthropodicide, such as an insecticide or an acaricide. Another aspect refers to the use of a compound of Formula (I) in the form of an antiectoparasitic agent, especially an arthropodicide, such as an insecticide or an acaricide, for example, in animal breeding, in animal reproduction, in stables or in the hygiene sector. Petition 870210086398, dated 09 / 20 / 2021, pp. 116 / 177 113 / 162 Vector Control [000453] The compounds of Formula (I) can also be used in vector control. In the context of the present invention, a vector is an arthropod, especially an insect or arachnid, capable of transmitting pathogens such as, for example, viruses, worms, unicellular organisms and bacteria, from a reservoir (plant, animal, human, etc.) to a host. Pathogens can be transmitted mechanically (e.g., trachoma by non-irritating flies) to a host or after injection (e.g., malaria parasites by mosquitoes) into a host. Examples of vectors and the diseases or pathogens they transmit are: 1) Mosquitoes - Anopheles: malaria, filariasis; - Culex: Japanese encephalitis, filariasis, other viral diseases, worm transmission; - Aedes mosquitoes: yellow fever, dengue fever, filariasis, other viral diseases; - Simuliidae: transmission of worms, especially Onchocerca volvulus; 2) Lice: skin infections, epidemic typhus; 3) Fleas: plague, endemic typhus; 4) Flies: sleeping sickness (trypanosomiasis); cholera, other bacterial diseases; 5) Mites: acariasis, typhus epidemic, rickettsial encephalitis, tularemia, Saint Louis encephalitis, tick-borne encephalitis (TBE), Crimean-Congo hemorrhagic fever, borreliosis; 6) Ticks: Lyme diseases, such as Borrelia duttoni, tick-borne encephalitis, Q fever (Coxiella burnetii), babesiosis (Babesia canis canis). Petition 870210086398, dated 09 / 20 / 2021, pp. 117 / 177 114 / 162 [000454] Examples of vectors in the context of the present invention are insects, for example, aphids, flies, leafhoppers or thrips, which are capable of transmitting plant viruses from plant to plant. Other vectors capable of transmitting plant viruses are mites, lice, beetles and nematodes. [000455] Examples of vectors in the context of the present invention are insects and arachnids, such as mosquitoes, especially of the genus Aedes, Anopheles, for example, A. gambiae, A. arabiensis, A. funestus, A. dirus (malaria) and Culex, lice, fleas, flies, mites and ticks capable of transmitting pathogens to animals and / or humans. [000456] Vector control is also possible if the compounds of Formula (I) break the resistance. [000457] The compounds of Formula (I) are suitable for use in the prevention of vector-borne diseases and / or pathogens. Thus, a further aspect of the present invention is the use of compounds of Formula (I) for vector control, for example, in agriculture, horticulture, forestry, gardens and recreational facilities, and also in the protection of stored materials and products. Protection of industrial materials [000458] The compounds of Formula (I) are suitable for protecting industrial materials against attack or destruction by insects, for example, of the orders Coleoptera, Hymenoptera, Isoptera, Lepidoptera, Psocoptera and Zygentoma. [000459] Industrial materials, in the present context, should be understood as inanimate materials such as, preferably, plastics, adhesives, glues, papers and cardboards, leather, wood, processed wood products and coating compositions. The use of the present invention for wood protection is particularly preferred. [000460] In another embodiment, the compounds of Formula (I) Petition 870210086398, dated 09 / 20 / 2021, pp. 118 / 177 115 / 162 are used together with at least one other insecticide and / or at least one fungicide. [000461] In another embodiment, the compounds of Formula (I) are present as a ready-to-use pesticide, that is, they can be applied to the material in question without further modifications. Other suitable insecticides or fungicides are, in particular, those mentioned above. [000462] Surprisingly, it was also found that the compounds of Formula (I) can be used for the protection of objects that come into contact with salt water or brackish water, especially hulls, screens, nets, buildings, moorings and signaling systems, against fouling. It is also possible to use the compounds of Formula (I), alone or in combination with other active ingredients as anti-fouling agents. Animal Pest Control in the Hygiene Sector [000463] The compounds of Formula (I) are suitable for controlling parasites in animals in the hygiene sector. More particularly, the invention can be used in the domestic sector, in the hygiene sector and in the protection of stored products, particularly for the control of insects, arachnids and mites found in enclosed spaces, for example, dwellings, textile sheds, offices, vehicle cabins. For the control of animal pests, the compounds of Formula (I) are used separately or in combination with other active and / or auxiliary ingredients. They are preferably used in household insecticidal products. The compounds of Formula (I) are effective against susceptible and resistant species and against all stages of development. [000464] These pests include, for example, pests of the class Arachnida, of the orders Scorpiones, Araneae and Opiliones, of the classes Chilopoda and Diplopoda, of the class Insecta of the order Blattodea, of the or Petition 870210086398, dated 09 / 20 / 2021, pp. 119 / 177 116 / 162 dens Coleoptera, Dermaptera, Diptera, Heteroptera, Hymenoptera, Isoptera, Lepidoptera, Phthiraptera, Psocoptera, Saltatoria or Orthoptera, Siphonaptera and Zygentoma and of the class Malacostraca of the order Isopoda. [000465] The application is carried out, for example, with products for non-pressure spraying, such as pump sprayers and atomizers, automatic misting systems, nebulizers, foams, gels, products for evaporators with evaporator pellets made of cellulose or plastic, liquid evaporators, gel and membrane evaporators, propeller evaporators, passive or free energy evaporation systems, moth papers, moth gels, moth bags, as granules or powders, in bait stations or baiting stations. Examples of preparation: Example of Preparation 1: 3-Methyl-2-[3-(methylsulfonyl)-5(trifluoromethyl)pyridin-2-yl]-6-(trifluoromethyl)-3H-imidazo[4,5c]pyridine (I-36) [000466] 41 mg (0.10 mmol) of 3-methyl-2-[3-(methylsulfanyl)-5(trifluoromethyl)pyridin-2-yl]-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridine are dissolved in 4 mL of dichloromethane, 86.5 mg (0.36 mmol) of meta-chloroperbenzoic acid are added at 0 °C and then the mixture is stirred at room temperature for 20 h. The mixture is mixed with sodium bisulfite solution, stirred for 10 min, diluted with 30 mL of water and the pH adjusted to 9-10 with 45% sodium hydroxide solution. The mixture is extracted three times with dichloromethane and then the combined organic phases are freed from the solvent under reduced pressure. [000467] (logP (neutral): 2.64; MH+: 425;1H NMR (400 MHz, D6 Petition 870210086398, dated 09 / 20 / 2021, pp. 120 / 177 117 / 162 DMSO) δ ppm: 3.70 (s, 3H), 3.93 (s, 3H), 8.35 (s, 1H), 8.83 (s, 1H), 9.32 (s, 1H), 9.58 (s, 1H). Preparation of 3-methyl-2-[3-(methylsulfinyl)-5-(trifluoromethyl)pyridin-2yl]-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridine (I-26) / o=s [000468] 41 mg (0.10 mmol) of 3-methyl-2-[3-(methylsulfanyl)-5(trifluoromethyl)pyridin-2-yl]-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridine are dissolved in 4 mL of dichloromethane, and 1.92 mg (0.04 mmol) of formic acid and 28.44 mg of a 35% hydrogen peroxide solution are added at room temperature. The mixture is stirred at room temperature for 5 h, sodium bisulfite solution is added, and the mixture is stirred for a further 3 h. Subsequently, the mixture is stirred with a 10% sodium bicarbonate solution, the organic phase is removed, the aqueous phase is extracted twice with dichloromethane, and the organic phases are combined and then decontaminated under reduced pressure. [000469] (logP (neutral): 2.76; MH+: 409.1H NMR (400 MHz, DeDMSO) δ ppm: 3.15 (s, 3H), 4.35 (s, 3H), 8.37 (s, 1H), 8.85 (s, 1H), 9.37 (s, 1H), 9.39 (s, 1H). Preparation of 3-methyl-2-[3-(methylsulfanyl)-5-(trifluoromethyl)pyridin2-yl]-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridine (I-3) / s [000470] 150 mg (0.39 mmol) of 2-[3-chloro-5-(trifluoromethyl)pyridin-2yl]-3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridine and 83 mg (1.18 mmol) of sodium methanethiolate are stirred in DMF at temperature Petition 870210086398, dated 09 / 20 / 2021, pp. 121 / 177 118 / 162 ambient for 6 h. The mixture is mixed with water and extracted three times with ethyl acetate. The combined organic phases are washed with a sodium chloride solution, removed, dried over sodium sulfate and relieved of solvent under reduced pressure. [000471] (logP (neutral): 3.16; MH+: 393.1H NMR (400 MHz, DeDMSO) δ ppm: 2.58 (s, 3H), 4.06 (s, 3H), 8.27 (s, 1H), 8.32 (s, 1H), 8.95 (s, 1H), 9.29 (s, 1H). Preparation of 2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridine (IX-01) [000472] 950 mg (4.97 mmol) of N3-methyl-6-(trifluoromethyl)pyridine-3,4-diamine (II-01), 1.12 g (4.97 mmol) of 3-chloro-5-(trifluoromethyl)pyridine-2-carboxylic acid and 953 mg (4.97 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) are stirred in 10 mL of pyridine at 115 °C for 7 h. The reaction mixture is desolventized under reduced pressure, then water is added and the mixture is extracted three times with ethyl acetate. The combined organic phases are dried over sodium sulfate, concentrated again and purified by preparative HPLC column chromatography purification with a water / acetonitrile gradient as eluent. [000473] (logP (neutral): 2.96; MH+: 381;1H NMR (400 MHz, DeDMSO) δ ppm: 4.00 (s, 3H), 8.35 (s, 1H), 8.86 (s, 1H), 9.22 (s, 1H), 9.30 (s, 1H). Preparation of 3-chloro-N-[5-(methylamino)-2-(trifluoromethyl)pyridin-4yl]-5-(trifluoromethyl)pyridine-2-carboxamide (VIII-01) [000474] By the above method for the preparation of 2-[3-chloro-5(trifluoromethyl)pyridin-2-yl]-3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5 Petition 870210086398, dated 09 / 20 / 2021, pp. 122 / 177 119 / 162 [c]pyridine (IX-01) from N3-methyl-6-(trifluoromethyl)pyridine-3,4-diamine (II-01) and 3-chloro-5-(trifluoromethyl)pyridine-2-carboxylic acid, it is likewise possible to prepare the compound 3-chloro-N-[5-(methylamino)2-(trifluoromethyl)pyridin-4-yl]-5-(trifluoromethyl)pyridine-2-carboxamide (VIII01) as an intermediate for compound (IX-01). [000475] (logP (neutral): 3.09; MH+: 399.1H NMR (400 MHz, DeDMSO) δ ppm: 2.87 (d, 3H), 5.97 (q, 1H), 8.10 (s, 1H), 8.18 (s, 1H), 8.73 (s, 1H), 9.09 (s, 1H), 10.40 (sl, 1H). Preparation of N3-methyl-6-(trifluoromethyl)pyridine-3,4-diamine (II-01) [000476] A solution of 0.93 g (3.0 mmol) of benzyl [4-amino-6(trifluoromethyl)pyridin-3-yl]carbamate in 85 mL of tetrahydrofuran is cooled to 0 °C and mixed with 0.65 g (17 mmol) of lithium aluminum hydride. The mixture is stirred under argon at 0 °C for 15 min and then at room temperature for 4 h. Excess lithium aluminum hydride is destroyed by the addition of ethyl acetate, the mixture is filtered, and the filtrate is extracted twice with 50 mL each time of 2 N hydrochloric acid. The combined hydrochloric acid extracts have their pH adjusted to 8 with sodium carbonate while cooling. Subsequently, the mixture is extracted twice with 100 mL of ethyl acetate each time, the organic phases are combined and dried with sodium sulfate, and the solvent is removed by distillation under reduced pressure. The product is further purified by recrystallization. Petition 870210086398, dated 09 / 20 / 2021, pp. 123 / 177 120 / 162 tion from a hexane / isopropanol mixture. [000477] (MH+: 192; 1H NMR (400 MHz, D6-DMSO) δ ppm: 2.81 (d, 3H), 5.22 (q, 1H), 5.82 (sl, 2H), 6.84 (s, 1H), 7.57 (s, 1H). Preparation of benzyl [4-amino-6-(trifluoromethyl)pyridin-3-yl]carbamate [000478] 0.91 g of 6-(trifluoromethyl)pyridine-3,4-diamine is dissolved in a mixture of 20 mL of tetrahydrofuran and 2 mL of pyridine. A solution of 1.07 g (6.3 mmol) of benzyl chlorocarbonate (benzyl chloroformate) in 2 mL of tetrahydrofuran is added dropwise while stirring. Subsequently, the reaction mixture is stirred overnight, diluted with 100 mL of water, and extracted twice with 100 mL each time of ethyl acetate. The combined organic phases are washed with 50 mL of water, dried over sodium sulfate, and concentrated. By washing the residue with 50 mL of chloroform, the product is obtained as a white solid. [000479] (1H NMR (500 MHz, D6-DMSO) δ ppm: 5.15 (s, 2H), 6.40 (sl 2H), 7.05 (s, 1H), 7.30-7.45 (m, 5H), 8.35 (s, 1H), 9.00 (sl, 1H). Example of Preparation 2: 2-[2-(Ethylsulfanyl)phenyl]-6-(trifluoromethyl)[1,3]oxazolo[5,4-c]pyridine (I-35) [000480] 400 mg (1.16 mmol) of 2-(ethylsulfanyl)-N-[5-hydroxy-2(trifluoromethyl)pyridin-4-yl]benzamide and 398 mg (1.51 mmol) of triphenylphosphine are dissolved in 12 mL of THF, and 661 mg (1.51 mmol) of Petition 870210086398, dated 09 / 20 / 2021, pp. 124 / 177 121 / 162 diethyl azodicarboxylate at 40% (DEAD) in toluene is added dropwise to room temperature. The mixture is stirred at room temperature for 3 h. Subsequently, the solvent is removed by distillation under reduced pressure and the residue is purified by column chromatography with a water / acetonitrile gradient as eluent. [000481] (logP (neutral): 4.07; MH+: 325; 1H NMR (400 MHz, DeDMSO) δ ppm: 1.32 (t, 3H), 3.10 (q, 2H), 7.42 (t, 1H), 7.60-7.69 (m, 2H), 8.21 (d, 1H), 8.54 (s, 1H), 9.33 (s, 1H). Preparation of 2-(ethylsulfanyl)-N-[5-hydroxy-2-(trifluoromethyl)pyridin-4-yl]benzamide (VIII-02) [000482] 206 mg (1.12 mmol) of 2-(ethylsulfanyl)benzoic acid and 201 mg (1.12 mmol) of 4-amino-6-(trifluoromethyl)pyridin-3-ol are dissolved in 5 mL of pyridine, 325 mg (1.69 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) are added and the mixture is stirred at 50 °C for 2 h to 80 °C for 3 h. The solvent is removed by distillation under reduced pressure, and the residue is absorbed in water and extracted with ethyl acetate. The organic phase is washed with a sodium chloride solution, removed, dried over sodium sulfate and concentrated. The residue is purified by preparative HPLC column chromatography using a water / acetonitrile gradient as eluent. [000483] (logP (neutral): 1.59; MH+: 343.1H NMR (400 MHz, DeDMSO) δ ppm: 1.21 (t, 3H), 2.98 (q, 2H), 7.29-7.34 (m, 1H), 7.48-7.53 (m, 2H), 7.61 (d, 1H), 8.29 (s, 1H), 8.55 (s, 1H), 9.99 (s, 1H), 11.31 (sl, 1H). Preparation of 4-amino-6-(trifluoromethyl)pyridin-3-ol (II-02) Petition 870210086398, dated 09 / 20 / 2021, pp. 125 / 177 122 / 162 [000484] 12.3 g (42.1 mmol) of tert-butyl [5-methoxy-2-(trifluoromethyl)pyridin-4-yl]carbamate are dissolved in 300 mL of dichloromethane and cooled to -78 °C, and 42.2 g (168 mmol) of boron tribromide in 150 mL of dichloromethane are added dropwise at this temperature. The mixture is allowed to reach room temperature overnight, then 400 mL of sodium bicarbonate solution are added and the mixture is extracted three times with 100 mL of dichloromethane each time. The solvent is removed by distillation and the residue is purified by silica gel chromatography. [000485] (1H NMR (90 MHz, D6-DMSO) δ ppm: 7.00 (s, 1H), 7.9 (s, 1H). Preparation of tert-butyl [5-methoxy-2-(trifluoromethyl)pyridin-4-yl]carbamate [000486] To a solution of 9.80 g (44.3 mmol) of 5-methoxy-2-(trifluoromethyl)isonicotinic acid in 980 mL of tert-butanol are added, at room temperature, 65 g of 4A molecular sieve, 14.6 g (53.1 mmol) of diphenylphosphoryl azide (DPPA), and 5.37 g (53.1 mmol) of triethylamine. The reaction mixture is stirred at 81 °C for 23 h, then the 4A molecular sieve is removed by filtration. After the tert-butanol has been removed by distillation under reduced pressure, the residue is mixed with 500 mL of ethyl acetate, washed with 250 mL of 2 N hydrochloric acid, 250 mL of saturated aqueous sodium bicarbonate solution, 250 mL of water, and 250 mL of chloride solution. Petition 870210086398, dated 09 / 20 / 2021, pp. 126 / 177 123 / 162 sodium, and dried over sodium sulfate. The solvent is removed under reduced pressure and the residue is washed three times with 15 mL each time of ethyl acetate and dried under reduced pressure. The ethyl acetate phase is purified by silica gel chromatography (hexane / EtOAc 4:1 => 2:1). [000487] (1H NMR (90 MHz, CDCh) δ ppm: 1.5 (s, 9H), 4.0 (s, 3H), 8.2 (s, 1H), 8.5 (s, 1H). Preparation of 2-[3-ethylsulfanyl-5-(trifluoromethyl)-2-pyridyl]-3-methyl-6-[4-(trifluoromethyl)-phenyl]imidazo[4,5-c]pyridine (I-64) [000488] A solution of 62 mg (0.58 mmol) of sodium carbonate in 2 mL of a 4:1 mixture of 1,2-dimethoxyethane and water is degassed in an ultrasonic bath, and 73 mg (0.19 mmol) of 6-chloro-2-[3-ethylsulfanyl-5-(trifluoromethyl)-2-pyridyl]-3-methylimidazo[4,5-c]pyridine and 67 mg (0.35 mmol) of [4-(trifluoromethyl)phenyl]boronic acid are added. The container is flooded with argon and then 23 mg (20 pmol) of tetrakis(triphenylphosphine)palladium are added. The mixture is heated in a CEM Discover microwave to 140 °C for 2 h 10 min, then mixed with an additional 68 mg (59 pmol) of tetrakis(triphenylphosphine)palladium and heated to 140 °C for a further 4 h. The reaction mixture is filtered through a Celite bed that has been rinsed with ethyl acetate. After the solvent has been removed under reduced pressure, the residue is separated chromatographically by MPLC on silica gel (gradient: ethyl acetate / cyclohexane).This is followed by another chromatographic separation by means of preparative HPLC (gradient: H2O / acetonitrile). In this sense, 14 mg (99% purity, 15% yield) of 2-[3-ethylsulfanyl-5-(trifluoromethyl)-2-pyridyl]-3-methyl-6-[4-Petition 870210086398, dated 20 / 09 / 2021, page 127 / 177. 124 / 162 (trifluoromethyl)phenyl]imidazo[4,5-c]pyridine are obtained. [000489] (logP (neutral): 3.95; MH+: 483; 1H NMR (400 MHz, DeDMSO) δ ppm: 9.275 (2.6); 9.271 (2.5); 8.943 (4.3); 8.584 (2.6); 8.580 (2.6); 8.318 (0.5); 7.701 (3.0); 7.680 (3.9); 7,410 (4.6); 3,890 (16.0); 3,329 (75.4); 3,140 (1.3); 3,122 (4.2); 3,104 (4.3); 3,086 (1.4); 2,676 (0.9); 2,671 (1.2); 2,667 (0.9); 2,507 (140.3); 2,502 (179.9); 2,498 (134.5); 2,334 (0.9); 2,329 (1.2); 2,325 (0.9); 1,281 (4.6); 1,263 (9.7); 1,245 (4.5); 0,146 (0.4); 0,008 (3.6); 0,000 (84.0); -0,150 (0.4). Preparation of 2-[3-ethylsulfanyl-5-(trifluoromethyl)-2-pyridyl]-3-methyl-6-[4-(trifluoromethyl)-imidazol-1-yl]imidazo[4,5-c]pyridine (I-74) [000490] Under argon, 99 mg (0.27 mmol) of 6-chloro-2-[3-ethylsulfanyl-5-(trifluoromethyl)-2-pyridyl]-3-methylimidazo[4,5-c]pyridine, 23 pmol (0.15 mmol) of trans-N,N-dimethylcyclohexane-1,2-diamine, 6.8 mg (36 pmol) of copper(I) iodide, 30 mg (0.22 mmol) of 4-(trifluoromethyl)-1-himidazole and 64 mg (0.46 mmol) of potassium carbonate are added to 1 mL of degassed toluene. The container is closed and the reaction mixture is heated in a CEM Discover microwave reactor to 110 °C for 4 h. After cooling to room temperature, ethyl acetate is added and the mixture is filtered through a Celite bed, which is subsequently rinsed with ethyl acetate. The solvent is removed under reduced pressure and the residue is separated chromatographically by MPLC on silica gel (gradient: ethyl acetate / cyclohexane).In this sense, 22 mg (100% purity, 18% yield) of 2-[3-ethylsulfanyl-5-(trifluoromethyl)-2-pyridyl]-3methyl-6-[4-(trifluoromethyl)imidazol-1-yl]imidazo[4,5-c]pyridine are obtained. Petition 870210086398, dated 09 / 20 / 2021, pp. 128 / 177 125 / 162 [000491] (logP (neutral): 3.36; MH+: 473.1H NMR (600 MHz, CD3CN) δ ppm: 8.905 (3.0); 8.903 (3.0); 8.852 (1.6); 8.850 (1.6); 8.500 (1.9); 8.313 (1.5); 8.311 (2.1); 7,962 (3.4); 7,961 (3.4); 4,001 (3.4); 3,099 (3.5); 3,087 (1.2); 8,309 (1.4); 8,183 (1.7); 8,181 (1.7); (16.0); 3.940 (0.4); 3.124 (1.1); 3.111 2.639 (0.7); 2.184 (55.7); 2.109 (1.2); 2,005 (2.2); 1,998 (195.7); 1,989 (2.7); 1,985 (1.8); 1,981 (10.0); 1,977 (18.2); 1,973 (26.5); 1,969 (18.0); 1,965 (9.0); 1,882 (1.2); 1,419 (0.4); 1,404 (0.7); 1,373 (0.6); 1,330 (4.1); 1,318 (9.0); 1,309 (1.6); 1,305 (5.2); 1,301 (3.4); 0,914 (0.6). [000492] By analogy to the examples and according to the preparation processes described above, the following compounds of Formula (I) can be obtained: (I) [000493] where A3 is oxygen and the other substituents are each as defined in the following table: Ex. R1 N A4 A5 R3 A2 A1 R2a R2b I-1 CH3 0 N CH CF3 O CH Cl H I-2 C2H5 0 CH CH CF3 N-methyl N CF3 H I-3 CH3 0 CH CH CF3 N-methyl N CF3 H I-4 CH3 0 CH CH CF3 N-methyl CH FH I-5 CH3 0 CH CH CF3 N-methyl CH CF3 H I-6 CH3 0 N CH CF3 N-methyl CH Cl H I-7 -(CH2)2-SO2C2H5 2 CH CH CF3 N-methyl N CF3 H I-8 i-C3H7 1 CH CH CF3 N-methyl N CF3 H I-9 C2H5 0 N CH CF3 O CH HH I-10 CH3 1 CH CH CF3 N-methyl CH Cl H I-11 CH3 2 CH CH CF3 N-methyl CH Cl H I-12 CH3 1 CH CH CF3 N-methyl CH FH Petition 870210086398, dated 09 / 20 / 2021, pp. 129 / 177 126 / 162 Ex. R1 N A4 A5 R3 A2 A1 R2a R2b I-13 C2H5 1 CH CH CF3 N-metil CH H 5-Cl* I-14 CH3 2 CH CH CF3 N-metil CH 3 H I-15 C2H5 2 CH CH CF3 N-metil NHH I-16 C3H7 2 CH CH CF3 N-metil N CF3 H I-17 C2H5 0 CH CH CF3 N-metil CH HH I-18 C2H5 2 CH CH CF3 N-metil CH HH I-19 C2H5 0 CH CH CF3 N-metil CH H 5-Cl* I-20 CH3 2 CH CH CF3 N-metil CH FH I-21 C2H5 2 CH CH CF3 N-metil N CF3 H I-22 C2H5 1 CH CH CF3 N-metil CH HH I-23 -(CH2)2-S-C2H5 0 CH CH CF3 N-metil N CF3 H I-24 C2H5 0 CH CH CF3 N-metil NHH I-25 CH3 0 CH CH CF3 N-metil CH Cl H I-26 CH3 1 CH CH CF3 N-metil N CF3 H I-27 oxetan-3-il 2 CH CH CF3 N-metil CH HH I-28 C2H5 0 N CH CF3 N-metil N CF3 H I-29 CF3 0 CH CH CF3 N-metil NHH I-30 CH3 1 CH CH CF3 N-metil CH CF3 H I-31 n-C3H7 0 CH CH CF3 N-metil N CF3 H I-32 n-C3H7 2CHCHCF3N-metilN N-metil N CF3 H I-38 C2H5 CF3 2CHCHCF3N-methyl CH H 5-Cl* I-39 n-C3H7 1 CH CH CF3 N-methyl N CF3 H I-40 oxetan-3-yl 0 CH CH CF3 O CH HH I-41 i-C3H7 0 CH CH CF3 N-methyl N CF3 H I-4 CH 2 CHH Cl H I-43 C2H5 2 CH CH CF3 N-methyl CH Cl H Petition 870210086398, of 20 / 09 / 2021, p. 130 / 177 127 / 162 Ex. R1 N A4 A5 R3 A2 A1 R2a R2b I-44 C2H5 1 CH CH CF3 N-metil CH Cl H I-45 C2H5 2 CH CH CF3 N-metil N H 5-OMe* I-46 C2H5 0 CH CH C2F5 N-metil N H H I-47 C2H5 0 CH CH C2F5 N-metil N CF3 H I-48 C2H5 2 CH CH CF3 N-metil N H 3-CF3* I-49 C2H5 2 CH CH CF3 N-metil N H 5- NHCOMe* I-50 C2H5 0 CH CH CF3 N-metil N H 5- NHCOMe* I-51 C2H5 1 CH CH CF3 N-metil N H 3-CF3* I-52 C2H5 2 CH CH Cl N-metil N CF3 H I-53 C2H5 0 CH CH CF3 N-metil N H 5-OMe* I-54 CH2-CH2F 2 CH CH CF3 N-metil N CF3 H I-55 C2H5 0 CH CH Cl N-metil N CF3 H I-56 C2H5 2 CH CH CF3 N-metil N CON H2 H I-57 CH2-CH2F 2 CH CH CF3 N-metil N CF3 H I-58 CH2-CH2OH 2 CH CH CF3 N-metil N CF3 H I-59 CH2-CH2OH 0 CH CH CF3 N-metil N CF3 H I-60 C2H5 0 CH CH CF3 N-metil N CON H2 H Petição 870210086398, de 20 / 09 / 2021, pág. 131 / 177 128 / 162 Ex. R1 N A4 A5 R3 A2 A1 R2a R2b I-61 C2H5 1 CH CH C2F5 N-metil NHH I-62 C2H5 2 CH CH CF3 N-metil CH H 3-Cl* I-63 C2H5 1 CH CH C2F5 N-metil N CF3 H I-64 C2H5 0 CH CH 4-CF3(C6H4) N-metil N CF3 H I-65 C2H5 0 CH CH 4(CF3)pirazol1-yl N-metil N CF3 H I-66 n-C3H7 0 CH CH CF3 N-metil NH 5-OMe* I-67 CH3 0 CH CH CF3 N-metil NH 5-OMe* I-68 C2H5 2 CH CH C2F5 N-metil NHH I-69 C2H5 0 CH CH3(CF3)pyrazol1-ila N-methyl N CF3 H I-70 C2H5 0 CH CH CF3 N-metil NH 3-CF3* I-71 n-C3H7 2 CH CH CF3 N-metil NH 5-OMe* I-72 C2H5 2 CH CH CF3 N-metil N CN H I-73 CH3 2 CH CH CF3 N-metil NH 5-OMe* I-74 C2H5 0 CH CH 4(CF3)imidazo l-1-ila N-metil N CF3 H I-75 C2H5 2 CH CH 4(CF3)imidazo l-1-ila N-metil N CF3 H Petition: 870210086398, on September 20, 2021, page. 132 / 177 129 / 162 Ex. R1 N A4 A5 R3 A2 A1 R2a R2b I-76 C2H5 2 CH CH 4(CF3)pirazol1-ila N-metil N CF3 H I-77 C2H5 2 CH CH 3(CF3)pirazol1-ila N-metil N CF3 H [000494] The logP values ​​are measured in accordance with EEC Directive 79 / 831 Annex V.A8 by means of HPLC (high-performance liquid chromatography) on a reversed-phase column (C 18). Temperature: 55 °C. [000495] The determination of LC-MS in the acidic range is carried out at pH 2.7 using 0.1% aqueous formic acid and acetonitrile (containing 0.1% formic acid) as eluents, linear gradient from 10% acetonitrile to 95% acetonitrile. Called logP(HCOOH) in the table. [000496] LC-MS determination in the neutral range is performed at pH 7.8 with 0.001 molar aqueous ammonium bicarbonate solution and acetonitrile as eluents; linear gradient from 10% acetonitrile to 95% acetonitrile. Called logP (neutral) in the table. [000497] Calibration is performed with branched non-alkanones (which have 3 to 16 carbon atoms) with known logP values ​​(logP values ​​determined based on retention times by linear interpolation between two successive alkanones). [000498] NMR data for selected examples are listed in conventional form (δ values, multiplet division, number of hydrogen atoms) or as lists of NMR peaks. Petition 870210086398, dated 09 / 20 / 2021, pp. 133 / 177 130 / 162 [000499] The solvent in which the NMR spectrum was recorded is reported in each case. NMR peak list method [000500] The 1H NMR data from selected examples are presented in the form of 1H NMR peak lists. For each signal peak, the δ value in ppm is listed first, followed by the signal intensity in parentheses. Pairs of signal intensity number - δ value for different signal peaks are listed separated from each other by a semicolon. [000501] The list of peaks for an example, therefore, takes the form of: [000502] δ1 (intensity1); δ2 (intensity2);........; δι (intensityi);......; δn (intensityn) [000503] The intensity of high-pitched signals correlates with the height of the signals in a printed example of an NMR spectrum in cm and shows the true ratios of the signal intensities. In the case of broad signals, several peaks or the middle of the signal and its relative intensity can be shown in comparison with the most intense signal in the spectrum. [000504] For the calibration of chemical shifts in 1H NMR spectra, tetramethylsilane and / or solvent chemical shift were used, particularly in the case of spectra measured in DMSO. Therefore, the tetramethylsilane peak may, but does not have to, occur in NMR peak lists. [000505] The peak lists of 1H NMR are similar to conventional 1H NMR printouts and thus typically contain all the peaks listed in a conventional NMR interpretation. [000506] In addition, as conventional 1H NMR prints can show solvent signals, signals of stereoisomers of the target compounds, which also form part of the object of the invention, Petition 870210086398, dated 09 / 20 / 2021, pp. 134 / 177 131 / 162 and / or impurity peaks. [000507] In the report of compound signals in the delta range of solvents and / or water, the inventors' lists of 1H NMR peaks show the normal solvent peaks, for example, DMSO peaks in DMSO-D6 and the water peak, which typically have a high intensity on average. [000508] The stereoisomer peaks of the target compounds and / or impurity peaks typically have a lower intensity on average than the peaks of the target compounds (e.g., with a purity of > 90%). [000509] Such stereoisomers and / or impurities may be typical of the particular preparation process. Their peaks may thus help in this case to identify the reproduction of our preparation process with reference to by-product fingerprints. [000510] A technician skilled in calculating peaks of target compounds using known methods (MasterC, ACD simulation, but also with empirically evaluated expected values) can, if required, isolate the peaks of the target compounds, optionally using additional intensity filters. This isolation could be similar to the relevant peak obtained in conventional 1H NMR interpretation. [000511] Additional details of 1H NMR peak lists can be found in Research Disclosure Database Number 564025. Example 1: 1H-NMR (400.0 MHz, d6-DMSO): δ= 9.544 (6.4); 8.335 (3.9); 8.314 (4.1); 7.568 (2.9); 7.563 (3.5); 7.534 (2.5); 7.529 (1.9); 7.513 (2.3); 7.508 (1.9); 3.323 (17.6); 2.671 (0.3); 2.631 (16.0); 2.524 (1.1); 2.511 (19.3); 2.507 (38.0); 2.502 (49.6); 2,498 (35.5); 2,493 (16.9); 2,075 (0.5); 0,008 (0.9); 0,000 (21.7); -0,008 (0.7) Petition 870210086398, dated 09 / 20 / 2021, pp. 135 / 177 132 / 162Example 1: LOGP NEUTRAL LOGP HCOOH I-2 3.48 3.52 Example 2: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.283 (3.7); 8.960 (2.3); 8.958 (2.3); 8.334 (2.7); 8.328 (4.1); 4.030 (16.0); 3.323 (69.7); 3.181 (1.1); 3.162 (3.6); 3.144 (3.6); 3.126 (1.1); 2.891 (1.2); 2.731 (1.0); 2.676 (0.4); 2.671 (0.6); 2.667 (0.4); 2.506 (64.4); 2.502 (83.6); 2,498 (61.3); 2.333 (0.4); 2.329 (0.5); 2.324 (0.4); 1.234 (4.1); 1.215 (8.1); 1.197 (3.8); 0.008 (0.6); 0.000 (17.0); -0.008 (0.7) I-3 3.16 3.22 Example 3: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.290 (4.0); 8.947 (2.7); 8.316 (4.5); 8.267 (2.9); 7.953 (0.4); 4.059 (16.0); 4.019 (0.7); 3.327 (63.2); 3.036 (0.3); 2.965 (0.4); 2.892 (2.5); 2.882 (0.5); 2.870 (0.5); 2.732 (2.2); 2.673 (0.5); 2,580 (15.1); 2.507 (59.9); 2.503 (71.6); 2,499 (52.5); 2.330 (0.5); 2.078 (0.4); 1.234 (0.4); 0.000 (0.4) I-4 2.65 2.70 Example 4: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.833 (0.3); 9.210 (3.9); 8,226 (4.1); 8,082 (0.6); 7,993 (0.5); 7,608 (1.3); 7,593 (1.5); 7,587 (1.6); 7,572 (1.4); 7,411 (1.3);7.405 (1.4); 7.386 (1.4); 7.380 (1.4); 7.244 (1.0); 7.238 (0.9); 7.222 (1.6); 7.216 (1.5); 7.201 (0.8); 7.195 (0.7); 3.785 (16.0); 3.325 (80.3); 2.875 (1.0); 2.863 (1.0); 2.671 (0.7); 2.667 (0.6); 2.506 (76.1); 2.502 (99.5); 2.498 (78.2); 2.464 (2.7); 2.329 (0.6); 2.075 (0.3); 0.000 (2.6) I-5 3.26 3.30 Example 5: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.249 (3.5); 8,267 (3.7); 7,787 (1.2); 7,778 (2.7); 7,768 (2.9); 7,749 (2.1); 7,729 (0.7); 3,807 (16.0); 3,324 (21.7); 2,671 (0.4); 2,557 (15.5); 2,524 (1.1); 2,511 (22.7); 2,507 (44.4); 2,502 (57.4); 2,498 (41.7); 2,493 (20.4); 2.329 (0.4); 0.008 (2.1); 0.000 (52.3); 0.009 (2.1) I-6 2.74 2.75 Example 6: 1H-NMR (601.6 MHz, CD3CN): δ= 9.182 (3.5); 7.526 (1.9); 7.523 (2.0); 7.459 (1.7); 7.445 (2.7); 7.403 (1.7); 7.400 (1.6); 7.390 (1.1); 7.386 (1.0); 3.927 (0.3); 3.770 (16.0); 2.978 (0.3); 2.494 (14.5); 2.222 (0.5); 2.152 (1.6); 1.966 (0.6); 1.958 (1.5); 1.954 (1.8); 1.950 (9.9); 1.946 (17.5); 1.942 (25.9); 1.938 (17.6); 1.934 (8.7); 1.387 (5.1);1.269 (0.3); 1.212 (0.4); 0.005 (0.3); 0.000 (11.9); 0.006 (0.4); Petition 870210086398, dated 09 / 20 / 2021, pp. 136 / 177 133 / 162 Example 7: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.411 (2.3); 9.408 (2.3); 9.379 (3.9); 9.333 (0.4); 8.751 (2.4); 8.746 (2.5); 8.460 (4.1); 8.316 (0.5); 7.903 (0.3); 4.391 (16.0); 4.199 (1.2); 4.147 (0.5); 4.138 (0.4); 4.121 (0.8); 4.114 (0.6); 4.107 (0.7); 4.100 (0.7); 4,088 (0.7); 4,068 (0.4); 3,976 (0.7); 3,854 (0.6); 3,843 (0.6); 3,833 (0.7); 3,829 (0.7); 3,819 (0.8); 3,803 (0.5); 3,795 (0.6); 3,556 (0.6); 3,543 (0.8); 3,531 (0.5); 3,523 (0.6); 3,518 (0.8); 3,510 (0.9); 3,494 (1.8); 3,477 (0.8); 3,468 (0.8); 3,464 (0.6); 3,455 (0.5); 3,443 (0.6); 3,429 (0.4); 3,325 (63.6); 3,260 (0.8); 3,257 (0.8); 3,241 (2.2); 3,238 (2.3); 3,223 (2.3); 3,219 (2.3); 3,201 (0.9); 2,676 (0.5); 2,671 (0.7); 2,667 (0.6); 2,524 (1.8); 2,511 (41.0); 2,506 (84.3); 2,502 (113.7); 2,498 (86.8); 2,493 (45.8); 2,333 (0.5); 2,329 (0.7); 2,324 (0.6); 1,252 (4,4); 1,233 (9,5); 1,214 (4,3); 0,146 (0,4); 0,008 (2,7); 0,000 (79,8); -0,008 (4,6);-0.150 (0.4) I-8 3.46 3.54 Exemplo 8: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.390 (2.1); 9.387 (2.1); 9.377 (3.6); 8.577 (2.1); 8.572 (2.2); 8.379 (3.7); 8.316 (0.6); 4.384 (16.0); 4.362 (0.4); 3.802 (0.3); 3.785 (0.9); 3.767 (1.3); 3.750 (0.9); 3.733 (0.4); 3.322 (86.4); 2.675 (1.0); 2.671 (1.4); 2.666 (1.0); 2.524 (3.7); 2.511 (79.1); 2.506 (160.9); 2.502 (213.1); 2.497 (155.9); 2.493 (76.9); 2.333 (1.0); 2.329 (1.4); 2.324 (1.0); 1.569 (6.3); 1.551 (6.2); 0.906 (6.4); 0.889 (6.3); 0.146 (1.3); 0.008 (10.0); 0.000 (280.2); -0.008 (11.2); - 0.150 (1.3) I-9 3.64 3.66 Exemplo 9: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.544 (9.2); 8.314 (2.7); 8.311 (2.8); 8.294 (2.9); 8.291 (2.8); 7.739 (1.1); 7.735 (1.2); 7.719 (2.5); 7.715 (2.1); 7.701 (2.2); 7.697 (2.1); 7.646 (3.6); 7.627 (2.2); 7.464 (1.9); 7.462 (1.8); 7.444 (3.0); 7.426 (1.6); 7.424 (1.5); 3.322 (31.6); 3.155 (1.9); 3.136 (6.3); 3.118 (6.4); 3.100 (2.0); 2.676 (0.6); 2.671 (0.8); 2.666 (0.6); 2.541 (0.6); 2.524 (2.7); 2.511 (49.3);2.507 (97.6); 2.502 (126.8); 2.497 (89.7); 2.493 (42.1); 2.333 (0.6); 2.329 (0.8); 2.324 (0.6); 2.075 (0.3); 1.360 (7.3); 1.341 (16.0); 1.323 (7.0); 0.146 (0.3); 0.008 (3.4); 0.000 (84.9); -0.009 (2.9); -0.150 (0.3); Petition 870210086398, dated 09 / 20 / 2021, pp. 137 / 177 134 / 162 Example 10: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.271 (3.7); 8.267 (3.9); 8.137 (2.9); 8.132 (3.0); 7.975 (2.1); 7.954 (3.6); 7.900 (2.2); 7.895 (2.1); 7.880 (1.3); 7.874 (1.3); 6.870 (0.3); 3.977 (15.9); 3.748 (0.9); 3.444 (0.8); 3.327 (95.2); 2.967 (16.0); 2.676 (0.3); 2.671 (0.5); 2.667 (0.3); 2.525 (1.4); 2.507 (54.5); 2.502 (70.2); 2,498 (50.6); 2,494 (24.6); 2.333 (0.3); 2.329 (0.4); 2.184 (0.5); 1.355 (3.8); 1.298 (0.9); 1.259 (1.2); 1.234 (0.6); 0.008 (2.1); 0.000 (54.1); -0.009 (2.3) I-11 2.34 2.39 Example 11: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.279 (0.6); 9,262 (3.9); 8,380 (0.5); 8,317 (0.5); 8,260 (4.2); 8,164 (2.8); 8,159 (3.4); 8,152 (0.5); 8,115 (1.7); 8,110 (1.5); 8,095 (2.1); 8,089 (1.9); 7,937 (3.4); 7,917 (3.0); 7,902 (0.8); 7,897 (0.9); 7,885 (0.5); 7,565 (0.4); 7,545 (0.6); 5,757 (1.6); 3,770 (0.5); 3,747 (16.0); 3,621 (0.4); 3,592 (1.6); 3,445 (15.1); 3,436 (2.1); 3,327 (141.8); 2,675 (0.9); 2,671 (1.2); 2,667 (0.9); 2,524 (4.2);2.506 (141.2); 2.502 (182.5); 2.498 (131.5); 2.333 (0.8); 2.329 (1.1); 2.324 (0.8); 1.298 (0.8); 1.259 (1.1); 1.235 (0.5); 1.166 (0.3); 0.008 (2.3); 0.000 (56.4); -0.008 (2.3) I-12 1.83 1.88 Exemplo 12: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.272 (4.2); 8.266 (4.5); 8.036 (1.3); 8.023 (1.4); 8.015 (1.6); 8.002 (1.5); 7.966 (1.4); 7.959 (1.6); 7.944 (1.5); 7.937 (1.5); 7.706 (0.8); 7.699 (0.8); 7.685 (1.5); 7.678 (1.5); 7.664 (0.8); 7.657 (0.7); 3.973 (16.0); 3.336 (80.5); 2.958 (16.0); 2.678 (0.4); 2.549 (0.3); 2.509 (67.3); 2.337 (0.4) I-13 2.34 2.44 Exemplo 13: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.285 (3.9); 8.280 (4.2); 8.088 (2.3); 8.066 (4.9); 8.060 (3.8); 8.009 (2.3); 8.004 (2.0); 7.988 (1.4); 7.983 (1.3); 3.973 (16.0); 3.327 (56.5); 3.313 (1.6); 3.294 (1.2); 3.279 (1.2); 3.261 (1.1); 3.242 (0.3); 2.905 (1.1); 2.886 (1.2); 2.871 (1.0); 2.853 (1.0); 2.671 (0.4); 2.507 (41.3); 2.502 (56.0); 2.498 (43.9); 2.329 (0.4); 1.150 (3.8); 1.132 (8.2); 1.113 (3.7);0.000 (2.5) I-14 2.63 2.67 Example 14: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.289 (3.7); 8,430 (1.3); 8.412 (5.2); 8.288 (3.9); 8.287 (3.9); 8,180 (1.6); 8.159 (1.4); 3,772 (16.0); 3,493 (14.4); 3.324 (34.4); 2.524 (0.9); 2,511 (17.9); 2,506 (36.4); 2,502 (48.8); 2,497 (36.6); 2,493 (18.8); 0.008 (1.9); 0.000 (52.6); -0.008 (2.6); Petition 870210086398, dated 09 / 20 / 2021, pp. 138 / 177 135 / 162 Example 15: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.295 (3.5); 9.139 (1.7); 9.135 (1.9); 9.127 (1.9); 9.123 (1.8); 8.579 (1.7); 8.575 (1.8); 8.559 (1.9); 8.555 (1.8); 8.300 (3.6); 8.298 (3.7); 8.021 (1.9); 8.009 (1.8); 8.001 (1.7); 7.989 (1.7); 3.867 (16.0); 3.794 (1.0); 3,775 (3.5); 3,757 (3.5); 3,738 (1.0); 3,327 (10.2); 2,526 (0.5); 2,521 (0.7); 2,512 (10.8); 2,508 (22.2); 2,503 (29.5); 2,499 (21.4); 2,494 (10.4); 1,209 (3.6); 1,191 (7.9); 1,172 (3.5); 0,008 (1.8); 0,000 (50.2); -0.009 (1.9) I-16 3.21 3.26 Example 16: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.588 (2.0); 9.585 (2.1); 9.314 (3.5); 8,780 (2.2); 8.776 (2.2); 8.331 (3.7); 8.316 (0.4); 4.409 (0.3); 4.392 (1.0); 4.375 (1.4); 4.357 (1.0); 4.340 (0.3); 3.914 (16.0); 3.322 (36.9); 2.676 (0.6); 2.671 (0.8); 2.667 (0.6); 2,524 (2.0); 2,520 (3.2); 2,511 (42.6); 2,507 (88.2); 2,502 (118.2); 2,497 (86.9); 2,493 (42.9); 2,333 (0.5); 2,329 (0.7); 2,324 (0.6); 1,260 (13.3); 1,243 (13.2); 0,146 (0.8);0.008 (6.7); 0.000 (191.2); -0.009 (7.6); -0.150 (0.8) I-17 2.87 2.94 Exemplo 17: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.204 (3.8); 8.228 (4.1); 7.627 (3.7); 7.618 (4.2); 7.536 (1.5); 7.517 (2.1); 7.433 (0.9); 7.422 (1.2); 7.413 (1.2); 7.403 (1.1); 7.392 (0.6); 3.768 (16.0); 3.327 (67.1); 2.986 (1.3); 2.968 (4.1); 2.950 (4.1); 2.931 (1.4); 2.671 (0.5); 2.667 (0.3); 2.507 (57.2); 2.503 (74.4); 2.498 (54.2); 2.334 (0.3); 2.329 (0.5); 2.325 (0.4); 1.180 (4.3); 1.161 (8.7); 1.143 (4.1); 0.146 (0.5); 0.008 (3.9); 0.000 (88.8); -0.007 (3.9); 0.150 (0.5) I-18 2.11 2.13 Exemplo 18: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.255 (3.5); 8.253 (3.7); 8.251 (3.6); 8.156 (1.3); 8.153 (1.3); 8.138 (1.8); 8.134 (1.6); 8.020 (0.4); 8.017 (0.5); 8.002 (1.4); 7.998 (1.4); 7.984 (1.6); 7.979 (1.5); 7.976 (1.4); 7.971 (1.6); 7.957 (1.5); 7.953 (1.5); 7.938 (0.6); 7.934 (0.5); 7.878 (1.7); 7.875 (1.8); 7.860 (1.2); 7.857 (1.2); 3.728 (16.0); 3.526 (0.5); 3.509 (1.3); 3.490 (1.3); 3.473 (0.5); 3.330 (61.8); 2.671 (0.4);2,525 (1,2); 2,511 (25,5); 2,507 (50,6); 2,502 (65,3); 2,498 (46,3); 2,493 (21,9); 2,329 (0,4); 1,119 (3,5); 1,101 (7,8); 1,082 (3,4); 0,008 (0,6); 0,000 (15,4); -0,009 (0,6); Petition 870210086398, dated 09 / 20 / 2021, pp. 139 / 177 136 / 162 Example 19: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.226 (3.9); 8.243 (4.1); 7.705 (0.9); 7.699 (1.3); 7.684 (1.6); 7.678 (2.9); 7.667 (3.6); 7.662 (2.3); 7.640 (3.4); 7.619 (1.8); 3.788 (16.0); 3.323 (25.4); 2.999 (1.2); 2.981 (4.0); 2.963 (4.1); 2.944 (1.3); 2.671 (0.4); 2.626 (0.3); 2.507 (47.1); 2.502 (61.4); 2,498 (45.8); 2.329 (0.4); 2,300 (0.5); 1.177 (4.3); 1.159 (8.9); 1.140 (4.1); 0.008 (1.9); 0.000 (45.5) I-20 2.05 2.08 Example 20: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.258 (4.1); 8.253 (4.3); 7,997 (1.5); 7,990 (2.5); 7.976 (2.4); 7,969 (3.3); 7.956 (1.7); 7,918 (1.1); 7,911 (0.9); 7,897 (1.6); 7,890 (1.4); 7,876 (0.7); 7,869 (0.6); 3,739 (16.0); 3,430 (15.0); 3,326 (81.6); 2,671 (0.7); 2,666 (0.6); 2,506 (84.7); 2,502 (108.3); 2,498 (84.4); 2,328 (0.7); 2,325 (0.5); 0,146 (0.6); 0,000 (128.1); -0.150 (0.6) I-21 2.93 2.98 Example 21: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.586 (2.4); 9.583 (2.5); 9.317 (4.1); 8,798 (2.5); 8,794 (2.6); 8.341 (4.3);3.925 (16.0); 3.912 (1.3); 3.893 (3.6); 3.874 (3.7); 3.856 (1.1); 3.324 (30.3); 2.671 (0.5); 2.506 (56.1); 2.502 (72.8); 2.498 (55.3); 2.329 (0.5); 1.258 (3.8); 1.239 (8.2); 1.221 (3.7); 0.146 (0.4); 0.007 (3.2); 0.000 (79.6); -0.150 (0.4) I-22 1.87 1.90 Exemplo 22: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.261 (3.9); 8.261 (4.1); 8.107 (1.6); 8.087 (2.0); 7.942 (0.8); 7.940 (1.0); 7.921 (1.7); 7.904 (2.1); 7.901 (2.4); 7.885 (2.2); 7.820 (1.2); 7.818 (1.3); 7.801 (1.6); 7.799 (1.6); 7.783 (0.6); 7.780 (0.7); 5.757 (1.1); 3.946 (16.0); 3.728 (0.5); 3.328 (59.2); 3.305 (1.0); 3.286 (1.1); 3.272 (1.1); 3.253 (1.1); 2.885 (1.1); 2.867 (1.2); 2.852 (1.0); 2.833 (1.0); 2.672 (0.3); 2.507 (37.2); 2.502 (48.9); 2.498 (35.7); 1.149 (3.9); 1.130 (8.2); 1.112 (3.7); 1.102 (0.4); 0.007 (1.5); 0.000 (35.2); -0.008 (1.5) I-23 3.96 4.02 Exemplo 23: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.288 (4.1); 8.977 (2.7); 8.456 (2.7); 8.327 (4.3); 8.317 (0.4); 4.033 (16.0); 3.395 (2.0); 3.377 (2.7); 3.357 (2.4);3,327 (77.5); 2,720 (2.3); 2,701 (2.8); 2,682 (2.2); 2,672 (0.7); 2,579 (1.5); 2,560 (4.6); 2,542 (4.9); 2,523 (3.2); 2,507 (65.1); 2,502 (87.7); 2,498 (70.2); 2,329 (0.6); 2,075 (0.9); 1,233 (0.6); 1,152 (4.7); 1,133 (9.3); 1,115 (4.4); 0,000 (3.7); Petition 870210086398, dated 09 / 20 / 2021, pp. 140 / 177 137 / 162 Example 24: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.241 (3.7); 8.588 (1.6); 8.585 (1.8); 8.577 (1.7); 8.574 (1.8); 8.279 (3.8); 8.090 (1.5); 8.087 (1.6); 8.069 (1.7); 8.066 (1.8); 7.638 (1.6); 7.627 (1.6); 7.618 (1.5); 7.606 (1.5); 3.975 (16.0); 3.324 (34.0); 3.041 (1.1); 3.022 (3.7); 3.004 (3.8); 2.986 (1.2); 2.672 (0.3); 2.525 (0.8); 2.507 (40.5); 2.503 (55.3); 2,498 (43.4); 2.329 (0.4); 1.218 (4.0); 1,199 (8.3); 1.181 (3.9); 0.008 (1.5); 0.000 (45.1) I-25 2.97 3.08 Example 25: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.217 (3.6); 8.235 (3.9); 7.564 (2.9); 7.560 (3.0); 7,555 (3.0); 7,544 (3.5); 7,460 (2.0); 7,455 (1.8); 7,440 (1.4); 7,435 (1.3); 3,791 (16.0); 3,323 (28.6); 2,671 (0.3); 2,506 (48.4); 2,502 (56.6); 2,498 (37.8); 2,329 (0.4); 1,398 (0.8); 0,008 (2.5); 0,000 (64.5); 0.008 (2.5) I-26 2.76 2.81 Example 26: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.389 (2.0); 9.386 (2.0); 9.366 (3.5); 8.849 (2.2); 8.845 (2.1); 8.370 (3.7); 6.870 (0.5); 5.756 (0.4);4.452 (0.5); 4.347 (15.7); 4.018 (0.6); 3.995 (0.4); 3.326 (80.4); 3.151 (16.0); 2.676 (0.4); 2.671 (0.5); 2.667 (0.3); 2.524 (1.2); 2.511 (28.7); 2.507 (56.3); 2.502 (72.6); 2.498 (52.3); 2.494 (25.3); 2.334 (0.4); 2.329 (0.5); 2.325 (0.3); 2.183 (0.8); 1.355 (5.8); 1.233 (0.6); 0.008 (1.2); 0.000 (33.6); -0.009 (1.3) I-27 1.84 1.87 Exemplo 27: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.253 (3.5); 8.275 (3.8); 8.273 (3.7); 8.257 (1.5); 8.254 (1.4); 8.237 (1.8); 8.234 (1.7); 8.038 (0.5); 8.035 (0.6); 8.020 (1.5); 8.016 (1.6); 8.001 (1.5); 7.998 (1.3); 7.984 (1.2); 7.980 (1.4); 7.965 (1.6); 7.961 (1.7); 7.946 (0.7); 7.942 (0.6); 7.903 (0.9); 7.895 (2.1); 7.892 (2.0); 7.877 (1.4); 7.873 (1.3); 7.567 (0.4); 7.547 (0.6); 5.756 (8.2); 5.231 (0.7); 5.226 (0.6); 5.216 (0.5); 5.211 (1.3); 5.205 (0.5); 5.196 (0.7); 5.190 (0.8); 5.175 (0.4); 4.802 (2.1); 4.783 (4.1); 4.763 (2.6); 4.673 (2.9); 4.657 (3.1); 4.639 (2.0); 3.746 (16.0); 3.732 (0.5); 3.602 (0.5); 3.594 (0.5); 3.325 (51.0); 2.676 (0.3);2.671 (0.4); 2.524 (1.2); 2.511 (26.7); 2.507 (53.3); 2.502 (69.4); 2.498 (49.5); 2.493 (23.4); 2.333 (0.3); 2.329 (0.5); 1.760 (0.5); 1.236 (0.7); 1.190 (0.3); 0.000 (2.3); Petition 870210086398, dated 09 / 20 / 2021, pp. 141 / 177 138 / 162 Example 28: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.561 (4.9); 8.983 (2.2); 8.362 (2.2); 8.359 (2.2); 4.075 (16.0); 4.032 (0.3); 4.022 (0.4); 3.323 (56.4); 3.202 (1.1); 3.184 (3.5); 3.165 (3.5); 3.147 (1.1); 2.676 (0.4); 2.671 (0.6); 2.667 (0.4); 2.511 (33.1); 2.507 (65.1); 2.502 (84.7); 2,498 (61.6); 2,494 (30.1); 2.333 (0.4); 2.329 (0.5); 2.324 (0.4); 1.355 (0.7); 1.252 (4.0); 1.233 (8.3); 1.215 (3.7); 0.008 (2.6); 0.000 (63.4); -0.008 (2.5) I-29 2.93 3.04 Example 29: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.302 (3.5); 8,962 (1.6); 8.959 (1.8); 8.951 (1.8); 8.947 (1.8); 8.457 (1.3); 8.437 (1.4); 8.334 (3.7); 7.856 (1.7); 7.845 (1.7); 7.836 (1.6); 7.824 (1.6); 4.092 (16.0); 3.329 (37.7); 2.526 (0.6); 2.512 (14.7); 2.508 (30.1); 2,504 (40.6); 2,499 (31.1); 2.495 (16.5); 0.000 (1.9) I-30 2.36 2.41 Example 30: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.307 (3.8); 8,443 (2.9); 8,305 (4.0); 8,190 (6.5); 4,008 (15.9); 3,327 (62.6); 2,995 (16.0); 2,676 (0.4); 2,671 (0.5);2.667 (0.4); 2.511 (28.7); 2.507 (57.0); 2.502 (75.3); 2.498 (56.9); 2.334 (0.4); 2.329 (0.5); 2.325 (0.4); 0.000 (3.6) I-31 3.86 3.94 Exemplo 31: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.283 (3.4); 8.955 (2.1); 8.952 (2.1); 8.347 (2.1); 8.343 (2.2); 8.334 (3.8); 4.021 (16.0); 3.324 (17.5); 3.137 (2.1); 3.119 (3.6); 3.101 (2.2); 2.892 (1.6); 2.732 (1.3); 2.672 (0.4); 2.525 (0.7); 2.512 (20.3); 2.507 (42.4); 2.503 (57.6); 2.498 (43.7); 2.494 (22.9); 2.329 (0.4); 1.607 (1.2); 1.588 (2.4); 1.570 (2.5); 1.552 (1.4); 0.961 (4.2); 0.943 (8.6); 0.924 (3.8); 0.008 (1.3); 0.000 (42.0); -0.009 (2.2) I-32 3.32 3.37 Exemplo 32: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.580 (2.3); 9.577 (2.3); 9.316 (3.9); 8.796 (2.4); 8.792 (2.4); 8.350 (4.1); 7.903 (0.5); 7.898 (0.5); 7.547 (0.5); 5.756 (2.2); 3.923 (16.0); 3.898 (2.3); 3.883 (1.8); 3.878 (2.4); 3.873 (1.8); 3.859 (2.3); 3.775 (0.8); 3.323 (27.3); 2.676 (0.3); 2.671 (0.5); 2.667 (0.3); 2.524 (1.0); 2.511 (25.7); 2.507 (52.2); 2.502 (69.6); 2.498 (51.6);2.493 (26.0); 2.329 (0.4); 2.324 (0.3); 1.737 (1.1); 1.718 (1.9); 1.699 (2.0); 1.680 (1.2); 1.013 (4.1); 1.002 (0.9); 0.995 (8.4); 0.976 (3.8); 0.000 (9.4); -0.008 (0.4); Petition 870210086398, dated 09 / 20 / 2021, pp. 142 / 177 139 / 162 Example 33: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.315 (3.7); 8.969 (1.6); 8.966 (1.8); 8.958 (1.8); 8.954 (1.7); 8.556 (1.6); 8.552 (1.7); 8.536 (1.8); 8.532 (1.7); 8.319 (4.0); 7.938 (1.7); 7.926 (1.6); 7.918 (1.6); 7.906 (1.5); 4.318 (16.0); 3.552 (0.9); 3.533 (1.0); 3.519 (1.1); 3,500 (1.1); 3.481 (0.3); 3.324 (25.2); 3.031 (1.1); 3.012 (1.2); 2,998 (1.0); 2.979 (1.0); 2.507 (37.9); 2.503 (49.7); 2,499 (37.5); 1.303 (3.8); 1.285 (8.0); 1.266 (3.7); 0.000 (5.3) I-34 4.41 4.38 Example 34: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.332 (3.7); 8.517 (4.3); 8.515 (4.4); 8,272 (3.7); 8,251 (3.9); 7,627 (0.5); 7,623 (0.6); 7,614 (0.4); 7,597 (0.5); 7,575 (0.4); 7,566 (0.4); 7,556 (0.4); 7,542 (2.9); 7,538 (3.4); 7,509 (2.4); 7,504 (1.7); 7,488 (2.1); 7,483 (1.8); 3,321 (35.3); 2,680 (0.4); 2,675 (0.9); 2,671 (1.2); 2,666 (0.8); 2,662 (0.4); 2,610 (16.0); 2,524 (3.5); 2,511 (65.6); 2,506 (129.9); 2,502 (168.9); 2,497 (120.0); 2,493 (56.5); 2,337 (0.4);2.333 (0.8); 2.329 (1.1); 2.324 (0.8); 2.320 (0.4); 1.355 (1.2); 1.328 (0.4); 1.207 (0.3); 1.189 (0.7); 1.168 (2.5); 1.160 (2.3); 1.145 (0.4); 1.058 (0.5); 0.146 (0.4); 0.008 (3.6); 0.000 (97.2); -0.009 (3.2); -0.150 (0.4) I-35 4.07 4.03 Exemplo 35: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.334 (5.6); 8.540 (6.8); 8.538 (6.7); 8.234 (2.7); 8.231 (2.8); 8.214 (3.0); 8.211 (2.8); 7.693 (1.0); 7.690 (1.0); 7.673 (2.6); 7.669 (2.1); 7.655 (2.3); 7.651 (2.2); 7.621 (3.9); 7.602 (2.0); 7.440 (1.8); 7.437 (1.8); 7.420 (3.0); 7.402 (1.5); 7.399 (1.4); 3.323 (126.5); 3.130 (2.0); 3.112 (6.6); 3.093 (6.7); 3.075 (2.1); 2.680 (0.5); 2.675 (1.1); 2.671 (1.5); 2.666 (1.1); 2.662 (0.5); 2.524 (4.8); 2.511 (84.8); 2.506 (166.1); 2.502 (215.2); 2.497 (153.7); 2.493 (72.9); 2.333 (1.0); 2.329 (1.4); 2.324 (1.0); 1.333 (7.5); 1.315 (16.0); 1.297 (7.2); 0.008 (1.0); 0.000 (28.0); -0.009 (0.9) I-36 2.64 2.67 Exemplo 36: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.577 (2.7); 9.575 (2.7); 9.320 (4.2); 8.825 (2.8);8,822 (2.8); 8,347 (4.5); 7,902 (0.7); 7,897 (0.7); 7,886 (0.4); 7,566 (0.3); 7,546 (0.5); 5,757 (1.3); 4,018 (1.1); 3,934 (16.0); 3,700 (15.4); 3,325 (73.6); 2,671 (0.7); 2,506 (74.4); 2,502 (95.9); 2,498 (76.5); 2,328 (0.6); 1,258 (0.3); 1,236 (1.0); 1,169 (0.8); 0,000 (2.4); Petition 870210086398, dated 09 / 20 / 2021, pp. 143 / 177 140 / 162 Example 37: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.392 (2.2); 9.388 (2.3); 9.369 (3.8); 8.726 (2.3); 8.721 (2.4); 8.385 (3.9); 8.316 (0.5); 4.362 (16.0); 3.627 (0.9); 3.608 (1.1); 3.594 (1.1); 3.575 (1.0); 3.324 (136.2); 3.117 (1.0); 3.098 (1.2); 3.084 (1.0); 3.065 (0.9); 2.676 (0.8); 2.671 (1.1); 2.667 (0.9); 2.507 (127.4); 2.502 (169.6); 2,498 (129.7); 2.333 (0.8); 2.329 (1.1); 2.325 (0.9); 1.330 (3.8); 1.312 (8.1); 1.293 (3.6); 0.146 (0.9); 0.008 (7.7); 0.000 (196.4); -0.150 (0.9) I-38 2.63 2.68 Example 38: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.273 (3.9); 8,266 (4.2); 8,141 (2.4); 8,120 (3.8); 8,105 (2.9); 8,100 (3.4); 8,055 (2.4); 8,049 (2.0); 8,033 (1.5); 8,028 (1.3); 7,904 (0.8); 7,899 (0.7); 7,894 (0.5); 7,887 (0.5); 7,697 (0.3); 7,568 (0.5); 7,548 (0.8); 7,528 (0.3); 3,763 (16.0); 3,530 (0.6); 3,513 (1.3); 3,495 (1.4); 3,476 (0.6); 3,357 (0.5); 3,328 (61.7); 2,676 (0.4); 2,671 (0.5); 2,667 (0.4); 2,525 (1.3); 2,507 (57.0); 2,502 (75.7);2.498 (56.3); 2.333 (0.3); 2.329 (0.5); 2.325 (0.3); 1.125 (3.8); 1.107 (8.1); 1.088 (3.6); 0.000 (0.6) I-39 3.45 3.52 Exemplo 39: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.386 (2.2); 9.383 (2.3); 9.374 (3.8); 8.774 (2.3); 8.769 (2.3); 8.316 (0.4); 8.302 (3.8); 5.756 (0.4); 4.362 (16.0); 3.637 (0.5); 3.616 (0.9); 3.605 (0.6); 3.596 (0.6); 3.585 (1.0); 3.564 (0.6); 3.322 (68.3); 2.993 (0.6); 2.981 (0.7); 2.973 (0.7); 2.961 (1.1); 2.949 (0.7); 2.941 (0.7); 2.928 (0.6); 2.676 (0.6); 2.671 (0.8); 2.666 (0.6); 2.511 (49.6); 2.506 (97.4); 2.502 (127.7); 2.497 (95.5); 2.493 (49.9); 2.333 (0.6); 2.329 (0.8); 2.324 (0.6); 2.029 (0.5); 2.010 (0.7); 1.994 (0.8); 1.975 (0.7); 1.956 (0.4); 1.804 (0.4); 1.789 (0.6); 1.783 (0.5); 1.770 (0.6); 1.757 (0.4); 1.754 (0.4); 1.146 (3.8); 1.128 (8.0); 1.109 (3.6); 0.146 (0.8); 0.008 (8.1); 0.000 (174.8); -0.008 (10.0); -0.150 (0.8) I-40 3.10 3.15 Exemplo 40: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.347 (4.8); 8.561 (5.7); 8.293 (2.2); 8.291 (2.3); 8.274 (2.4); 8.271 (2.3);7.668 (1.0); 7.665 (1.1); 7.647 (2.2); 7.630 (1.4); 7.627 (1.3); 7.480 (1.7); 7.460 (2.8); 7.442 (1.3); 7.179 (2.9); 7.159 (2.6); 6.870 (1.5); 6.647 (0.8); 5.165 (3.3); 5.147 (6.3); 5.130 (3.6); 4.804 (0.5); 4.788 (1.2); 4.771 (1.9); 4.755 (1.2); 4.738 (0.4); 4.512 (3.8); 4.496 (6.3); 4,480 (3.3); 3,328 (53.8); 2,672 (0.6); 2,507 (73.4); 2,503 (93.5); 2,499 (70.8); 2,330 (0.6); 2,183 (2.4); 1,355 (16.0); 1,233 (0.9); 1,182 (0.6); 0,008 (3.2); 0,000 (57.9); Petition 870210086398, dated 09 / 20 / 2021, pp. 144 / 177 141 / 162 Example 41: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.277 (3.9); 8.989 (2.5); 8.456 (2.5); 8.453 (2.5); 8.345 (0.3); 8.333 (4.2); 7.954 (0.5); 4.021 (0.4); 4.003 (1.1); 3.988 (16.0); 3.949 (0.4); 3.932 (1.0); 3.916 (1.4); 3.899 (1.1); 3.883 (0.4); 3.325 (35.1); 2.892 (3.7); 2.732 (3.3); 2.672 (0.3); 2.507 (40.5); 2.503 (53.7); 2,499 (41.6); 2.330 (0.4); 1.235 (14.8); 1.219 (14.7); 0.008 (1.4); 0.000 (30.8) I-42 3.39 3.46 Example I-42: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.881 (0.4); 9.213 (3.4); 8.238 (3.6); 8.236 (3.6); 8.136 (0.4); 8.085 (0.7); 7.683 (0.3); 7,639 (2.8); 7,634 (2.9); 7,572 (2.4); 7,552 (3.7); 7,504 (0.5); 7,499 (0.5); 7,483 (2.1); 7,478 (2.0); 7,462 (1.4); 7,457 (1.3); 6,870 (0.4); 3,779 (16.0); 3,618 (0.4); 3,608 (0.3); 3,602 (1.0); 3,585 (0.4); 3,325 (20.2); 3,098 (0.6); 3,067 (1.2); 3,048 (3.9); 3,030 (4.0); 3,016 (0.9); 3,012 (1.3); 2,877 (1.1); 2,865 (1.1); 2,676 (0.4); 2,671 (0.5); 2,667 (0.4); 2,525 (1.4); 2,520 (2.1); 2,511 (30.1);2.507 (61.5); 2.502 (81.2); 2.498 (58.8); 2.493 (28.4); 2.333 (0.4); 2.329 (0.5); 2.324 (0.4); 2.183 (0.7); 1.776 (0.4); 1.769 (0.4); 1.760 (1.2); 1.752 (0.4); 1.744 (0.4); 1.355 (5.3); 1.245 (0.8); 1.236 (0.4); 1.226 (1.7); 1.218 (0.5); 1.208 (0.8); 1.193 (4.1); 1.175 (8.7); 1.156 (3.9); 0.146 (0.4); 0.008 (2.9); 0.000 (88.8); 0.009 (3.1); -0.150 (0.4) I-43 2.61 2.69 Exemplo I-43: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.259 (3.8); 8.259 (4.0); 8.123 (6.1); 8.118 (3.1); 8.107 (2.5); 8.102 (1.5); 7.945 (2.9); 7.939 (0.8); 7.929 (0.7); 7.923 (2.3); 5.757 (11.4); 3.742 (16.0); 3.600 (0.7); 3.581 (2.2); 3.563 (2.2); 3.545 (0.7); 3.329 (38.9); 2.671 (0.4); 2.525 (1.2); 2.511 (23.7); 2.507 (48.0); 2.502 (63.6); 2.498 (47.5); 2.494 (24.1); 2.329 (0.4); 1.146 (3.7); 1.128 (8.2); 1.109 (3.6); 0.008 (0.3); 0.000 (9.3); -0.008 (0.4) I-44 2.36 2.45 Exemplo I-44: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.270 (3.8); 8.317 (0.5); 8.273 (4.1); 8.022 (2.9); 8.016 (3.1); 7.986 (2.2); 7.966 (3.6); 7.905 (2.1);7,899 (1.9); 7,884 (1.3); 7,879 (1.2); 3,969 (16.0); 3,377 (1.0); 3,359 (1.3); 3,344 (1.9); 3,329 (150.3); 3,307 (0.6); 2,945 (1.1); 2,927 (1.2); 2,912 (1.0); 2,893 (0.9); 2,676 (0.9); 2,671 (1.2); 2,667 (0.9); 2,524 (3.1); 2,507 (141.2); 2,502 (185.0); 2,498 (135.5); 2,333 (0.9); 2,329 (1,2); 2,325 (0,9); 1,179 (3,8); 1,160 (8,2); 1,142 (3,7); 0,008 (2,3); 0,000 (70,9); -0,009 (2,6); -0,150 (0,3); Petition 870210086398, dated 09 / 20 / 2021, pp. 145 / 177 142 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-45 2,53 Exemplo I-45: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,295 (3,9); 8,364 (3,2); 8,342 (3,4); 8,292 (4,1); 7,347 (3,4); 7,325 (3,3); 4,015 (1,0); 3,987 (16,0); 3,922 (15,6); 3,910 (1,3); 3,733 (1,0); 3,714 (3,4); 3,695 (3,4); 3,677 (1,0); 3,506 (0,3); 3,331 (66,6); 2,672 (0,5); 2,668 (0,4); 2,507 (58,9); 2,503 (75,4); 2,498 (56,9); 2,334 (0,4); 2,329 (0,5); 2,325 (0,4); 2,087 (2,0); 1,234 (0,8); 1,203 (3,6); 1,185 (7,9); 1,166 (3,5); 0,008 (2,1); 0,000 (43,3) I-46 2,92 2,98 Exemplo I-46: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,269 (4,1); 8,592 (1,8); 8,590 (1,9); 8,581 (1,9); 8,578 (1,8); 8,306 (4,3); 8,094 (1,7); 8,092 (1,7); 8,074 (1,9); 8,071 (1,8); 7,955 (0,8); 7,642 (1,6); 7,631 (1,6); 7,622 (1,5); 7,610 (1,5); 3,979 (16,0); 3,334 (9,6); 3,046 (1,2); 3,027 (3,8); 3,009 (3,9); 2,991 (1,3); 2,893 (4,9); 2,734 (4,4); 2,509 (22,7); 2,505 (28,6); 2,501 (21,4); 1,220 (4,2); 1,202 (8,6); 1,184 (4,1);0.000 (4.6) I-47 4.02 4.10 Exemplo I-47: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.308 (3.5); 8.964 (2.1); 8.961 (2.1); 8.355 (3.9); 8.353 (3.9); 8.341 (2.2); 8.338 (2.2); 8.317 (0.3); 4.030 (16.0); 3.328 (183.2); 3.184 (1.1); 3.165 (3.5); 3.147 (3.6); 3.129 (1.1); 2.676 (0.8); 2.671 (1.1); 2.667 (0.8); 2.525 (2.5); 2.520 (3.8); 2.511 (53.3); 2.507 (109.8); 2.502 (147.2); 2.498 (110.1); 2.494 (55.4); 2.334 (0.7); 2.329 (1.0); 2.325 (0.7); 1.235 (4.2); 1.217 (8.3); 1.198 (3.8); 0.146 (1.1); 0.008 (8.0); 0.000 (229.8); -0.009 (9.5); -0.150 (1.1) I-48 2.64 2.70 Exemplo I-48: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.337 (2.2); 9.324 (2.3); 9.295 (4.0); 8.366 (2.9); 8.353 (2.8); 8.273 (4.3); 5.757 (0.8); 3.919 (16.0); 3.894 (0.7); 3.879 (1.3); 3.862 (1.3); 3.327 (92.4); 2.676 (0.6); 2.671 (0.8); 2.667 (0.6); 2.507 (88.5); 2.502 (113.9); 2.498 (86.6); 2.333 (0.6); 2.329 (0.8); 2.325 (0.6); 1.243 (3.6); 1.224 (7.4); 1.206 (3.4); 0.146 (0.6); 0.008 (6.3); 0.000 (128.4);-0.150 (0.6) I-49 1.99 2.05 Example I-49: 1H-NMR (400.0 MHz, de-DMSO): δ= 11.328 (3.1); 9.295 (4.3); 8.532 (1.7); 8.509 (4.8); 8,487 (4.4); 8,465 (1.5); 8.318 (0.6); 8.304 (4.7); 3,876 (16.0); 3.847 (0.7); 3,658 (1.1); 3.639 (3.5); 3.621 (3.5); 3,602 (1.1); 3,331 (78.4); 2,892 (0.3); 2,676 (1.0); 2.672 (1.3); 2.668 (1.0); 2.565 (0.4); 2.507 (157.3); 2.503 (200.0); 2.498 (150.8); 2.344 (0.8); 2.334 (1.0); 2.329 (1.4); 2.169 (15.8); 1.989 (1.1); 1.234 (0.5); 1.184 (3.8); 1.175 (1.3); 1.166 (8.3); 1.148 (3.7); 0.008 (0.9); 0.000 (19.7); Petition 870210086398, dated 09 / 20 / 2021, pp. 146 / 177 143 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-50 2,27 2,39 Exemplo I-50: 1H-RMN (400,0 MHz, de-DMSO): δ= 10,770 (2,6); 9,256 (3,9); 8,290 (1,9); 8,277 (4,3); 8,268 (2,5); 8,242 (0,7); 8,115 (3,0); 8,093 (2,4); 8,063 (0,4); 4,456 (1,9); 4,038 (0,6); 4,020 (0,7); 3,979 (16,0); 3,332 (83,1); 2,966 (1,2); 2,948 (4,0); 2,929 (4,1); 2,911 (1,3); 2,676 (0,4); 2,672 (0,5); 2,668 (0,4); 2,507 (62,3); 2,503 (81,2); 2,498 (61,4); 2,334 (0,4); 2,330 (0,5); 2,325 (0,4); 2,184 (1,9); 2,119 (15,2); 1,989 (2,6); 1,193 (0,7); 1,172 (4,5); 1,154 (9,1); 1,135 (4,2); 0,008 (2,6); 0,000 (55,6); -0,008 (3,1) I-51 2,48 Exemplo I-51: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,259 (4,5); 9,210 (2,4); 9,198 (2,5); 8,278 (4,7); 8,276 (4,8); 8,226 (3,2); 8,214 (3,1); 5,757 (2,5); 3,965 (0,7); 3,946 (0,8); 3,932 (0,8); 3,920 (0,7); 3,914 (0,8); 3,795 (16,0); 3,375 (0,6); 3,356 (0,8); 3,328 (59,8); 3,305 (0,3); 2,676 (0,4); 2,672 (0,5); 2,667 (0,4); 2,525 (1,2); 2,511 (27,2); 2,507 (56,1); 2,502 (75,0); 2,498 (55,5); 2,494 (27,5);2.334 (0.4); 2.329 (0.5); 2.325 (0.4); 1.264 (3.7); 1.245 (7.9); 1.227 (3.8); 0.008 (1.2); 0.000 (39.0); -0.008 (1.4) I-52 2.51 2.61 Example I-52: 1H-NMR (601.6 MHz, CD3CN): δ= 9.321 (2.5); 8.780 (3.9); 8.736 (2.6); 7.746 (3.8); 3.824 (1.3); 3.809 (16.0); 3.799 (3.9); 3.787 (1.3); 2.141 (2.3); 1,965 (10.4); 1.957 (0.4); 1,944 (3.9); 1,940 (5.2); 1,937 (3.8); 1,933 (2.0); 1,297 (3.8); 1,285 (7.6); 1,273 (3.7); 0.000 (3.3) I-53 3.12 Example I-53: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.242 (3.5); 8,270 (3.7); 8,119 (0.4); 8,064 (2.9); 8,042 (3.1); 7,123 (3.3); 7,101 (3.1); 4,012 (16.0); 3.959 (0.4); 3.909 (1.6); 3.899 (16.0); 3.332 (95.1); 2.942 (1.2); 2.923 (3.9); 2.905 (3.9); 2.887 (1.3); 2.677 (0.4); 2.672 (0.6); 2.668 (0.4); 2.525 (1.6); 2.511 (32.5); 2.507 (64.4); 2.503 (84.3); 2.499 (63.2); 2.334 (0.4); 2.330 (0.6); 2.325 (0.4); 1.990 (0.8); 1.175 (0.5); 1.144 (4.1); 1.126 (8.6); 1.107 (4.0); 0.008 (2.3); 0.000 (60.3);-0.008 (3.0) I-54 3.07 3.16 Example I-54: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.293 (3.9); 8,987 (2.7); 8,490 (2.7); 8.335 (4.1); 5,757 (0.6); 4.713 (1.2); 4,699 (2.4); 4,685 (1.2); 4,595 (1.1); 4,581 (2.3); 4,567 (1.3); 4,041 (16.0); 3,581 (1.1); 3,567 (2.2); 3,553 (1.1); 3.521 (1.2); 3,507 (2.2); 3.493 (1.1); 3.327 (105.4); 2.671 (0.8); 2.506 (88.1); 2.502 (120.1); 2.498 (96.8); 2.333 (0.6); 2.329 (0.8); 1.234 (0.4); 0.146 (0.4); 0.008 (2.7); 0.000 (84.4); -0.150 (0.4); Petition 870210086398, dated 09 / 20 / 2021, pp. 147 / 177 144 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-55 3,01 3,12 Exemplo I-55: 1H-RMN (400,0 MHz, de-DMSO): δ= 8,956 (3,9); 8,953 (4,0); 8,942 (2,0); 8,940 (2,0); 8,317 (2,1); 7,904 (3,7); 7,902 (3,7); 3,950 (16,0); 3,332 (109,0); 3,172 (1,0); 3,154 (3,3); 3,135 (3,4); 3,117 (1,0); 2,676 (0,3); 2,672 (0,5); 2,667 (0,4); 2,525 (1,2); 2,520 (1,8); 2,512 (26,2); 2,507 (53,9); 2,503 (71,3); 2,498 (52,0); 2,494 (25,3); 2,334 (0,3); 2,330 (0,5); 2,325 (0,4); 1,251 (0,5); 1,232 (5,1); 1,214 (7,9); 1,195 (3,5); 1,103 (0,3); 0,000 (6,1) I-56 1,56 1,61 Exemplo I-56: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,502 (3,9); 9,497 (3,4); 9,306 (4,1); 8,900 (4,0); 8,895 (3,4); 8,645 (1,9); 8,322 (4,5); 8,057 (1,9); 3,892 (16,0); 3,843 (1,3); 3,825 (3,8); 3,806 (3,7); 3,788 (1,1); 3,332 (180,7); 2,676 (0,9); 2,672 (1,1); 2,667 (0,8); 2,507 (135,9); 2,503 (156,6); 2,498 (111,5); 2,334 (0,9); 2,330 (1,0); 2,325 (0,7); 1,298 (0,5); 1,259 (1,0); 1,235 (5,5); 1,217 (8,5); 1,198 (3,8); 0,000 (14,4);-0.062 (0.6) I-57 2.82 2.89 Exemplo I-57: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.596 (2.3); 9.593 (2.2); 9.330 (3.8); 9.320 (0.5); 8.830 (2.3); 8.826 (2.2); 8.353 (4.1); 4.994 (1.0); 4.982 (1.5); 4.969 (1.1); 4.877 (1.0); 4.865 (1.5); 4.852 (1.2); 4.493 (1.1); 4.480 (1.5); 4.468 (1.0); 4.427 (1.2); 4.414 (1.5); 4.402 (1.0); 3.957 (16.0); 3.947 (1.6); 3.919 (0.4); 3.813 (0.3); 3.328 (182.7); 2.676 (0.7); 2.671 (1.0); 2.667 (0.7); 2.663 (0.4); 2.524 (3.6); 2.511 (61.5); 2.507 (120.1); 2.502 (156.5); 2.498 (114.9); 2.493 (57.0); 2.333 (0.7); 2.329 (1.0); 2.325 (0.7); 2.074 (0.5); 1.235 (0.6); 0.008 (2.3); 0.000 (63.1); -0.008 (2.5) I-58 2.19 Exemplo I-58: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.553 (2.2); 9.550 (2.2); 9.320 (3.9); 8.786 (2.4); 8.781 (2.4); 8.336 (4.1); 5.755 (1.0); 5.119 (1.2); 5.106 (2.9); 5.093 (1.3); 4.066 (1.6); 4.052 (3.3); 4.038 (2.1); 3.919 (16.0); 3.869 (1.1); 3.855 (2.7); 3.842 (2.5); 3.828 (0.9); 3.400 (0.4); 3.393 (0.4); 3.384 (0.5); 3.345 (268.1); 3.309 (0.6);2,672 (0.4); 2.526 (1.1); 2,512 (22.7); 2,508 (46.1); 2,503 (61.2); 2,499 (45.2); 2,494 (22.6); 2,330 (0.4); 0.000 (0.6) I-59 2.31 2.41 Example I-59: 1H-NMR (600.1 MHz, CD3CN): δ= 9.085 (2.6); 8.843 (1.4); 8.842 (1.6); 8,840 (1.5); 8.333 (1.7); 8.331 (1.6); 8.165 (2.9); 5,447 (1.4); 3.979 (16.0); 3.725 (0.9); 3.715 (2.8); 3.705 (2.9); 3.695 (1.0); 3.459 (0.9); 3.449 (1.8); 3.439 (0.8); 3.177 (2.4); 3.167 (4.3); 3.157 (2.2); 2.145 (5.7); 1.957 (0.5); 1.953 (0.6); 1.949 (3.0); 1.945 (5.2); 1.941 (7.5); 1.937 (5.0); 1.933 (2.5); Petition 870210086398, dated 09 / 20 / 2021, pp. 148 / 177 145 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-60 1,76 1,77 Exemplo I-60: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,262 (4,0); 8,968 (3,2); 8,963 (3,3); 8,415 (1,6); 8,354 (3,0); 8,350 (3,1); 8,303 (4,3); 7,862 (1,6); 4,008 (16,0); 3,331 (33,2); 3,113 (1,1); 3,095 (3,7); 3,076 (3,8); 3,058 (1,2); 2,508 (35,4); 2,504 (46,2); 2,499 (34,8); 1,246 (4,0); 1,228 (8,5); 1,209 (3,9); 0,008 (1,7); 0,000 (46,1); -0,008 (2,2) I-61 2,63 2,71 Exemplo I-61: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,343 (3,7); 8,973 (1,6); 8,969 (1,8); 8,961 (1,8); 8,957 (1,8); 8,559 (1,6); 8,555 (1,7); 8,539 (1,8); 8,535 (1,8); 8,347 (4,0); 8,345 (4,0); 7,941 (1,7); 7,929 (1,6); 7,921 (1,6); 7,909 (1,6); 4,320 (16,0); 3,561 (1,0); 3,542 (1,0); 3,528 (1,1); 3,509 (1,1); 3,490 (0,3); 3,330 (33,2); 3,048 (1,1); 3,030 (1,2); 3,015 (1,0); 2,997 (1,0); 2,677 (0,4); 2,672 (0,5); 2,668 (0,4); 2,525 (1,3); 2,507 (56,6); 2,503 (75,2); 2,499 (56,4); 2,334 (0,4); 2,330 (0,5); 2,325 (0,4); 1,301 (3,8); 1,282 (8,2); 1,264 (3,7); 0,146 (0,5); 0,008 (4,0);0.000 (110.8); -0.008 (5.6); -0.150 (0.5) I-62 2.15 2.17 Exemplo I-62: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.207 (3.4); 8.318 (0.5); 8.194 (3.7); 8.192 (3.6); 8.062 (1.6); 8.059 (1.7); 8.042 (2.2); 8.039 (2.2); 7.947 (1.8); 7.928 (2.7); 7.908 (1.6); 7.735 (2.0); 7.732 (2.1); 7.716 (1.8); 7.713 (1.7); 3.742 (16.0); 3.593 (1.0); 3.574 (3.5); 3.556 (3.6); 3.537 (1.2); 3.329 (74.8); 2.676 (0.7); 2.671 (0.9); 2.667 (0.7); 2.662 (0.4); 2.525 (2.4); 2.520 (3.6); 2.511 (50.5); 2.507 (105.6); 2.502 (140.5); 2.498 (101.4); 2.493 (48.8); 2.334 (0.6); 2.329 (0.9); 2.324 (0.6); 2.086 (0.7); 1.235 (1.3); 1.184 (4.0); 1.166 (9.0); 1.147 (3.9); 1.140 (0.6); 0.146 (0.7); 0.008 (5.0); 0.000 (161.5); -0.009 (5.9); -0.150 (0.7) I-63 3.62 3.75 Exemplo I-63: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.396 (5.6); 8.728 (2.2); 8.723 (2.3); 8.416 (4.1); 8.414 (3.9); 8.318 (0.5); 4.362 (16.0); 3.635 (0.9); 3.617 (1.0); 3.602 (1.1); 3.583 (1.0); 3.332 (165.3); 3.134 (1.0); 3.116 (1.2); 3.101 (1.0); 3.083 (1.0); 2.676 (0.8);2.672 (1.1); 2.667 (0.8); 2.525 (2.6); 2.511 (62.1); 2.507 (126.3); 2.503 (165.5); 2.498 (121.7); 2.494 (60.8); 2.334 (0.8); 2.329 (1.1); 2.325 (0.8); 1.327 (3.7); 1.308 (8.1); 1.290 (3.6); 0.146 (0.4); 0.008 (3.1); 0.000 (96.0); -0.008 (4.1); -0.150 (0.4); Petition 870210086398, dated 09 / 20 / 2021, pp. 149 / 177 146 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-64 3,95 3,93 Exemplo I-64: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,275 (2,6); 9,271 (2,5); 8,943 (4,3); 8,584 (2,6); 8,580 (2,6); 8,318 (0,5); 7,701 (3,0); 7,680 (3,9); 7,548 (3,8); 7,527 (3,0); 7,410 (4,6); 3,890 (16,0); 3,329 (75,4); 3,140 (1,3); 3,122 (4,2); 3,104 (4,3); 3,086 (1,4); 2,676 (0,9); 2,671 (1,2); 2,667 (0,9); 2,507 (140,3); 2,502 (179,9); 2,498 (134,5); 2,334 (0,9); 2,329 (1,2); 2,325 (0,9); 1,281 (4,6); 1,263 (9,7); 1,245 (4,5); 0,146 (0,4); 0,008 (3,6); 0,000 (84,0); -0,150 (0,4) I-65 4,31 4,37 Exemplo I-65: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,217 (3,1); 9,076 (4,1); 9,074 (4,1); 8,959 (2,3); 8,956 (2,3); 8,334 (2,3); 8,318 (1,7); 8,288 (3,7); 8,211 (4,1); 8,209 (4,1); 5,758 (1,1); 4,005 (16,0); 3,328 (226,4); 3,189 (1,1); 3,171 (3,5); 3,153 (3,6); 3,134 (1,1); 2,676 (2,7); 2,671 (3,8); 2,667 (2,8); 2,525 (9,3); 2,520 (14,6); 2,511 (211,4); 2,507 (434,4); 2,502 (573,8); 2,498 (421,2); 2,493 (209,9); 2,333 (2,7); 2,329 (3,7); 2,324 (2,8);1.258 (0.3); 1.243 (4.1); 1.225 (8.8); 1.206 (3.9); 1.148 (0.3); 0.146 (1.3); 0.008 (9.7); 0.000 (308.8); -0.008 (13.1); -0.150 (1.4) I-66 3.42 3.50 Exemplo I-66: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.243 (3.5); 8.317 (0.4); 8.274 (3.7); 8.069 (2.9); 8.047 (3.1); 7.116 (3.3); 7.094 (3.2); 4.017 (0.4); 4.000 (16.0); 3.893 (15.8); 3.329 (74.5); 2.884 (2.3); 2.867 (3.7); 2.848 (2.4); 2.676 (0.7); 2.671 (0.9); 2.667 (0.7); 2.525 (2.3); 2.511 (50.8); 2.507 (105.0); 2.502 (139.6); 2.498 (102.9); 2.494 (51.4); 2.334 (0.6); 2.329 (0.9); 2.325 (0.7); 1.496 (1.2); 1.478 (2.4); 1.460 (2.5); 1.442 (1.4); 0.875 (4.2); 0.857 (8.4); 0.838 (3.7); 0.008 (0.8); 0.000 (28.2); -0.008 (1.2) I-67 2.70 2.75 Exemplo I-67: 1H-RMN (400.0 MHz, de-DMSO): δ= 10.028 (0.5); 9.850 (0.4); 9.268 (0.7); 9.248 (3.0); 8.317 (1.0); 8.302 (0.7); 8.262 (3.1); 8.236 (0.6); 8.194 (0.5); 8.119 (1.3); 8.097 (0.7); 8.026 (2.6); 8.004 (2.6); 7.996 (0.5); 7.978 (0.6); 7.181 (0.8); 7.159 (0.6); 7.133 (2.8); 7.111 (2.7); 4.442 (2.5);4.071 (13.8); 4.017 (3.3); 4.014 (3.6); 3.959 (1.9); 3.910 (16.0); 3.329 (346.6); 2.881 (1.4); 2.869 (1.4); 2.676 (1.7); 2.671 (2.3); 2.667 (1.7); 2.525 (5.8); 2.511 (128.4); 2.507 (263.1); 2.502 (348.1); 2.498 (256.2); 2.494 (127.6); 2.422 (14.2); 2.334 (1.7); 2.329 (2.3); 2.325 (1.7); 1.989 (0.9); 1.234 (0.3); 1.175 (0.5); 0.146 (0.4); 0.008 (3.2); 0.000 (99.9); -0.008 (3.8); 0.150 (0.5); Petition 870210086398, dated 09 / 20 / 2021, pp. 150 / 177 147 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-68 2,46 2,50 Exemplo I-68: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,319 (4,1); 9,142 (1,6); 9,139 (1,9); 9,130 (1,8); 9,126 (1,9); 8,582 (1,6); 8,578 (1,8); 8,562 (1,9); 8,558 (1,9); 8,328 (4,3); 8,024 (1,7); 8,012 (1,7); 8,003 (1,6); 7,991 (1,6); 3,870 (16,0); 3,802 (1,0); 3,783 (3,5); 3,765 (3,6); 3,746 (1,1); 3,333 (44,0); 2,676 (0,3); 2,672 (0,5); 2,668 (0,4); 2,507 (56,6); 2,503 (74,8); 2,499 (56,9); 2,330 (0,5); 1,209 (3,7); 1,191 (8,1); 1,172 (3,6); 0,008 (1,1); 0,000 (28,7) I-69 4,32 4,37 Exemplo I-69: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,080 (4,3); 9,078 (4,2); 8,959 (2,4); 8,956 (2,4); 8,873 (1,8); 8,871 (2,0); 8,867 (2,1); 8,865 (1,8); 8,337 (2,4); 8,334 (2,4); 8,181 (4,2); 8,180 (4,2); 7,062 (2,5); 7,056 (2,5); 4,007 (16,0); 3,330 (22,5); 3,189 (1,1); 3,170 (3,7); 3,152 (3,7); 3,133 (1,2); 2,677 (0,3); 2,672 (0,5); 2,668 (0,3); 2,526 (1,2); 2,512 (26,3); 2,508 (53,3); 2,503 (70,1); 2,499 (51,8); 2,495 (26,3); 2,330 (0,4); 2,326 (0,3); 2,077 (0,6);1.244 (4.0); 1.225 (8.7); 1.207 (3.9); 0.008 (1.3); 0.000 (37.3); -0.008 (1.8) I-70 3.24 3.29 Exemplo I-70: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.272 (4.0); 9.057 (2.0); 9.044 (2.1); 8.309 (4.2); 8.135 (2.8); 8.122 (2.7); 4.021 (0.4); 3.846 (16.0); 3.328 (22.9); 2.736 (1.1); 2.717 (3.4); 2.699 (3.5); 2.680 (1.3); 2.507 (37.7); 2.503 (49.4); 2.499 (37.9); 1.990 (1.3); 1.397 (1.1); 1.193 (0.3); 1.176 (0.7); 1.158 (0.4); 0.985 (4.0); 0.966 (8.1); 0.948 (3.8); 0.008 (1.7); 0.000 (44.7); -0.008 (2.1) I-71 2.93 Exemplo I-71: 1H-RMN (400.0 MHz, de-DMSO): δ= 9.293 (4.1); 8.368 (3.1); 8.345 (3.3); 8.299 (4.3); 7.342 (3.4); 7.320 (3.2); 5.758 (0.9); 4.017 (0.4); 3.985 (16.0); 3.918 (15.5); 3.716 (2.2); 3.701 (1.9); 3.696 (2.5); 3.692 (1.8); 3.677 (2.2); 3.330 (25.0); 2.676 (0.4); 2.672 (0.5); 2.668 (0.4); 2.507 (54.4); 2.503 (69.4); 2.499 (51.7); 2.330 (0.5); 2.326 (0.3); 1.668 (1.1); 1.649 (2.0); 1.630 (2.0); 1.611 (1.2); 1.235 (0.7); 0.993 (4.1); 0.974 (8.2); 0.956 (3.7);0.000 (2.4) I-72 2.26 2.32 Example I-72: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.581 (3.0); 9,576 (3.0); 9.312 (4.1); 9,070 (3.3); 9,065 (3.2); 8,716 (1.0); 8.704 (0.9); 8.335 (4.3); 8,091 (0.4); 7,660 (0.6); 7,645 (0.8); 7.641 (0.7); 7.626 (0.6); 3,916 (16.0); 3,872 (1.3); 3,854 (3.8); 3.835 (3.9); 3,817 (1.4); 3,736 (0.6); 3,694 (0.7); 3,626 (0.8); 3,613 (0.8); 2,671 (1.0); 2,506 (105.6); 2,502 (135.4); 2,498 (103.6); 2,333 (0.7); 2,329 (0.9); 1,989 (0.7); 1,298 (0.6); 1,252 (4.0); 1,234 (9.7); 1,215 (3.9); 1,193 (0.3); 1,175 (0.5); 0,000 (3.0); Petition 870210086398, dated 09 / 20 / 2021, pp. 151 / 177 148 / 162 Ex. LOGP NEUTRO LOGP HCOOH I-73 2,20 2,25 Exemplo I-73: 1H-RMN (400,0 MHz, de-DMSO): δ= 9,297 (3,6); 9,268 (0,9); 9,255 (0,6); 9,208 (0,4); 8,404 (3,2); 8,382 (3,4); 8,317 (0,4); 8,298 (3,9); 8,238 (0,6); 8,119 (0,8); 8,106 (0,4); 8,097 (0,9); 8,084 (0,4); 8,024 (0,5); 8,022 (0,5); 7,996 (0,4); 7,975 (0,4); 7,352 (3,6); 7,330 (3,5); 7,181 (0,8); 7,159 (0,8); 7,087 (0,4); 7,069 (0,4); 7,067 (0,4); 5,758 (2,8); 4,564 (1,5); 4,442 (3,0); 4,115 (0,7); 4,015 (4,7); 3,988 (16,0); 3,931 (15,4); 3,909 (3,9); 3,568 (0,8); 3,544 (14,4); 3,331 (131,8); 2,676 (0,7); 2,672 (0,9); 2,667 (0,7); 2,525 (2,7); 2,511 (52,5); 2,507 (106,0); 2,503 (139,4); 2,498 (102,4); 2,494 (51,6); 2,334 (0,6); 2,329 (0,9); 2,325 (0,7); 1,259 (0,5); 1,234 (1,5); 0,000 (5,6) I-74 3,36 3,49 Exemplo I-74: 1H-RMN (601,6 MHz, CD3CN): δ= 8,905 (3,0); 8,903 (3,0); 8,852 (1,6); 8,850 (1,6); 8,500 (1,9); 8,313 (1,5); 8,311 (2,1); 8,309 (1,4); 8,183 (1,7); 8,181 (1,7); 7,962 (3,4); 7,961 (3,4); 4,001 (16,0); 3,940 (0,4);3.124 (1.1); 3.111 (3.4); 3.099 (3.5); 3.087 (1.2); 2.639 (0.7); 2.184 (55.7); 2.109 (1.2); 2.005 (2.2); 1.998 (195.7); 1.989 (2.7); 1.985 (1.8); 1.981 (10.0); 1.977 (18.2); 1.973 (26.5); 1.969 (18.0); 1.965 (9.0); 1.882 (1.2); 1.419 (0.4); 1.404 (0.7); 1.373 (0.6); 1.330 (4.1); 1,318 (9.0); 1,309 (1.6); 1,305 (5.2); 1,301 (3.4); 0.914 (0.6) I-75 2.84 2.94 Example I-75: 1H-NMR (400.0 MHz, de-DMSO): δ= 9.582 (2.6); 9,107 (4.5); 8,797 (2.6); 8,794 (2.8); 8,761 (3.5); 8,668 (2.9); 8,361 (4.6); 8,314 (0.3); 5,754 (2.9); 3,939 (1.0); 3,920 (3.5); 3,897 (16.0); 3,883 (1.4); 3.316 (65.0); 2.675 (0.8); 2.671 (1.1); 2.666 (0.9); 2.506 (121.1); 2.502 (165.0); 2.497 (131.6); 2.333 (0.7); 2.328 (1.1); 2.324 (0.9); 1.988 (0.8); 1.272 (3.7); 1.253 (8.2); 1.235 (4.5); 1.175 (0.4); 0.146 (0.5); 0.008 (3.6); 0.000 (102.8); -0.150 (0.5) I-76 3.73 3.84 Example I-76: 1H-NMR (601.6 MHz, CD3CN): δ= 9.334 (1.1); 9.333 (1.2); 9.331 (1.2); 9.329 (1.1); 9.015 (1.4); 9.014 (1.7); 8.867 (2.5); 8.865 (2.3);8,751 (1.2); 8,750 (1.3); 8,747 (1.3); 8,287 (2.6); 8,286 (2.3); 8,036 (1.9); 5,446 (0.6); 3,879 (0.9); 3,867 (16.0); 3,855 (3.0); 3,842 (0.9); 2,129 (16.5); 1,964 (0.3); 1,955 (0.9); 1,951 (1.2); 1,947 (9.5); 1,943 (17.4); 1,939 (24.5); 1,935 (16.4); 1,931 (8.6); 1,313 (3.1); 1,300 (6.6); 1,288 (3.1); 1,270 (0.6); 0,005 (0.6); 0,000 (19.1); -0,006 (0.7); Petition 870210086398, dated 09 / 20 / 2021, pp. 152 / 177 149 / 162 Ex. LOGP NEUTRAL LOGP HCOOH I-77 3.81 3.90 Example I-77: 1H-NMR (601.6 MHz, CD3CN): δ= 9.333 (1.3); 9.332 (1.5); 9.330 (1.5); 8.871 (3.2); 8.869 (3.1); 8,750 (1.6); 8.748 (1.6); 8.736 (1.3); 8.734 (1.4); 8.731 (1.4); 8.730 (1.2); 8.250 (3.0); 8.249 (3.0); 6.869 (1.7); 6.865 (1.7); 5.446 (0.7); 3.884 (1.1); 3,871 (4.7); 3,869 (16.0); 3,859 (3.6); 3,847 (1.1); 2,133 (5.1); 1,956 (0.3); 1,952 (0.4); 1,948 (3.5); 1,944 (6.3); 1,940 (9.0); 1,936 (6.1); 1,932 (3.2); 1,314 (3.5); 1,302 (7.5); 1,290 (3.6); 1,285 (0.4); 1,267 (0.5); 0,000 (5.6) Examples of use Ctenocephalides felis - in vitro patch test [000512] For coating test tubes, 9 mg of active ingredient are first dissolved in 1 mL of acetone (PA grade) and then diluted to the desired concentration with 250 μg of acetone (PA grade). The solution is homogeneously distributed on the inner walls and base of a 25 mL test tube by turning and shaking in an orbital shaker (swing rotation at 30 rpm for 2 h). With 900 ppm of active ingredient solution and an internal surface area of ​​44.7 cm², given the homogeneous distribution, an area-based dose of 5 μg / cm² is achieved. [000513] After the solvent has been removed by evaporation, the tubes are populated with 5-10 adult cat fleas (Ctenocephalides felis), sealed with a perforated plastic cap, and incubated in a horizontal position at room temperature and humidity. After 48 h, efficacy is determined. For this purpose, the test tubes are left upright and the fleas are hatched at the base of the tube. Fleas that remain motionless at the base or move in a disorganized manner are considered dead or dying. [000514] A substance shows good efficacy against Ctenocephalides felis if at least 80% efficacy is achieved in this test at an application rate of 5 μg / cm2. 100% efficacy means that all fleas were killed or are dying. 0% efficacy means that no fleas were harmed. Petition 870210086398, dated 09 / 20 / 2021, pp. 153 / 177 150 / 162 [000515] In this test, for example, the following compounds from the preparation examples show 100% effectiveness at an application rate of 5 pg / cm2: I-18, I-21 Boophilus microplus - injection test (BOOPMI injection) [000516] Solvent: dimethyl sulfoxide [000517] To produce an appropriate active ingredient formulation, 10 mg of active ingredient are mixed with 0.5 mL of solvent and the concentrate is diluted with solvent to the desired concentration. [000518] 1 ml of the active ingredient solution is injected into the abdomen of 5 adult swollen female ticks (Boophilus microplus). The animals are transferred in trays and kept in a climate-controlled enclosure. [000519] Effectiveness is assessed after 7 days by the laying of fertile eggs. Eggs that are not visibly fertile are stored in a climate-controlled chamber until the larva hatches after approximately 42 days. 100% effectiveness means that none of the ticks laid fertile eggs; 0% means that all eggs are fertile. [000520] In this test, for example, the following compounds from the example preparations show an efficacy of 80% at an application rate of 20 pg / animal: I-21 Ctenocephalides felis - oral test (CTECFE) [000521] Solvent: dimethyl sulfoxide [000522] For the purpose of producing an appropriate active ingredient formulation, 10 mg of active ingredient are mixed with 0.5 mL of dimethyl sulfoxide. Dilution with citrated cattle blood gives the desired concentration. [000523] Approximately 20 adult cat fleas (Ctenocephalides felis) on a fast are placed in a chamber that is closed at the top and bottom with gauze. A metal cylinder, the lower end of which is sealed with parafilm, is placed in the chamber. Petition 870210086398, dated 09 / 20 / 2021, pp. 154 / 177 151 / 162 The cylinder contains the active ingredient / blood preparation, which can be absorbed by fleas through the parafilm membrane. [000524] After 2 days, the death rate is determined as a percentage. 100% means that all fleas were killed; 0% means that none of the fleas were killed. [000525] In this test, for example, the following compounds from the example preparations show an efficacy of 90% at an application rate of 100 ppm: I-21 Lucilia cuprina (LUCICU) test [000526] Solvent: dimethyl sulfoxide [000527] To produce an appropriate active ingredient formulation, 10 mg of active ingredient are mixed with 0.5 mL of dimethyl sulfoxide, and the concentrate is diluted with water to the desired concentration. [000528] Approximately 20 L1 larvae of the Australian sheep blowfly (Lucilia cuprina) are transferred to an assay container containing minced horse meat and the active ingredient preparation at the desired concentration. [000529] After 2 days, the death rate is determined as a percentage. 100% means that all larvae were killed; 0% means that none of the larvae were killed. [000530] In this test, for example, the following compounds from the example preparations show 100% effectiveness at an application rate of 100 ppm: I-18, I-21 Musca domestica Test (MUSCDO) [000531] Solvent: dimethyl sulfoxide [000532] To produce an appropriate active ingredient formulation, 10 mg of active ingredient are mixed with 0.5 mL of dimethyl sulfoxide, and the concentrate is diluted with water to the desired concentration. Petition 870210086398, dated 09 / 20 / 2021, pages 155 / 177 152 / 162 [000533] Containers containing a sponge treated with a sugar solution and the active ingredient formulation at the desired concentration are populated with 10 adult flies (Musca domestica). [000534] After 2 days, the death rate is determined as a percentage. 100% means that all flies were killed; 0% means that none of the flies were killed. [000535] In this test, for example, the following compounds from the example preparations show an efficacy of 95% at an application rate of 20 ppm: I-21 Myzus persicae - spray test (MYZUPE) Solvent: 78 parts by weight of acetone 1.5 parts by weight of dimethylformamide. Emulsifier: alkylaryl polyglycol ether. [000536] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the specified parts by weight of solvent and made up with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce additional test concentrations, the preparation is diluted with water containing emulsifier. [000537] Discs of Chinese cabbage (Brassica pekinensis) leaf infested with all stages of the green peach aphid (Myzus persicae) are sprayed with an active ingredient formulation at the desired concentration. [000538] After 6 days, the effectiveness in % is determined. 100% means that all aphids were killed; 0% means that none of the aphids were killed. [000539] In this test, for example, the following compounds from the example preparations show 100% effectiveness at an application rate of 500 g / ha: I-10, I-13, I-18, I-22, I-23, I-24, I-43, I-44, Petition 870210086398, dated 09 / 20 / 2021, pp. 156 / 177 153 / 162 I-48, I-52 [000540] In this test, for example, the following compounds from the example preparations show an efficacy of 90% at an application rate of 500 g / ha: I-4, I-12, I-14, I-17, I-18, I-19, I-21, I-38, I-42, I-45, I-46, I-49, I-50, I-51, I-56, I-61, I-68 [000541] In this test, for example, the following compounds from the preparation examples show an efficacy of 90% at an application rate of 20 g / ha: I-39 Phaedon cochleariae - spray test (PHAECO) Solvent: 78.0 parts by weight of acetone 1.5 parts by weight of dimethylformamide. Emulsifier: alkylaryl polyglycol ether. [000542] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the specified parts by weight of solvent and made up with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce additional test concentrations, the preparation is diluted with water containing emulsifier. [000543] Discs of Chinese cabbage (Brassica pekinensis) leaves are sprayed with an active ingredient formulation of the desired concentration and, after drying, populated with mustard beetle larvae (Phaedon cochleariae). [000544] After 7 days, the effectiveness in % is determined. 100% means that all beetle larvae were killed; 0% means that no beetle larvae were killed. [000545] In this test, for example, the following compounds from the example preparations show 100% effectiveness at an application rate of 500 g / ha: I-2, I-3, I-4, I-5, I-10, I-12, I-13, I-14, I-18, I-19, I-21, I-22, I-24, I-25, I-26, I-28, I-29, I-31, I-36, I-37, I-38, I-39, I-41, I-42, I-43, I-44, I-45, I-46, I-47, I-48, I-49, I-50, I-51, I-52, I-53, I-54, Petition 870210086398, dated 09 / 20 / 2021, pp. 157 / 177 154 / 162 I-55, I-61, I-68, I-73 [000546] In this test, for example, the following compounds from the preparation examples show an efficacy of 83% at an application rate of 500 g / ha: I-30, I-63 [000547] In this test, for example, the following compounds from the preparation examples show an efficacy of 100% at an application rate of 100 g / ha: I-11 [000548] In this test, for example, the following compounds from the preparation examples show an efficacy of 83% at an application rate of 100 g / ha: I-17 Spodoptera frugiperda - spray test (SPODFR) Solvent: 78.0 parts by weight of acetone 1.5 parts by weight of dimethylformamide. Emulsifier: alkylaryl polyglycol ether. [000549] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the specified parts by weight of solvent and made up with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce additional test concentrations, the preparation is diluted with water containing emulsifier. [000550] Corn leaf discs (Zea mays) are sprayed with an active ingredient formulation of the desired concentration and, after drying, populated with fall armyworm caterpillars (Spodoptera frugiperda). [000551] After 7 days, the effectiveness in % is determined. 100% means that all caterpillars were killed; 0% means that no caterpillars were killed. [000552] In this test, for example, the following compounds from the preparation examples show 100% effectiveness in a Petition 870210086398, dated 09 / 20 / 2021, page 158 / 177 155 / 162 application rate of 500 g / ha: I-2, I-21, I-26, I-37, I-39, I-42, I-46, I-47, I54, I-61, I-63, I-68 [000553] In this test, for example, the following compounds from the preparation examples show an efficacy of 83% at an application rate of 500 g / ha: I-14, I-19, I-48 Tetranychus urticae - spray test, resistant to OP (TETRUR) Solvent: 78.0 parts by weight of acetone 1.5 parts by weight of dimethylformamide. Emulsifier: alkylaryl polyglycol ether. [000554] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the specified parts by weight of solvent and made up with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce additional test concentrations, the preparation is diluted with water containing emulsifier. [000555] Bean leaf discs (Phaseolus vulgaris) infested with all stages of the two-spotted spider mite (Tetranychus urticae) are sprayed with an active ingredient formulation at the desired concentration. [000556] After 6 days, the effectiveness in % is determined. 100% means that all spider mites were killed; 0% means that none of the spider mites were killed. [000557] In this test, for example, the following compound from the preparation examples shows 100% effectiveness at an application rate of 500 g / ha: I-68 [000558] In this test, for example, the following compounds from the preparation examples show an effectiveness of 90% at an application rate of 500 g / ha: I-2, I-13, I-19, I-22, I-28, I-42, I-44, I-53 [000559] In this test, for example, the following compound from the exem Petition 870210086398, dated 09 / 20 / 2021, pp. 159 / 177 156 / 162 plos of preparation shows an effectiveness of 90% at an application rate of 100 g / ha: I-48 Myzus persicae - spray test (MYZUPE) Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000560] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce further test concentrations, the preparation is diluted with water containing emulsifier. If the addition of ammonium salts and / or penetrants is required, these are each added at a concentration of 1000 ppm to the formulation solution. [000561] Pepper plants (Capsicum annuum) heavily infested with the green aphid (Myzus persicae) are treated by spraying with the active ingredient formulation at the desired concentration. [000562] After 6 days, the death rate is determined as a percentage. 100% means all aphids were killed; 0% means no aphids were killed. [000563] In this test, for example, the following compound from the preparation examples shows an efficacy of 97% at an application rate of 100 ppm: I-11 Meloidogyne incognita test Solvent: 125.0 parts by weight of acetone [000564] To produce a suitable active ingredient formulation, 1 part by weight of active ingredient is mixed with the indicated amount of solvent and the concentrate is diluted with water to the desired concentration. Petition 870210086398, dated 09 / 20 / 2021, pp. 160 / 177 157 / 162 [000565] The pots are filled with sand, an active ingredient solution, a suspension of eggs / larvae of the southern root-knot nematode (Meloidogyne incognita), and lettuce seeds. The lettuce seeds germinate and the plants develop. Galls develop on the roots. [000566] After 14 days, the nematicide efficacy in % is determined by gall formation. 100% means that no galls were found; 0% means that the number of galls on the treated plants corresponds to the untreated control. [000567] In this test, for example, the following compound from the preparation examples shows 100% effectiveness at an application rate of 20 ppm: I-68 Comparative Examples: Myzus persicae - contact test (MYZUPE c) Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000568] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce further test concentrations, the preparation is diluted with water containing emulsifier. In the event that the addition of ammonium salts and / or penetrants (rapeseed oil methyl ester) is required, these are each pipetted in at a concentration of 1000 ppm after the formulation solution has just been diluted. [000569] Single-leaf pepper plants (Capsicum annuum) heavily infested with the green aphid (Myzus persicae) are treated by spraying the underside of the leaf with the active ingredient formulation at the desired concentration. Petition 870210086398, dated 09 / 20 / 2021, pages 161 / 177 158 / 162 [000570] After the desired time, the death rate is determined as a percentage. 100% means that all aphids were killed, and 0% means that none of the aphids were killed. [000571] In this test, for example, the following compound from the preparation examples shows good efficacy compared to the known compound from document WO2013018928 (see table): Myzus persicae - translaminar test (MYZUPE t) Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000572] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce further test concentrations, the preparation is diluted with water containing emulsifier. In the event that the addition of ammonium salts and / or penetrants (rapeseed oil methyl ester) is required, these are each pipetted in at a concentration of 1000 ppm after the formulation solution has just been diluted. [000573] Single-leaf pepper plants (Capsicum annuum) heavily infested with the green aphid (Myzus persicae) are treated by spraying the upper side of the leaf with the active ingredient formulation at the desired concentration. [000574] After the desired time, the death rate is determined as a percentage. 100% means that all aphids were killed and 0% means that none of the aphids were killed. [000575] In this test, for example, the following compound from the preparation examples shows good efficacy compared to the known compound from document WO2013018928 (see table): Aphis gossypii - patch test (APHIGO c) Petition 870210086398, dated 09 / 20 / 2021, pp. 162 / 177 159 / 162 Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000576] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce further test concentrations, the preparation is diluted with water containing emulsifier. In the event that the addition of ammonium salts and / or penetrants (rapeseed oil methyl ester) is required, these are each pipetted in at a concentration of 1000 ppm after the formulation solution has just been diluted. [000577] Single-leaf cotton plants (Gossypium hirsutum) heavily infested with the cotton aphid (Aphis gossypii) are treated by spraying the underside of the leaf with the active ingredient formulation at the desired concentration. [000578] After the desired time, the death rate is determined as a percentage. 100% means that all aphids were killed and 0% means that none of the aphids were killed. [000579] In this test, for example, the following compound from the preparation examples shows good efficacy compared to the known compound from document WO2013018928 (see table): Aphis gossypii - translaminar test (APHIGO t) Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000580] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce higher concentrations of Petition 870210086398, dated 09 / 20 / 2021, pages 163 / 177 160 / 162 test, the preparation is diluted with water containing emulsifier. In the event that the addition of ammonium salts and / or penetrants (rapeseed oil methyl ester) is required, these are each pipetted in at a concentration of 1000 ppm after the solution has just been diluted. [000581] Single-leaf cotton plants (Gossypium hirsutum) heavily infested with the cotton aphid (Aphis gossypii) are treated by spraying the upper side of the leaf with the active ingredient formulation at the desired concentration. [000582] After the desired time, the death rate is determined as a percentage. 100% means that all aphids were killed and 0% means that none of the aphids were killed. [000583] In this test, for example, the following compound from the preparation examples shows good efficacy compared to the known compound from document WO2013018928 (see table): Nephotettix cincticeps test (NEPHCI) Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000584] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce further test concentrations, the preparation is diluted with water containing emulsifier. In the event that the addition of ammonium salts and / or penetrants (rapeseed oil methyl ester) is required, these are each pipetted in at a concentration of 1000 ppm after the formulation solution has just been diluted. [000585] Rice plants (Oryza sativa, var. Balilla) are treated by spraying with the active ingredient formulation in Petition 870210086398, dated 09 / 20 / 2021, pp. 164 / 177 161 / 162 desired concentration and then populated with green rice leafhopper larvae (Nephotettix cincticeps). [000586] After the desired time, the death rate is determined as a percentage. 100% means that all leafhoppers were killed; 0% means that none of the leafhoppers were killed. [000587] In this test, for example, the following compound from the preparation examples shows good efficacy compared to the known compound from document WO2013018928 (see table): Nilaparvata lugens (NILALU) test Solvent: 7 parts by weight of dimethylformamide Emulsifier: alkylaryl polyglycol ether [000588] To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is dissolved using the indicated parts by weight of solvent and fermented with water containing an emulsifier concentration of 1000 ppm until the desired concentration is reached. To produce further test concentrations, the preparation is diluted with water containing emulsifier. In the event that the addition of ammonium salts and / or penetrants (rapeseed oil methyl ester) is required, these are each pipetted in at a concentration of 1000 ppm after the formulation solution has just been diluted. [000589] Rice plants (Oryza sativa, var. Balilla) are treated by spraying with the active ingredient formulation at the desired concentration and then populated with L3 larvae of the brown leafhopper (Nilaparvata lugens). [000590] After the desired time, the feed damage in % is determined. 100% means that no feed damage is found; 0% means that the feed damage to the treated plant corresponds to that of the untreated control. [000591] In this test, for example, the following compound of examples Petition 870210086398, dated 09 / 20 / 2021, pages 165 / 177 162 / 162 specimens of preparation show good efficacy compared to the known compound from document WO2013018928 (see table): Substance Structure Animal species Concentration % of dat* efficacy Ex. I-21 o=s^° J JL W / ACF3 n—9 \ MYZUPE c MYZUPE t MYZUPE t APHIGO c APHIGO t NEPHCI NEPHCI NEPHCI NILALU NILALU 2.4 g / ha 12 g / ha 2.4 g / ha 2.4 g / ha 2.4 g / ha 2.16 phapm ppm 0.16 ppm 4 ppm 4 ppm 85 98 90 98 65 90 95 100 90 100 14 that 14 that 14 that 7 that 7 that 14 that 21 that 34 that 21 that 28 that Ex. 5 os==° MYZUPE c 2.4 g / ha 50 14 dat conhecido do F3C,syX^!v-'N \=\ 1 JZ V<\ / >-cf= MYZUPE t 12 g / ha 0 14 dat documento \ MYZUPE t 2.4 g / ha date WO 029140 APHIGO c APHIGO t NEPHCI NEPHCI NEPHCI NILALU NILALU 2.4 g / ha 2.4 g / ha 0.16 ppm 0.16 ppm 0.16 ppm 4 ppm 4 ppm

Claims

REIVINDICAÇÕES 1. Compound, characterized by the fate of which is presented in Formula (I), in which A3 is oxygen, and R1, R2a, R2b, R3, A1, A2, A4, A5 in the following table: Example R1 n A4 A5 R3 A2 A1 Rüa R2b 1-1 CH3 0 N CH cf3 0 CH Cl H I-4 CH3 0 CH CH cf3 N-Methyl CH FH I-6 CH3 0 N CH cf3 N-Methyl CH Cl H I-7 -(CH2)2-SO2c2h5 2 CH CH cf3 N-Methyl N CF3 H I-8 í-C3H7 1 CH CH cf3 N-Methyl N CF3 H I-9 c2h5 0 N CH cf3 O CH HH 1-12 ch3 1 CH CH cf3 N-Methyl CH FH 1-13 c2h5 1 CH CH cf3 N-Methyl CH H 5-CI 1-16 Í-C3H7 2 CH CH cf3 N-Methyl N cf3 H 1-19 c2h5 0 CH CH cf3 N-Methyl CH H 5-CI I-20 ch3 2 CH CH cf3 N-Methyl CH FH I-23 -(CH2)2-Sc2h5 0 CH CH cf3 N-Methyl N cf3 H I-27 Oxetan-3-ila 2 CH CH cf3 N-Methyl CH HH I-28 c2h5 0 N CH cf3 N-Methyl N cf3 H I-29 cf3 0 CH CH cf3 N-Methyl NHH 1-31 n-C3H7 0 CH CH cf3 N-Metil N cf3 H I-32 n-C3H7 2 CH CH cf3 N-Metil N cf3 H I-34 CH3 0 CH CH cf3 O CH Cl H I-35 c2h5 1 CH CH cf3 O CH HH I-38 c2h5 2 CH CH cf3 N-Metil CH H 5-CI Request870210086398, September 20, 2021, page. 167 / 177 2 / 3 Example R1 n A4 A5 R3 A2 A1 R2a R2b I-39 n-C3H7 1 CH CH CF3 N-Metil N CF3 H I-40 Oxetan-3-ila 0 CH CH CF3 O CH HH I-41 i-C3H7 0 CH CH CF3 N-Metil N CF3 H I-45 C2H5 2 CH CH CF3 N-Metil NH 5-OMe I-46 C2H5 0 CH CH C2F5 N-Metil NHH I-47 C2H5 0 CH CH C2F5 N-Metil N CF3 H I-48 C2H5 2 CH CH CF3 N-Metil NH 3-CF3 I-49 C2H5 2 CH CH CF3 N-Metil NH 5-NHCOMe I-50 C2H5 0 CH CH CF3 N-Metil NH 5-NHCOMe I-51 C2H5 1 CH CH CF3 N-Metil NH 3-CF3 I-52 C2H5 2 CH CH Cl N-Metil N CF3 H I-53 C2H5 0 CH CH CF3 N-Metil NH 5-OMe I-54 CH2-CH2F 2 CH CH CF3 N-Metil N CF3 H I-55 C2H5 0 CH CH Cl N-Metil N CF3 H I-56 C2H5 2 CH CH CF3 N-Metil N CONH2 H I-57 CH2-CH2F 2 CH CH CF3 N-Metil N CF3 H I-58 CH2-CH2OH 2 CH CH CF3 N-Metil N CF3 H I-59 CH2-CH2OH 0 CH CH CF3 N-Metil N CF3 H I-60 C2H5 0 CH CH CF3 N-Metil N CONH2 H I-61 C2H5 1 CH CH C2F5 N-Metil NHH I-62 C2H5 2 CH CH CF3 N-Metil CH H 3-Cl I-63 C2H5 1 CH CH C2F5 N-Metil N CF3 H I-64 C2H5 0 CH CH 4-CF3(CeH4)N-MetilN CF3 H I-65 C2H5 0 CH CH 4-(CF3)Pyrazol-1-yl N-Methyl N CF3 H I-66 n-C3H7 0 CH CH CF3 N-Methyl NH 5-OMe I-67 CH3 0 CH CH CF3 N-Methyl NH 5-OMe I-68 C2H5 2 CH CH C2F5 N-Methyl NHH I-69 C2H5 0 CH CH 3-(CF3)Pyrazol-1-yl N-Methyl N CF3 H I-70 C2H5 0 CH CH CF3 N-Methyl NH 3-CF3 I-71 n-C3H7 2 CH CH CF3 N-Methyl NH 5-OMe I-72 C2H5 2 CH CH CF3 N-Methyl N CN H I-73 CH3 2 CH CH CF3 N-Methyl NH 5-OMe I-74 C2H5 0 CH CH 4-(CF3)Imidazol-1-yl N-Methyl N CF3 H I-75 C2H5 2 CH CH 4-(CF3)Imidazol-1-yl N-Methyl N CF3 H I-76 C2H5 2 CH CH 4-(CF3)Pyrazol-1-yl N-Methyl N CF3 H I-77 C2H5 2 CH CH 3-(CF3)Pyrazol-1-yl N-Methyl N CF3 H 2. Composition, characterized in that it comprises a content of at least one compound of Formula (I), as defined in claim 1, and one or more usual diluents and / or surfactants. Petition 870210086398, dated 20 / 09 / 2021, pp. 168 / 177 3 / 3 3. Method for controlling pests, characterized in that it comprises allowing a compound of Formula (I), as defined in claim 1, or a composition, as defined in claim 2, to act on pests and / or their habitat, provided that treatment of humans and / or animals is excluded.

4. Use of compounds of Formula (I), as defined in claim 1, or of compositions, as defined in claim 2, characterized in that it is for controlling pests, provided that treatment in humans and / or animals is excluded.

5. Compound, characterized by the fact that it has Formula (IIa), (11a) in which R3 is C2F5.

6. Compound, characterized by the fact that it has the formula (11-02):